http://jnci.oxfordjournals.org/content/100/24/1780.full
<!DOCTYPE html
  PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">
<html
      xmlns="http://www.w3.org/1999/xhtml"
      xml:lang="en"
      lang="en">
   <head>
      <meta http-equiv="Content-Type" content="text/html; charset=UTF-8" />
      <title>Multiple-Treatments Meta-analysis of Chemotherapy and Targeted Therapies in Advanced Breast Cancer </title>
      <meta name="googlebot" content="NOODP" />
      <meta name="HW.ad-path" content="/cgi/content/full/100/24/1780" />
      <meta content="/jnci/100/24/1780.atom" name="HW.identifier" />
      <meta name="DC.Format" content="text/html" />
      <meta name="DC.Language" content="en" />
      <meta content="Multiple-Treatments Meta-analysis of Chemotherapy and Targeted Therapies in Advanced Breast Cancer"
            name="DC.Title" />
      <meta content="10.1093/jnci/djn414" name="DC.Identifier" />
      <meta content="2008-12-17" name="DC.Date" />
      <meta content="Oxford University Press" name="DC.Publisher" />
      <meta content="Davide Mauri" name="DC.Contributor" />
      <meta content="Nikolaos P. Polyzos" name="DC.Contributor" />
      <meta content="Georgia Salanti" name="DC.Contributor" />
      <meta content="Nicholas Pavlidis" name="DC.Contributor" />
      <meta content="John P. A. Ioannidis" name="DC.Contributor" />
      <meta content="Journal of the National Cancer Institute"
            name="citation_journal_title" />
      <meta content="JNCI J Natl Cancer Inst" name="citation_journal_abbrev" />
      <meta content="0027-8874" name="citation_issn" />
      <meta content="1460-2105" name="citation_issn" />
      <meta name="citation_author" content="Davide Mauri" />
      <meta name="citation_author" content="Nikolaos P. Polyzos" />
      <meta name="citation_author" content="Georgia Salanti" />
      <meta name="citation_author" content="Nicholas Pavlidis" />
      <meta name="citation_author" content="John P. A. Ioannidis" />
      <meta content="Multiple-Treatments Meta-analysis of Chemotherapy and Targeted Therapies in Advanced Breast Cancer"
            name="citation_title" />
      <meta content="100" name="citation_volume" />
      <meta content="24" name="citation_issue" />
      <meta content="1780" name="citation_firstpage" />
      <meta content="1791" name="citation_lastpage" />
      <meta content="100/24/1780" name="citation_id" />
      <meta content="100/24/1780" name="citation_id_from_sass_path" />
      <meta content="jnci;100/24/1780" name="citation_mjid" />
      <meta content="10.1093/jnci/djn414" name="citation_doi" />
      <meta content="http://jnci.oxfordjournals.org/content/100/24/1780.abstract"
            name="citation_abstract_html_url" />
      <meta content="http://jnci.oxfordjournals.org/content/100/24/1780.full"
            name="citation_fulltext_html_url" />
      <meta content="http://jnci.oxfordjournals.org/content/100/24/1780.full.pdf"
            name="citation_pdf_url" />
      <meta content="/content/100/24.cover.gif" name="issue_cover_image" />
      <meta content="http://jnci.oxfordjournals.org/content/100/24/1780"
            name="citation_public_url" />
      <meta content="19066278" name="citation_pmid" />
      <meta name="citation_section" content="Article" />
      <meta name="robots" content="noarchive,nofollow" />
      <meta name="googlebot" content="noarchive" />
      <link href="/content/100/24/1771.short" rel="prev" />
      <link href="/content/100/24/1792.short" rel="next" />
      <link rel="stylesheet" type="text/css" media="all" href="/shared/css/hw-global.css" />
      <link rel="stylesheet" type="text/css" media="print" href="/shared/css/hw-print.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/local/css/hw-local-global.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/publisher/css/hw-publisher-global.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/publisher/css/hw-publisher-ac.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/shared/css/hw-page-content.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/shared/css/jquery.fancybox-1.3.4.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/shared/css/hw-global-colexpand.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/publisher/css/hw-publisher-page-content.css" /><script type="text/javascript" id="session-d27278766e1">var callbackToken='537FD1B1F5496E2';</script><script type="text/javascript" id="session-d27278766e3">
                      var subCode='oupjournal_sub';
                    </script><script type="text/javascript">
            var gAuthTimeStamp = '2015-10-27T12:12:28.518-07:00';
            var gSessionId = 'RcxrgRNj9EXJDM588YaotA';
            var gAuthzRequired = 'false';
            var gAuthnMethods1 = 'ip ip';
            var gAuthnMethods2 = 'ip,ip';
            var gAuthnIPs = '18.189.59.169,18.189.59.169';
            var gAuthnIndividuals = '';
            var gAuthnInstitutions = '10005282,10072538,10328193,100274300,10082403,05094000,10093227,153074108,10080507,21879000,10095822,10081742,10082405,10004595,10019502,10082401,07635000,10082404,06602000';
            </script><script type="text/javascript" src="/shared/js/jquery-min.js"></script><script type="text/javascript" src="/shared/js/fingerprint.js"></script><script type="text/javascript" src="/shared/js/hw-shared.js"></script><script type="text/javascript" src="/publisher/js/hw-publisher-site.js"></script><script type="text/javascript" src="/local/js/local-js-vars.js"></script><script type="text/javascript" src="/shared/js/pages/hw-content.js"></script><script type="text/javascript" src="/shared/js/fancybox/jquery.fancybox-1.3.4.js"></script><script type="text/javascript" src="/shared/js/fancybox/jquery.easing-1.3.pack.js"></script><script type="text/javascript"
              src="/shared/js/fancybox/jquery.mousewheel-3.0.4.pack.js"></script><script type="text/javascript" src="/shared/js/util/content.jquery.addVariantLink.js"></script><script type="text/javascript" src="/shared/js/util/hw-col-expand.js"></script><script type="text/javascript" src="/publisher/js/hw-publisher-modalwin-vars.js"></script><script type="text/javascript"
              src="/publisher/js/hw-publisher-article-dynamic-elements.js"></script><script type="text/javascript" src="/publisher/js/hw-publisher-content.js"></script><script type="text/javascript" src="/shared/js/util/hw-mathjax.js"></script><script type="text/x-mathjax-config">
          MathJax.Hub.Config({
              tex2jax: {
                inlineMath: [["$","$"],["\\(","\\)"]],
                processClass: "tex2jax_process|mathjax"
              }
            });
          MathJax.Hub.Queue(function() {
            gColTempResize = true;
            fixColHeights(1);
            gColTempResize = false;
          });
       </script><script type="text/javascript"
              src="http://cdn.mathjax.org/mathjax/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script><script type="text/javascript">
	    
	    
	    
	    var siqDOI = encodeURIComponent("10.1093/jnci/djn414");
	    var siqIsOpenAccess = encodeURIComponent("");
	    var siqPubDate = encodeURIComponent("20081217");

	    if (siqDOI.length == 0) {
	        siqDOI = "UNKNOWN";
	    }
	    
	    
		
		
	    if (gAuthnIndividuals.length != 0) {
		if (gAuthnInstitutions.length != 0) {
		    authnEntity = encodeURIComponent(gAuthnIndividuals
		        + ',' + gAuthnInstitutions);
		} else {
		    authnEntity = encodeURIComponent(gAuthnIndividuals);
		}
	    } else {
	        authnEntity = encodeURIComponent(gAuthnInstitutions);
	    }

	    var commonString =
		'authSessionId=' + gSessionId + String.fromCharCode(0x26)
		+ 'authzRequired=' + gAuthzRequired + String.fromCharCode(0x26)
		+ 'authentication_method=' + encodeURIComponent(gAuthnMethods2) + String.fromCharCode(0x26)
		+ 'authnIPs=' + gAuthnIPs + String.fromCharCode(0x26)
		+ 'authnInstitutions=' + authnEntity;

		
		
		
		

	    var gPageId = "pageid-content";
	    var gVariant = "full-text";

	    
		// Not completely done
		var eventType = "full-text";
		var accessType;
		if (siqIsOpenAccess == 'true') {
		    accessType = 'SOA';
		} else {
		    accessType = 'subscription';
		}
		    
		var NTPT_PGEXTRA =
		    commonString + String.fromCharCode(0x26)
		    + 'event_type=' + eventType + String.fromCharCode(0x26)
		    + 'publication_date=' + siqPubDate + String.fromCharCode(0x26)
		    + 'access_type=' + accessType + String.fromCharCode(0x26)
		    + 'doi=' + siqDOI ;
		    
		

	    // alert("NTPT_PGEXTRA is " + NTPT_PGEXTRA);
	</script><link rel="stylesheet" type="text/css" media="all" href="/resource/css/hw20.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/resource/css/h20-oup-header.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/resource/css/h20-oup-footer.css" />
      <link rel="stylesheet" type="text/css" media="all"
            href="/resource/css/h20-oup-sidebars.css" />
      <link type="text/css" media="all" rel="stylesheet" href="/site/resource/jnci_h20.css" />
      <link rel="stylesheet" type="text/css" href="/resource/css/print.css" media="print" /><script type="text/javascript" src="/resource/js/main.js"></script><link rel="stylesheet" type="text/css" media="all"
            href="http://oi-underbar.ifactory.com/underbar/css/pf_oiunderbar.css" />
      <link rel="stylesheet" type="text/css" media="screen"
            href="http://gab.cookie.oup.com/aws-cookie/jquery.fancybox-1.3.4_1.css" /><script type="text/javascript" src="/resource/js/oup_ad_size.js"></script></head>
   <body class="general_page journal jnci">
      <div class="hw-gen-page pagetype-content hw-pub-id-article" id="pageid-content"
           itemscope="itemscope"
           itemtype="http://schema.org/ScholarlyArticle">
         <noscript>
            <p>We use cookies to enhance your experience on our website. By continuing to use our website, you are agreeing to our use of
               cookies. You can change your cookie settings at any time. <a href="http://global.oup.com/cookiepolicy/">Find out more</a></p>
         </noscript>
         
         
         <p class="hide">
            <a href="#content">Skip Navigation</a>
            
         </p>
         
         
         <div id="secondary_nav">
            <strong id="page_logo" title="Oxford Journals"><a href="http://www.oxfordjournals.org/"><span>Oxford Journals</span></a></strong>
            
            <ul>
               <li id="nav_contact_us" title="Contact Us"><a href="http://www.oxfordjournals.org/contact_us.html"><span>Contact Us</span></a></li>
               <li id="nav_my_basket" title="My Basket"><a href="https://secure.oxfordjournals.org/basket.html"><span>My Basket</span></a></li>
               <li id="nav_my_account" title="My Account"><a href="http://services.oxfordjournals.org/cgi/tslogin?url=http://www.oxfordjournals.org/service/Register"><span>My 
                        
                        Account</span></a></li>
            </ul>
            
         </div>
         
         
         <div id="header">
            
            <h1 id="page_title" title="JNCI J Natl Cancer Inst"><a href="/"><span>
                     JNCI J Natl Cancer Inst
                     </span></a></h1>
            
         </div>
         
         
         <div id="primary_nav">
            
            <ul>
               <li id="nav_about_this_journal" title="About This Journal">
                  <a href="http://www.oxfordjournals.org/jnci/about.html">
                     
                     <span>About This Journal</span>
                     </a>
                  
               </li>
               <li id="nav_contact_this_journal" title="Contact This Journal"><a href="/cgi/feedback/"><span>Contact This Journal</span></a></li>
               <li id="nav_subscriptions" title="Subscriptions">
                  <a href="http://www.oxfordjournals.org/jnci/access_purchase/buy_online.html">
                     
                     <span>Subscriptions</span>
                     </a>
                  
               </li>
               <li id="nav_current_issue" title="Current"><a href="/content/current"><span>View Current Issue (Volume 107 Issue 10 October 2015)</span></a></li>
               <li id="nav_archive" title="Archive"><a href="/content/by/year"><span>Archive</span></a></li>
               <li id="nav_search" title="Search"><a href="/search"><span>Search</span></a></li>
            </ul>
            
         </div>
         
         
         <div id="user_nav">
            
            <div class="header-ac-elements">
               
               <div id="authstring">
                  
                  <ul>
                     <li class="subscr-ref">Institution:  MIT Libraries</li>
                     <li class="no-left-border">
                        <a href="/login?uri=http%3A%2F%2Fjnci.oxfordjournals.org%2Fcontent%2F100%2F24%2F1780.full">
                           Sign In as Personal Subscriber
                           </a>
                        
                     </li>
                  </ul>           
                  
               </div>   
               
            </div>
            
         </div>
         
         
         <ul id="site-breadcrumbs">
            <li class="first"><a href="http://services.oxfordjournals.org/cgi/tslogin?url=http%3A%2F%2Fwww.oxfordjournals.org">Oxford Journals</a></li>
            <li><span class="breadcrumb_subjects"><a href="http://www.oxfordjournals.org/subject/medicine/"
                     class="breadcrumb_subject">Medicine &amp; Health</a></span></li>
            <li><a href="/">JNCI J Natl Cancer Inst</a></li>
            <li><a href="/content/100/24.toc">
                  <span xmlns="" class="volume-value">Volume 100</span>
                  <span xmlns="" class="issue-value"> Issue 24</span></a></li>
            <li>Pp. <span class="slug-pages">
                  1780-1791.
                  </span></li>
         </ul>
         
         
         
         
         <div id="oas_top" class="ad_hidden">
            <iframe id="id_advertframe_top"
                    src="/resource/htmlfiles/advert.html?p=Top&amp;u=jnci.oxfordjournals.org/content/100/24/1780.full"
                    width="0"
                    height="0"
                    frameborder="0"
                    scrolling="no"
                    class="resize_ad"></iframe>
            
         </div>
         
         
         <a name="content"></a>
         
         
         <div id="h20_page"></div>
         
         <div id="content-block">
            <div class="article fulltext-view" itemprop="articleBody"><span class="highwire-journal-article-marker-start"></span><h1 id="article-title-1" itemprop="headline">Multiple-Treatments Meta-analysis of Chemotherapy and Targeted Therapies in Advanced Breast Cancer</h1>
               <div class="contributors">
                  <ol class="contributor-list" id="contrib-group-1">
                     <li class="contributor" id="contrib-1" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Davide+Mauri&amp;sortspec=date&amp;submit=Submit">Davide Mauri</a></span>, 
                     </li>
                     <li class="contributor" id="contrib-2" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Nikolaos+P.+Polyzos&amp;sortspec=date&amp;submit=Submit">Nikolaos P. Polyzos</a></span>, 
                     </li>
                     <li class="contributor" id="contrib-3" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Georgia+Salanti&amp;sortspec=date&amp;submit=Submit">Georgia Salanti</a></span>, 
                     </li>
                     <li class="contributor" id="contrib-4" itemprop="author" itemscope="itemscope"
                         itemtype="http://schema.org/Person"><span class="name" itemprop="name"><a class="name-search"
                              href="/search?author1=Nicholas+Pavlidis&amp;sortspec=date&amp;submit=Submit">Nicholas Pavlidis</a></span> and 
                     </li>
                     <li class="last" id="contrib-5"><span class="name"><a class="name-search"
                              href="/search?author1=John+P.+A.+Ioannidis&amp;sortspec=date&amp;submit=Submit">John P. A. Ioannidis</a></span></li>
                  </ol>
                  <ol class="affiliation-list">
                     <li class="aff"><a id="aff-1" name="aff-1"></a><address><strong>Affiliations of authors:</strong> Clinical Trials and Evidence-Based Medicine Unit, Department of Hygiene and Epidemiology (DM, NPP, GS, JPAI) and Department
                           of Medical Oncology (DM, NP), University of Ioannina School of Medicine, Ioannina, Greece; Department of Medical Oncology,
                           Lamia Polyclinic, Lamia, Greece (DM); Biomedical Research Institute, Foundation for Research and Technology—Hellas, Ioannina,
                           Greece (JPAI); Institute for Clinical Research and Health Policy Studies, Department of Medicine, Tufts Medical Center, Tufts
                           University School of Medicine, Boston, MA (JPAI)
                        </address>
                     </li>
                  </ol>
                  <ol class="corresp-list">
                     <li class="fn" id="corresp-1"><strong>Correspondence to:</strong><br /> John P. A. Ioannidis, MD, Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina 45110,
                        Greece (e-mail: <span class="em-link"><span class="em-addr">jioannid{at}cc.uoi.gr</span></span>).
                     </li>
                  </ol>
                  <ul class="history-list">
                     <li xmlns:hwp="http://schema.highwire.org/Journal" class="received"
                         hwp:start="2008-03-24"><span class="received-label">Received </span>March 24, 2008.
                     </li>
                     <li xmlns:hwp="http://schema.highwire.org/Journal" class="rev-recd"
                         hwp:start="2008-08-20"><span class="rev-recd-label">Revision received </span>August 20, 2008.
                     </li>
                     <li xmlns:hwp="http://schema.highwire.org/Journal" class="accepted"
                         hwp:start="2008-10-16"><span class="accepted-label">Accepted </span>October 16, 2008.
                     </li>
                  </ul>
               </div>
               <div class="section abstract" id="abstract-1" itemprop="description">
                  <div class="section-nav">
                     <div class="nav-placeholder"> </div><a href="#sec-11" title="Methods" class="next-section-link"><span>Next Section</span></a></div>
                  <h2>Abstract</h2>
                  <div id="sec-1" class="subsection">
                     <p id="p-1"><strong>Background</strong> Many systemic nonhormonal regimens have been evaluated across several hundreds of randomized trials in advanced breast cancer.
                        We aimed to quantify the relative merits of these regimens in prolonging survival.
                     </p>
                  </div>
                  <div id="sec-2" class="subsection">
                     <p id="p-2"><strong>Methods</strong> We performed a systematic review of all trials that compared different regimens involving chemotherapy and/or targeted therapy
                        in advanced breast cancer (1973–2007). Regimens were categorized a priori into different treatment types. We performed multiple-treatments
                        meta-analysis and calculated hazard ratios for each treatment category relative to monotherapy with old agents (ie, regimens
                        not including anthracyclines, anthracenediones, vinorelbine, gemcitabine, capecitabine, taxanes, marimastat, thalidomide,
                        trastuzumab, lapatinib, or bevacizumab).
                     </p>
                  </div>
                  <div id="sec-3" class="subsection">
                     <p id="p-3"><strong>Results</strong> We identified 370 eligible randomized trials (54 189 patients), of which 172 (31 552 patients) compared different types of
                        treatment. Survival data from 148 comparisons pertaining to 128 of the 172 trials (26 031 patients, 22 different types of
                        treatment) were available for inclusion in the multiple-treatments meta-analysis. Compared with single-agent chemotherapy
                        with old nonanthracycline drugs, anthracycline regimens achieved 22%–33% relative risk reductions in mortality (ie, hazard
                        ratio [HR] for standard-dose anthracycline-based combination: 0.67, 95% credibility interval [CrI] 0.57–0.78). Several newer
                        regimens achieved further benefits (eg, HR [95% CrI] 0.67 [0.55–0.81] for single-drug taxane, 0.64 [0.53–0.78] for combination
                        of anthracyclines with taxane, 0.49 [0.37–0.67] for taxane-based combination with capecitabine or gemcitabine), and similar
                        benefits were seen with several regimens including molecular targeted treatments. Most regimens had very similar efficacy
                        profiles (&lt;5% difference in HR) as first- and subsequent-line therapies.
                     </p>
                  </div>
                  <div id="sec-4" class="subsection">
                     <p id="p-4"><strong>Conclusions</strong> Stepwise improvements in efficacy of chemotherapy and targeted treatments cumulatively have achieved major improvements in
                        the survival of patients with advanced breast cancer. Many options that can be used in first and subsequent lines of therapy
                        have comparable efficacy profiles.
                     </p>
                  </div>
               </div>
               <p id="p-5">
                  <div class="boxed-text" id="boxed-text-1">
                     <div id="sec-5" class="subsection">
                        <h4>Context and Caveats</h4>
                        <div id="sec-6" class="subsection">
                           <h5>Prior knowledge</h5>
                           <p id="p-6">Although many nonhormonal regimens for advanced breast cancer have been evaluated across hundreds of randomized clinical trials,
                              the relative merits of these regimens were not known with precision.
                           </p>
                        </div>
                        <div id="sec-7" class="subsection">
                           <h5>Study design</h5>
                           <p id="p-7">Multiple-treatments meta-analysis of survival data based upon direct and indirect comparisons to estimate hazard ratios for
                              different chemotherapy regimens as first- and subsequent-line treatments relative to older nonanthracycline single-agent therapy.
                           </p>
                        </div>
                        <div id="sec-8" class="subsection">
                           <h5>Contribution</h5>
                           <p id="p-8">This study quantified the survival gains of 21 different classes of therapy relative to older single-agent therapy.</p>
                        </div>
                        <div id="sec-9" class="subsection">
                           <h5>Implications</h5>
                           <p id="p-9">Whether used in first or subsequent lines of therapy, many classes of modern breast cancer therapy, including anthracyclines,
                              taxanes, novel non-taxane agents, and molecular targeted therapies used in the context of single-agent or combination therapy,
                              produce gains in absolute survival over older single agents.
                           </p>
                        </div>
                        <div id="sec-10" class="subsection">
                           <h5>Limitations</h5>
                           <p id="p-10">A comprehensive understanding of the effectiveness of newer molecular targeted therapies will require additional trial information.
                              The extent of intertrial variability and its effect on the results of the meta-analysis cannot be known with certainty.
                           </p>
                           <p id="p-11"><em>From the Editors</em></p>
                        </div>
                     </div>
                  </div>
               </p>
               <p id="p-12">The morbidity band mortality impact of breast cancer is very large worldwide (1-3) and treatment can be challenging. Many
                  pharmacological compounds and administration modalities have been developed for the treatment of advanced breast cancer (<a id="xref-ref-4-1" class="xref-bibr" href="#ref-4">4</a>). Key milestones in the systemic treatments for breast cancer were the introduction of hormonal treatment in the 1940s (<a id="xref-ref-5-1" class="xref-bibr" href="#ref-5">5</a>), combined chemotherapy in 1969, and anthracyclines in 1972 (<a id="xref-ref-6-1" class="xref-bibr" href="#ref-6">6</a>). In the 1990s, gemcitabine, vinorelbine, and capecitabine also entered clinical care, followed by taxanes. Additional expensive
                  targeted treatments were introduced in the last decade.
               </p>
               <p id="p-13">Although progress has been achieved in the field and patients live longer, the relative merits of the many different chemotherapy
                  and targeted treatment regimens are not well understood. Hundreds of trials have been conducted to compare treatments for
                  advanced breast cancer, but because each has compared only two or a few treatments, it is difficult to integrate information
                  on the relative efficacy of all tested regimens. This integration is important because different regimens vary both in cost
                  and in toxicity. Therefore, we performed a comprehensive systematic review of chemotherapy and targeted treatment regimens
                  in advanced breast cancer and evaluated, through a multiple-treatments meta-analysis (<a id="xref-ref-7-1" class="xref-bibr" href="#ref-7">7</a>,<a id="xref-ref-8-1" class="xref-bibr" href="#ref-8">8</a>), the relative merits of the many different regimens used to prolong survival in advanced breast cancer patients. Data were
                  analyzed on all eligible trials as well as separately for first- and subsequent-line treatment.
               </p>
               <div class="section methods" id="sec-11">
                  <div class="section-nav"><a href="#abstract-1" title="Abstract" class="prev-section-link"><span>Previous Section</span></a><a href="#sec-17" title="Results" class="next-section-link"><span>Next Section</span></a></div>
                  <h2>Methods</h2>
                  <div id="sec-12" class="subsection">
                     <h3>Identification of Randomized Studies</h3>
                     <p id="p-14">We searched for randomized studies in any language in PubMed and the Cochrane Central Registry of Controlled Trials looking
                        for studies with the key words mammary or breast that also contained the search terms cancer, malign*, neoplasm*, or carcinoma*.
                        The last search update was done on October 9, 2007. PubMed searches used the restriction limit: randomized controlled trial.
                        We searched the reference lists of every primary study and also retrieved previous meta-analyses addressing comparisons of
                        regimens in advanced breast cancer. Considering the recent introduction of targeted treatment agents and the paucity of information
                        available to date on these agents, we ensured that electronic searches would not miss any major reports of eligible studies
                        by hand-searching the volumes published from 2004 to 2007 inclusive of the three journals with the highest number of electronically
                        identified cancer trials (<a id="xref-ref-9-1" class="xref-bibr" href="#ref-9">9</a>). Furthermore, because recent trials with novel or targeted treatment agents may still be unpublished, we also reviewed abstract
                        books and presentations of major recent meetings in 2006–2007 of the American Society of Clinical Oncology, the European Society
                        of Clinical Oncology, and the European Cancer Conference to identify any other trial that had presented final (not preliminary)
                        data on drugs that were already studied in the published trials and comparisons that would be eligible for consideration in
                        the multiple-treatments meta-analysis. Earlier meeting abstracts were not included.
                     </p>
                  </div>
                  <div id="sec-13" class="subsection">
                     <h3>Eligibility Criteria</h3>
                     <p id="p-15">We considered all randomized trials that compared at least two arms of different regimens involving chemotherapy and/or targeted
                        treatments in patients with advanced breast adenocarcinoma in any line of treatment. Advanced-stage disease was defined by
                        the presence of metastatic or recurrent disease that was not amenable to surgical treatment. We excluded trials on earlier
                        stages of the disease (when trials included both advanced and earlier stage, we included only the relevant population) and
                        trials comparing regimens in breast malignancies other than adenocarcinoma (inflammatory breast cancer, sarcoma, etc). We
                        also excluded nonrandomized and pseudo-randomized trials (eg, those with alternate allocation of subjects). If trials included
                        other concomitant interventions such as hormonal treatment, surgery, radiotherapy, or radioisotopic treatment that differed
                        systematically between the investigated arms, they were excluded. Whenever reports pertained to sets of patients that overlapped,
                        only the report with longest follow-up (having the largest number of events) was used in the analysis.
                     </p>
                  </div>
                  <div id="sec-14" class="subsection">
                     <h3>Data Extraction</h3>
                     <p id="p-16">From each eligible trial, we recorded authors’ names, journal and year of publication, country of origin (as noted in their
                        affiliations), years of patient enrolment, sample size (randomized and analyzed) per arm, performance status, regimens used,
                        line of treatment, additional treatments given to both arms, and information pertaining to study design (whether the trial
                        reported the mode of randomization, allocation concealment, description of withdrawals per arm, and blinding). We also recorded
                        the median survival per arm and whether there was any statistically significant difference (<em>P</em> &lt; .05) in median survival between any compared arms.
                     </p>
                     <p id="p-17">For trials comparing different types of treatment (as defined below), we also extracted or estimated the logarithm of the
                        hazard ratio for death and its variance. We used the hazard ratio and 95% confidence intervals from Cox regressions, as reported
                        or retrieved by contacting the investigators. Unadjusted hazard ratios were preferred over multivariable ones. If only the
                        variance of the hazard ratio was unavailable, we calculated it using the log-rank <em>P</em> value. When neither hazard ratio nor variance was available, we estimated the variance as (<em>T</em><sub>1</sub> + <em>T</em><sub>2</sub>)<sup>2</sup>/[(<em>E</em><sub>1</sub> + <em>E</em><sub>2</sub>)<em>T</em><sub>1</sub><em>T</em><sub>2</sub>], where <em>E</em><sub>1</sub> and <em>E</em><sub>2</sub> are the number of events and <em>T</em><sub>1</sub> and <em>T</em><sub>2</sub> the number of randomly assigned patients in each arm, and then estimated the log(HR), such that it would have the <em>P</em> value of the log-rank test (<a id="xref-ref-10-1" class="xref-bibr" href="#ref-10">10</a>). When <em>P</em> values were unavailable, the hazard ratio was approximated by the ratio of median survivals.
                     </p>
                     <p id="p-18">Data were independently extracted by two investigators (D. Mauri and N. P. Polyzos). Discrepancies were discussed with a third
                        investigator (J. P. A. Ioannidis). J. P. A. Ioannidis and G. Salanti also cross-checked against the original articles all
                        the data entered into calculations.
                     </p>
                  </div>
                  <div id="sec-15" class="subsection">
                     <h3>Categories for Analyses</h3>
                     <p id="p-19">In our analysis, we grouped the regimens into the following nine categories: anthracyclines, anthracenediones, non-taxane
                        novel chemotherapy agents (vinorelbine, gemcitabine, or capecitabine), taxanes, marimastat, thalidomide, trastuzumab, lapatinib,
                        and bevacizumab. Other compounds, such as cyclophosphamide, fluorouracil, methotrexate, mitomycin, vincristine, and vinblastine,
                        and all other agents not included in the previous categories were grouped in a miscellaneous category as old agents.
                     </p>
                     <p id="p-20">Considering that combined chemotherapy has been demonstrated to produce statistically significant survival advantages over
                        monotherapy (<a id="xref-ref-4-2" class="xref-bibr" href="#ref-4">4</a>,<a id="xref-ref-11-1" class="xref-bibr" href="#ref-11">11</a>), all categories of drugs analyzed were further split into combination therapies (when two or more different agents were
                        given together) or monotherapies. Regimens using lower dosages of anthracyclines may be inferior to those using higher doses
                        (<a id="xref-ref-4-3" class="xref-bibr" href="#ref-4">4</a>); thus, anthracycline-based regimens were further split into low and standard vs high doses. The anthracycline dose equivalence
                        for doxorubicin and epirubicin was derived from isodose studies (<a id="xref-ref-12-1" class="xref-bibr" href="#ref-12">12</a>). For monotherapy, we considered as low dose a 21-day dose intensity of less than 60 mg/m<sup>2</sup> doxorubicin or less than 78 mg/m<sup>2</sup> epirubicin. For combination treatment, we designated low dose as a 21-day dose intensity of less than 45 mg/m<sup>2</sup> doxorubicin or less than 58 mg/m<sup>2</sup> epirubicin. For mitoxantrone monotherapy, we designated as low dose a 21-day dose intensity of less than 12 mg/m<sup>2</sup>; a low dose for combination regimens was a 21-day dose intensity of less than 8 mg/m<sup>2</sup>.
                     </p>
                  </div>
                  <div id="sec-16" class="subsection">
                     <h3>Statistical Analyses</h3>
                     <p id="p-21">We generated descriptive statistics for trial and study population characteristics across all eligible trials. We described
                        the types of comparisons and how these had evolved over time. We used the probability of interspecific encounter (PIE) and
                        PIE′ metrics to evaluate the diversity of the network, and the <em>C</em> metric to measure co-occurrence. Details of these metrics have been described previously (<a id="xref-ref-13-1" class="xref-bibr" href="#ref-13">13</a>). In brief, a PIE of less than 0.75 suggests that there is lack of diversity, which could be due to either few regimens or
                        large unevenness of available evidence across the represented regimens. The PIE′ index divides PIE by the maximum possible
                        PIE given the number of regimens and thus removes the effect of the number of regimens in the estimation of diversity. The
                        <em>C</em> test, based on a permutation procedure, examines whether there are pairs of regimens in the networks that are systematically
                        preferred or avoided, after accounting for the overall frequency of representation of each regimen in the network.
                     </p>
                     <p id="p-22">Quantitative analyses of mortality were limited to trials that compared different types of chemotherapy. In the multiple-treatments
                        meta-analyses, we also performed subgroup analyses for first- and subsequent-line treatment.
                     </p>
                     <p id="p-23">We conducted a series of “head-to-head” meta-analyses with a random effects model. Between-study heterogeneity was estimated
                        using the <em>I</em><sup>2</sup> statistic; typically, values greater than 50% are considered large, 25%–50% modest, and less than 25% low heterogeneity.
                        These estimates can have large uncertainty, especially in the presence of few trials, and should be interpreted cautiously
                        (<a id="xref-ref-14-1" class="xref-bibr" href="#ref-14">14</a>).
                     </p>
                     <p id="p-24">Multiple-treatments meta-analysis synthesizes information from a network of trials (<a id="xref-ref-7-2" class="xref-bibr" href="#ref-7">7</a>,<a id="xref-ref-10-2" class="xref-bibr" href="#ref-10">10</a>). It combines direct and indirect evidence on the relative effectiveness of two interventions A and B, respecting randomization.
                        Direct evidence comes from trials of A vs B. Indirect evidence, through an “intermediate” comparator C, comes by combining
                        trials of A vs C and of C vs B; many intermediate comparators are possible. Combination of the many sources of evidence increases
                        precision. Combination of direct and indirect evidence for any given treatment comparison can be extended over a complex network
                        of multiple treatments. We assumed a common heterogeneity parameter <em>τ</em><sup>2</sup> across all comparisons. The model applied to analyze the data is a Bayesian consistency model as described in reference 7.
                        From each trial (denoted with <em>i</em>) with, say, three randomized chemotherapy arms (say A, B, and C), we extract two hazard ratios (in log scale) with their
                        associated variances. We then model the observed log(HR<sub>AB,<em>i</em></sub>), log(HR<sub>AC,<em>i</em></sub>), which compare the effectiveness of A to B and C, respectively, as:<span class="disp-formula" id="disp-formula-1"><img class="inline-graphic" alt="Graphic" src="1780/embed/inline-graphic-1.gif" /></span></p>
                     <p id="p-25">where <em>ν</em> denotes the sample variance and <em>c</em> is the sample covariance between the log hazard ratios. The random effects <em>θ</em><sub>AB,<em>i</em></sub>, <em>θ</em><sub>AC,<em>i</em></sub> are subsequently combined across all studies that address the same comparison as:<span class="disp-formula" id="disp-formula-2"><img class="inline-graphic" alt="Graphic" src="1780/embed/inline-graphic-2.gif" /></span></p>
                     <p id="p-26">where <em>μ</em> is the summary effect of a specific comparison and <em>τ</em><sup>2</sup> is the between-study variance. In the simpler case, where a study has two arms only, the distributions above reduce to one
                        dimension. The idea described above extends to all reported regimen comparisons. In the Bayesian framework, effect sizes are
                        estimated along with 95% credibility intervals.
                     </p>
                     <p id="p-27">Multiple-treatments meta-analysis assumes that the different sources of evidence are coherent (<a id="xref-ref-8-2" class="xref-bibr" href="#ref-8">8</a>,<a id="xref-ref-15-1" class="xref-bibr" href="#ref-15">15</a>–<a id="xref-ref-17-1" class="xref-bibr" href="#ref-17">17</a>). On the top of the estimation of heterogeneity in each head-to-head comparison, we also estimate the incoherence (disagreement
                        between direct and indirect evidence) in each closed loop in the network. Except for one loop with modest incoherence, no
                        incoherence was noted.
                     </p>
                     <p id="p-28">Analyses were conducted in WinBUGS 1.4 (MRC Biostatistics Unit, Cambridge, UK; <a href="http://www.mrc-bsu.cam.ac.uk/bugs/winbugs/contents.shtml">http://www.mrc-bsu.cam.ac.uk/bugs/winbugs/contents.shtml</a>) and S-PLUS 8 (Insightful Corporation, Seattle, WA; <a href="http://www.insightful.com">http://www.insightful.com</a>).
                     </p>
                  </div>
               </div>
               <div class="section results" id="sec-17">
                  <div class="section-nav"><a href="#sec-11" title="Methods" class="prev-section-link"><span>Previous Section</span></a><a href="#sec-22" title="Discussion" class="next-section-link"><span>Next Section</span></a></div>
                  <h2>Results</h2>
                  <div id="sec-18" class="subsection">
                     <h3>Eligible Trials</h3>
                     <p id="p-29">The 13 651 scrutinized reports yielded 367 eligible trials (<a id="xref-fig-1-1" class="xref-fig" href="#F1">Figure 1</a>). Another three eligible trials were identified from recent major meetings, bringing the total to 370 trials with 54 189
                        randomly assigned patients (<a id="xref-table-wrap-1-1" class="xref-table" href="#T1">Table 1</a>). Trials had been published for a period of 35 years (1973–2007), and most included only two arms. Two-thirds addressed first-line
                        treatment, and patients with poor performance status were either absent or a small minority in most trials. Most trials had
                        been performed in the United States or Europe, with approximately a quarter involving several countries. Details on the regimens
                        used over time appear in <a href="http://jnci.oxfordjournals.org/cgi/content/full/djn414/DC1">Supplementary Table 1</a> (available online,) and detailed study design information on all the 370 trials is available from the authors upon request.
                     </p>
                     <div class="table pos-float" id="T1">
                        <div class="table-inline">
                           <div class="callout"><span>View this table:</span><ul class="callout-links">
                                 <li><a href="1780/T1.expansion.html">In this window</a></li>
                                 <li><a class="in-nw" href="1780/T1.expansion.html">In a new window</a></li>
                              </ul>
                           </div>
                        </div>
                        <div class="table-caption"><span class="table-label">Table 1</span> 
                           <p id="p-30" class="first-child">Characteristics of the eligible trials*</p>
                           <div class="sb-div caption-clear"></div>
                        </div>
                     </div>
                     <div id="F1" class="fig pos-float odd">
                        <div class="fig-inline"><a href="1780/F1.expansion.html"><img alt="Figure 1" src="1780/F1.small.gif" /></a><div class="callout"><span>View larger version:</span><ul class="callout-links">
                                 <li><a href="1780/F1.expansion.html">In this window</a></li>
                                 <li><a class="in-nw" href="1780/F1.expansion.html">In a new window</a></li>
                              </ul>
                              <ul class="fig-services">
                                 <li class="ppt-link"><a href="/powerpoint/100/24/1780/F1">Download as PowerPoint Slide</a></li>
                              </ul>
                           </div>
                        </div>
                        <div class="fig-caption"><span class="fig-label">Figure 1</span> 
                           <p id="p-34" class="first-child">Flow chart for trial selection for multiple-treatments meta-analysis of chemotherapy and targeted therapies for advanced breast
                              cancer. Trials comparing the same types of chemotherapy were defined as those that compared regimens that were considered
                              the same type of treatment in our protocol.
                           </p>
                           <div class="sb-div caption-clear"></div>
                        </div>
                     </div>
                     <p id="p-35">Of the 370 trials, 32 presented formally statistically significant differences between arms in the original report (<a href="http://jnci.oxfordjournals.org/cgi/content/full/djn414/DC1">Supplementary Table 2</a>, available online). Of 198 trials comparing regimens that were categorized as the same type of treatment in our protocol,
                        only 8 (4%) presented formally statistically significant results. The other 172 trials with 31 552 patients compared different
                        types of treatment (<a id="xref-fig-1-2" class="xref-fig" href="#F1">Figure 1</a>; <a id="xref-table-wrap-1-2" class="xref-table" href="#T1">Table 1</a>).
                     </p>
                     <div class="table pos-float" id="T2">
                        <div class="table-inline">
                           <div class="callout"><span>View this table:</span><ul class="callout-links">
                                 <li><a href="1780/T2.expansion.html">In this window</a></li>
                                 <li><a class="in-nw" href="1780/T2.expansion.html">In a new window</a></li>
                              </ul>
                           </div>
                        </div>
                        <div class="table-caption"><span class="table-label">Table 2</span> 
                           <p id="p-36" class="first-child">Estimates of effect (HR and uncertainty 95% CI) for mortality in 45 direct comparisons*</p>
                           <div class="sb-div caption-clear"></div>
                        </div>
                     </div>
                  </div>
                  <div id="sec-19" class="subsection">
                     <h3>Comparisons of Different Types of Treatment</h3>
                     <p id="p-40">Of the 172 trials, survival data could be analyzed in 128 trials, representing 26 031 randomly assigned patients, of whom
                        25 850 were analyzed in the trials (<a href="http://jnci.oxfordjournals.org/cgi/content/full/djn414/DC1">Supplementary Table 3</a>, available online) (<a id="xref-ref-18-1" class="xref-bibr" href="#ref-18">18</a>–<a id="xref-ref-144-1" class="xref-bibr" href="#ref-144">144</a>). Data from 121 of these trials could be obtained from published reports, and data from the other seven were obtained by
                        contacting investigators (<a id="xref-ref-37-1" class="xref-bibr" href="#ref-37">37</a>,<a id="xref-ref-64-1" class="xref-bibr" href="#ref-64">64</a>,<a id="xref-ref-75-1" class="xref-bibr" href="#ref-75">75</a>,<a id="xref-ref-76-1" class="xref-bibr" href="#ref-76">76</a>,<a id="xref-ref-98-1" class="xref-bibr" href="#ref-98">98</a>,<a id="xref-ref-114-1" class="xref-bibr" href="#ref-114">114</a>,<a id="xref-ref-127-1" class="xref-bibr" href="#ref-127">127</a>). The 44 trials without analyzable survival information included 5521 patients and were mostly small phase 2 trials that
                        did not collect or present survival data. The meta-analysis included 148 comparisons (18 trials had more than two eligible
                        arms).
                     </p>
                     <div class="table pos-float" id="T3">
                        <div class="table-inline">
                           <div class="callout"><span>View this table:</span><ul class="callout-links">
                                 <li><a href="1780/T3.expansion.html">In this window</a></li>
                                 <li><a class="in-nw" href="1780/T3.expansion.html">In a new window</a></li>
                              </ul>
                           </div>
                        </div>
                        <div class="table-caption"><span class="table-label">Table 3</span> 
                           <p id="p-41" class="first-child">Multiple-treatments meta-analysis and subgroup analyses by line of treatment</p>
                           <div class="sb-div caption-clear"></div>
                        </div>
                     </div>
                     <p id="p-43">Twenty-two different types of treatment were represented in the 148 comparisons. The geometry of the network of comparisons
                        was complex (<a id="xref-fig-2-1" class="xref-fig" href="#F2">Figure 2</a>). Older regimens generally had somewhat more data than the more recently introduced regimens (<a id="xref-fig-2-2" class="xref-fig" href="#F2">Figure 2, A</a>). The PIE index for the network is 0.88, and the PIE′ is 0.96. Moreover, although regimens involving older agents had been
                        thoroughly compared against each other, most regimens involving novel agents, taxanes, and/or targeted treatments (the regimens
                        introduced more recently and thus shown with larger circles in <a id="xref-fig-2-3" class="xref-fig" href="#F2">Figure 2, B</a>) had been compared against one or few other comparator regimens. The co-occurrence index <em>C</em> was 132 (<em>P</em> &lt; 0.001), which suggests that there is a clear preference for specific comparisons (or avoidance for others), aside from
                        what would be expected according to the relative representation of each regimen in the network.
                     </p>
                     <div id="F2" class="fig pos-float odd">
                        <div class="fig-inline"><a href="1780/F2.expansion.html"><img alt="Figure 2" src="1780/F2.small.gif" /></a><div class="callout"><span>View larger version:</span><ul class="callout-links">
                                 <li><a href="1780/F2.expansion.html">In this window</a></li>
                                 <li><a class="in-nw" href="1780/F2.expansion.html">In a new window</a></li>
                              </ul>
                              <ul class="fig-services">
                                 <li class="ppt-link"><a href="/powerpoint/100/24/1780/F2">Download as PowerPoint Slide</a></li>
                              </ul>
                           </div>
                        </div>
                        <div class="fig-caption"><span class="fig-label">Figure 2</span> 
                           <p id="p-44" class="first-child">Network of eligible comparisons for the multiple-treatments meta-analysis. Thickness of connecting lines indicates the number
                              of available comparisons. <strong>A</strong>) The size of each node is proportional to the amount of information (sample size). <strong>B</strong>) A larger node means more recent year of first publication of a trial for this type of regimen. A c LD = low-dose anthracycline
                              (combination regimen); A c SD = standard-dose anthracycline (combination regimen); A s LD = low-dose anthracycline (single
                              agent); A s SD = standard-dose anthracycline (single agent); A+tzmb SD = standard-dose anthracycline + trastuzumab; AN SD
                              = standard-dose anthracycline + novel non-taxane agents; ANT SD = standard-dose anthracycline + novel non-taxane agents +
                              taxanes; AT SD = standard-dose anthracycline + taxanes; M c LD = low-dose mitoxantrone (combination regimen); M c SD = standard-dose
                              mitoxantrone (combination regimen); M s SD = standard-dose mitoxantrone (single agent); N c = novel non-taxane agents (combination
                              regimen); N s = novel non-taxane agents (single agent); N+bmab = novel non-taxane agents + bevacizumab (single agent); N+lpnb
                              = novel non-taxane agents + lapatinib; NT = novel non-taxane agents + taxanes; O c = old agents (combination regimen); O s
                              = old agents (single agent); Tc = taxanes (combination regimen); T s = taxanes (single agent); T+tzmb = taxanes + trastuzumab;
                              Ts+lpnb = taxanes + lapatinib.
                           </p>
                           <div class="sb-div caption-clear"></div>
                        </div>
                     </div>
                  </div>
                  <div id="sec-20" class="subsection">
                     <h3>Direct Comparisons</h3>
                     <p id="p-45">For 22 different types of chemotherapy, 231 different comparisons are theoretically possible, but only 45 of these (20%) had
                        been performed (<a id="xref-table-wrap-2-1" class="xref-table" href="#T2">Table 2</a>). Only 10 of these comparisons had been made in more than three trials; thus, the results of these analyses should be interpreted
                        very cautiously. Formally statistically significant differences were seen in 10 analyses, and an estimate consistent with
                        large heterogeneity (<em>I</em><sup>2</sup> &gt; 50%) was seen in five comparisons; uncertainty in the heterogeneity estimates is unavoidably large with few trials per
                        analysis.
                     </p>
                     <p id="p-46">In particular, old agents as monotherapy were formally statistically inferior to novel non-taxane agents, low-dose anthracycline-based
                        combinations, standard-dose anthracycline, and combinations of the same old agents. Formally statistically significant improvement
                        in survival with the use of combined agents vs single agents was found in six comparisons; conversely, monotherapy with novel
                        non-taxane agents fared better than combinations of old agents. The combination of old agents was statistically significantly
                        inferior to standard-dose anthracycline-based combinations as well but was better than low-dose anthracycline monotherapy.
                        Survival benefits were observed when taxanes were combined with novel non-taxane agents or trastuzumab (<a id="xref-table-wrap-2-2" class="xref-table" href="#T2">Table 2</a>).
                     </p>
                  </div>
                  <div id="sec-21" class="subsection">
                     <h3>Multiple-Treatments Meta-analysis</h3>
                     <p id="p-47">Data derived from direct and indirect evidence were analyzed in the multiple-treatment meta-analysis. Results are expressed
                        for convenience as hazard ratio relative to the regimen of monotherapy with an old agent (<a id="xref-table-wrap-3-1" class="xref-table" href="#T3">Table 3</a>). Taxanes in combination with novel agents, trastuzumab, or old agents, had the largest decrease in mortality risk (hazard
                        ratios [HRs] 0.49, 0.50, and 0.53, respectively). Considerable survival benefits, relative to monotherapy with an old agent,
                        were observed for taxanes in combination with lapatinib, anthracyclines, or both anthracycline + novel non-taxane agents (HRs
                        = 0.57, 0.64, and 0.56, respectively). Combination of trastuzumab with standard-dose anthracyclines offered similar benefits
                        (HR = 0.55). Taxanes as single agents and standard-dose anthracyline-based combinations reduced mortality risk by approximately
                        one-third (HR = 0.67). Old combination regimens without anthracyclines or taxanes achieved a 25% relative risk reduction in
                        mortality.
                     </p>
                     <p id="p-48">Therapy line–specific effect estimates were similar to estimates for all available comparisons regardless of line. Effect
                        estimates for the overall analysis and first-line trials only typically differed by less than 5%. Subsequent-line treatment
                        data were more sparse and thus less conclusive, but the overall pattern did not differ, with the exception of a trend for
                        lower efficacy for anthracycline-based combinations when compared with the first-line setting (<a id="xref-table-wrap-3-2" class="xref-table" href="#T3">Table 3</a>).
                     </p>
                     <p id="p-49">When plotting hazard ratios as a function of the year of publication of the first trial that used each type of treatment (<a id="xref-fig-3-1" class="xref-fig" href="#F3">Figure 3</a>), it appeared that early regimens such as combination of old agents and anthracycline-based regimens achieved a 25%–30% relative
                        risk reduction, with little further progress for two decades; the introduction of additional agents attained larger (30%–50%)
                        relative risk reductions.
                     </p>
                     <div id="F3" class="fig pos-float odd">
                        <div class="fig-inline"><a href="1780/F3.expansion.html"><img alt="Figure 3" src="1780/F3.small.gif" /></a><div class="callout"><span>View larger version:</span><ul class="callout-links">
                                 <li><a href="1780/F3.expansion.html">In this window</a></li>
                                 <li><a class="in-nw" href="1780/F3.expansion.html">In a new window</a></li>
                              </ul>
                              <ul class="fig-services">
                                 <li class="ppt-link"><a href="/powerpoint/100/24/1780/F3">Download as PowerPoint Slide</a></li>
                              </ul>
                           </div>
                        </div>
                        <div class="fig-caption"><span class="fig-label">Figure 3</span> 
                           <p id="p-50" class="first-child">Hazard ratios for mortality using monotherapy, with old agent as the reference comparator as a function of the first year
                              of publication of a trial for each type of treatment. The abbreviated name of each regimen is placed at the point representing
                              the first year of publication, and the hazard ratio estimated from the multiple-treatments meta-analysis. Also shown is a
                              <strong>spline fitted line</strong>. In <strong>dashed lines</strong> are the piecewise 95% credibility intervals. A c LD = low-dose anthracycline (combination regimen); A c SD = standard-dose
                              anthracycline (combination regimen); A s LD = Low-dose anthracycline (single agent); A s SD = standard-dose anthracycline
                              (single agent); A+tzmbSD = standard-dose anthracycline + trastuzumab; AN SD = standard-dose anthracycline + novel non-taxane
                              agents; ANT SD = standard-dose anthracycline + novel non-taxane agents + taxanes; AT SD = standard-dose anthracycline + taxanes;
                              M c LD = low-dose mitoxantrone (combination regimen); M c SD = standard-dose mitoxantrone (combination regimen); M s SD =
                              standard-dose mitoxantrone (single agent); N c = novel non-taxane agents (combination regimen); Ns = novel non-taxane agents
                              (single agent); N+bmab = novel non-taxane agents + bevacizumab (single agent); N+lpnb = novel non-taxane agents + lapatinib;
                              NT = novel non-taxane agents + taxanes; O c = old agents (combination regimen); T c = taxanes (combination regimen); T s =
                              taxanes (single agent); T+tzmb = taxanes + trastuzumab; Ts+lpnb = taxanes + lapatinib.
                           </p>
                           <div class="sb-div caption-clear"></div>
                        </div>
                     </div>
                  </div>
               </div>
               <div class="section discussion" id="sec-22">
                  <div class="section-nav"><a href="#sec-17" title="Results" class="prev-section-link"><span>Previous Section</span></a><a href="#sec-23" title="Funding" class="next-section-link"><span>Next Section</span></a></div>
                  <h2>Discussion</h2>
                  <p id="p-51">Our meta-analysis quantifies the progress achieved in the treatment of advanced breast cancer with nonhormonal systemic treatment
                     in the last 35 years. Several regimens have shown effectiveness, and for some of them, the treatment effects are practically
                     indistinguishable in magnitude. Given that subsequent lines of treatment can confer similar relative benefits as the first-line
                     setting, one can exploit the survival benefits conferred by several effective regimens used in sequential fashion. For example,
                     if three regimens are used, each one prolonging survival by 1 year for a patient who would have had 1 year of survival without
                     effective treatment, life expectancy may be quadrupled. The availability of multiple effective options suggests that it is
                     essential to identify appropriate indications for timely changes of regimens in patients in whom treatment is no longer effective.
                  </p>
                  <p id="p-52">Progress in chemotherapeutic treatment of advanced breast cancer has been stepwise. After the achievement of a 25% reduction
                     in the risk of death in 1975 with the use of anthracycline-based combination regimens (<a id="xref-ref-145-1" class="xref-bibr" href="#ref-145">145</a>), little additional progress was made for almost two decades. Subsequently, several new agents (vinorelbine, gemcitabine,
                     capecitabine, taxanes, and molecular targeted treatments) were introduced that proved more effective (<a id="xref-ref-58-1" class="xref-bibr" href="#ref-58">59</a>,<a id="xref-ref-84-1" class="xref-bibr" href="#ref-84">85</a>,<a id="xref-ref-146-1" class="xref-bibr" href="#ref-146">146</a>–<a id="xref-ref-148-1" class="xref-bibr" href="#ref-148">148</a>). These agents have not yet been tested in all possible combinations. Moreover, less data have been collected on combinations
                     involving these newer agents than are available for the standard earlier treatments. Comparisons for which there is at present
                     little or no data should be the focus of future investigations so that more direct evidence about the relative merits of these
                     regimens can be obtained.
                  </p>
                  <p id="p-53">Interventions should be tailored to the individual patient, and benefits should be weighed against adverse events for each
                     treatment. Toxicity should not be underestimated. For example, taxane-based combinations that include capecitabine and gemcitabine
                     cause serious hematologic toxicity, diarrhea, mucositis, hand–foot syndrome, neurosensory disorders, and fatigue (<a id="xref-ref-39-1" class="xref-bibr" href="#ref-39">39</a>,<a id="xref-ref-125-1" class="xref-bibr" href="#ref-125">125</a>,<a id="xref-ref-128-1" class="xref-bibr" href="#ref-128">128</a>). Administration of anthracycline with trastuzumab was associated with major cardiotoxicity (<a id="xref-ref-84-2" class="xref-bibr" href="#ref-84">84</a>), and preliminary data (<a id="xref-ref-149-1" class="xref-bibr" href="#ref-149">149</a>) suggest that the combination of gefitinib with docetaxel is very toxic. Very few patients with poor performance status,
                     who may be especially susceptible to adverse effects, have been enrolled in recent trials.
                  </p>
                  <p id="p-54">Our meta-analysis includes data on results of treatment with trastuzumab, bevacizumab, and lapatinib as of October 2007. The
                     available data on lapatinib and bevacizumab in particular are quite limited. After data freeze and analysis, a trial on 722
                     patients (<a id="xref-ref-150-1" class="xref-bibr" href="#ref-150">150</a>) was published, showing no statistically significant survival benefit with bevacizumab + paclitaxel vs paclitaxel, but clear
                     benefit was seen for disease progression. It is possible that many patients switched treatment upon disease progression and
                     that this may have eroded any survival difference. With many available treatment options and early switches to other effective
                     agents, differences in survival by intention to treat may become small. Cautious optimism as to the effectiveness of molecular
                     targeted treatments is needed until more data accumulate, and it is important to correctly identify the patients who would
                     benefit from them. Targeted therapies are not appropriate for all breast cancer patients. Trastuzumab and lapatinib are effective
                     in treating HER2-positive cancers, but these account only for approximately 20% of breast cancers (<a id="xref-ref-129-1" class="xref-bibr" href="#ref-129">129</a>). Although molecular targeted therapies have an increasing range of applications for different cancers, trials with less
                     impressive results (not stopped early) may still be ongoing, and the complete picture of effectiveness and toxicity has not
                     yet emerged.
                  </p>
                  <p id="p-55">Overall, it would be useful to design trials that fill in important gaps for key treatment comparisons that have minimal or
                     no information. For some treatment comparisons in the examined network of treatments, no direct evidence was available, and
                     thus, evaluation of incoherence (ie, the extent of disagreement between direct and indirect evidence) was also impossible.
                  </p>
                  <p id="p-56">Furthermore, it has to be considered that over time, anthracycline- and taxane-based chemotherapy has been increasingly used
                     for the treatment of early-stage disease. Thus, estimates of the relative merits of these agents in the advanced setting could
                     be in part biased by when the study was conducted.
                  </p>
                  <p id="p-57">Also in the last three decades, there has been much change in supportive care of cancer patients. Thus, there is uncertainty
                     as to the validity of the transitivity assumption (ie, that the treatment effect of a regimen does not change over time) for
                     early introduced regimens. Would the relative risk reduction be the same as several decades ago, if early trials were to be
                     repeated? Obviously, repetition of the trials is not feasible for ethical reasons. Changes in supportive care and other adjunct
                     management would certainly change the absolute survival for both compared arms, but there is no strong reason to believe that
                     these changes would influence the relative performance of the compared regimens, and it is the relative performance of one
                     regimen vs the other that enters in the multiple-treatments meta-analysis calculations.
                  </p>
                  <p id="p-58">A possible limitation of the current analysis is that it is based on published group data, rather than individual patient
                     information. However, we have included patients across a rather narrow range of prognoses, namely, metastatic breast cancer
                     (stage IV). Individual patient data might allow a more detailed appraisal of outcomes at different risk groups (<a id="xref-ref-151-1" class="xref-bibr" href="#ref-151">151</a>). Still, the power to detect effect modifications might still be limited even with individual patient information in such
                     a complex network of multiple treatments. The available data for each regimen are relatively limited, and thus, strong inferences
                     about the specific superiority of one particular regimen should be avoided. Finally, given the retrospective nature of the
                     meta-analysis, publication bias and selective reporting biases cannot be excluded. Although such biases may affect sporadic
                     comparisons, they are unlikely to refute the overall picture of progress. Prospective registration of trials has been adopted
                     in the last few years. Registration, if complete and transparent, would allow updating this and similar analyses with more
                     comprehensive information and keeping track of the improvements in the treatment of advanced breast cancer.
                  </p>
               </div>
               <div class="section" id="sec-23">
                  <div class="section-nav"><a href="#sec-22" title="Discussion" class="prev-section-link"><span>Previous Section</span></a><a href="#fn-group-1" title="Footnotes" class="next-section-link"><span>Next Section</span></a></div>
                  <h2>Funding</h2>
                  <p id="p-59">There was no funding source for this study.</p>
               </div>
               <div class="section fn-group" id="fn-group-1">
                  <div class="section-nav"><a href="#sec-23" title="Funding" class="prev-section-link"><span>Previous Section</span></a><a href="#ref-list-1" title="References" class="next-section-link"><span>Next Section</span></a></div>
                  <h2>Footnotes</h2>
                  <ul>
                     <li class="fn" id="fn-8">
                        <p id="p-60">The original idea was developed by J. P. A. Ioannidis and N. Pavlidis. All the authors participated in the design of the study;
                           D. Mauri, N. P. Polyzos, and J. P. A. Ioannidis participated in data extraction; G. Salanti and J. P. A. Ioannidis performed
                           the statistical analyses; all the authors interpreted the results; D. Mauri and J. P. A. Ioannidis wrote the manuscript and
                           all other authors commented critically on it. All the authors approved the final version. The corresponding author had full
                           access to all the data in the study and had final responsibility for the decision to submit for publication.
                        </p>
                     </li>
                     <li class="fn" id="fn-9">
                        <p id="p-61">All authors declare that they have no conflicts of interest.</p>
                     </li>
                     <li class="fn" id="fn-10">
                        <p id="p-62">We are grateful to Dr Evangelos Briasoullis for helpful discussions and to Dr Lamprini Tsali for help in data collection.</p>
                     </li>
                  </ul>
               </div>
               <ul>
                  <li class="fn" id="copyright-statement-1">© The Author 2008. Published by Oxford University Press.</li>
               </ul>
               <div class="section ref-list" id="ref-list-1">
                  <div class="section-nav"><a href="#fn-group-1" title="Footnotes" class="prev-section-link"><span>Previous Section</span></a><div class="nav-placeholder"> </div>
                  </div>
                  <h2>References</h2>
                  <ol class="cit-list ref-use-labels">
                     <li><span class="ref-label">1.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.1"
                             data-doi="10.3322/canjclin.55.2.74">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Parkin</span>  <span class="cit-name-given-names">DM</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Bray</span>  <span class="cit-name-given-names">F</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Ferlay</span>  <span class="cit-name-given-names">J</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Pisani</span>  <span class="cit-name-given-names">P</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Global cancer statistics, 2002</span>. <abbr class="cit-jnl-abbrev">CA Cancer J Clin</abbr> <span class="cit-pub-date">2005</span>;<span class="cit-vol">55</span>(<span class="cit-issue">2</span>):<span class="cit-fpage">74</span>-<span class="cit-lpage">108</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.3322/canjclin.55.2.74&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=15761078&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000231484000005&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Global%20cancer%20statistics%2C%202002&amp;author=DM%20Parkin&amp;author=F%20Bray&amp;author=J%20Ferlay&amp;author=P%20Pisani&amp;publication_year=2005&amp;journal=CA%20Cancer%20J%20Clin&amp;volume=55&amp;issue=2&amp;pages=74-108">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">2.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.2"
                             data-doi="10.3322/canjclin.57.1.43">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Jemal</span>  <span class="cit-name-given-names">A</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Siegel</span>  <span class="cit-name-given-names">R</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Ward</span>  <span class="cit-name-given-names">E</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Murray</span>  <span class="cit-name-given-names">T</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Xu</span>  <span class="cit-name-given-names">J</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Thun</span>  <span class="cit-name-given-names">MJ</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Cancer statistics, 2007</span>. <abbr class="cit-jnl-abbrev">CA Cancer J Clin</abbr> <span class="cit-pub-date">2007</span>;<span class="cit-vol">57</span>(<span class="cit-issue">1</span>):<span class="cit-fpage">43</span>-<span class="cit-lpage">66</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.3322/canjclin.57.1.43&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=17237035&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000244007900008&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Cancer%20statistics%2C%202007&amp;author=A%20Jemal&amp;author=R%20Siegel&amp;author=E%20Ward&amp;author=T%20Murray&amp;author=J%20Xu&amp;author=MJ%20Thun&amp;publication_year=2007&amp;journal=CA%20Cancer%20J%20Clin&amp;volume=57&amp;issue=1&amp;pages=43-66">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">3.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.3"
                             data-doi="10.1093/annonc/mdl498">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Ferlay</span>  <span class="cit-name-given-names">J</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Autier</span>  <span class="cit-name-given-names">P</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Boniol</span>  <span class="cit-name-given-names">M</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Heanue</span>  <span class="cit-name-given-names">M</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Colombet</span>  <span class="cit-name-given-names">M</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Boyle</span>  <span class="cit-name-given-names">P</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Estimates of the cancer incidence and mortality in Europe in 2006</span>. <abbr class="cit-jnl-abbrev">Ann Oncol</abbr> <span class="cit-pub-date">2007</span>;<span class="cit-vol">18</span>(<span class="cit-issue">3</span>):<span class="cit-fpage">581</span>-<span class="cit-lpage">592</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=annonc&amp;resid=18/3/581"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">4.</span><a class="rev-xref-ref" href="#xref-ref-4-1" title="View reference 4. in text"
                           id="ref-4">↵</a><div class="cit ref-cit ref-journal" id="cit-100.24.1780.4">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Fossati</span>  <span class="cit-name-given-names">R</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Confalonieri</span>  <span class="cit-name-given-names">C</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Torri</span>  <span class="cit-name-given-names">V</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving
                                    31 510 women</span>. <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr> <span class="cit-pub-date">1998</span>;<span class="cit-vol">16</span>(<span class="cit-issue">10</span>):<span class="cit-fpage">3439</span>-<span class="cit-lpage">3460</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=16/10/3439"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">5.</span><a class="rev-xref-ref" href="#xref-ref-5-1" title="View reference 5. in text"
                           id="ref-5">↵</a><div class="cit ref-cit ref-journal" id="cit-100.24.1780.5"
                             data-doi="10.1136/bmj.2.4368.393">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Haddow</span>  <span class="cit-name-given-names">A</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Watkinson</span>  <span class="cit-name-given-names">JM</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Paterson</span>  <span class="cit-name-given-names">E</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Influence of synthetic oestrogens upon advanced malignant disease</span>. <abbr class="cit-jnl-abbrev">Br Med J</abbr> <span class="cit-pub-date">1944</span>;<span class="cit-vol">2</span>(<span class="cit-issue">4368</span>):<span class="cit-fpage">393</span>-<span class="cit-lpage">408</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=PDF&amp;journalCode=bmj&amp;resid=2/4368/393"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">6.</span><a class="rev-xref-ref" href="#xref-ref-6-1" title="View reference 6. in text"
                           id="ref-6">↵</a><div class="cit ref-cit ref-journal" id="cit-100.24.1780.6"
                             data-doi="10.1021/jm00241a013">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Arcamone</span>  <span class="cit-name-given-names">F</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Penco</span>  <span class="cit-name-given-names">S</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Vigevani</span>  <span class="cit-name-given-names">A</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Synthesis and antitumor properties of new glycosides of daumomycinone and adriamycinone</span>. <abbr class="cit-jnl-abbrev">J Med Chem.</abbr> <span class="cit-pub-date">1975</span>;<span class="cit-vol">18</span>(<span class="cit-issue">7</span>):<span class="cit-fpage">703</span>-<span class="cit-lpage">707</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1021/jm00241a013&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=168385&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1975AG10800012&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Synthesis%20and%20antitumor%20properties%20of%20new%20glycosides%20of%20daumomycinone%20and%20adriamycinone&amp;author=F%20Arcamone&amp;author=S%20Penco&amp;author=A%20Vigevani&amp;publication_year=1975&amp;journal=J%20Med%20Chem.&amp;volume=18&amp;issue=7&amp;pages=703-707">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">7.</span><a class="rev-xref-ref" href="#xref-ref-7-1" title="View reference 7. in text"
                           id="ref-7">↵</a><div class="cit ref-cit ref-journal" id="cit-100.24.1780.7"
                             data-doi="10.1177/0962280207080643">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Salanti</span>  <span class="cit-name-given-names">G</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Higgins</span>  <span class="cit-name-given-names">J</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Ades</span>  <span class="cit-name-given-names">AE</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Ioannidis</span>  <span class="cit-name-given-names">JP</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Evaluation of networks of randomized trials</span>. <abbr class="cit-jnl-abbrev">Stat Methods Med Res.</abbr> <span class="cit-pub-date">2008</span>;<span class="cit-vol">17</span>(<span class="cit-issue">3</span>):<span class="cit-fpage">279</span>-<span class="cit-lpage">301</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=spsmm&amp;resid=17/3/279"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">8.</span><a class="rev-xref-ref" href="#xref-ref-8-1" title="View reference 8. in text"
                           id="ref-8">↵</a><div class="cit ref-cit ref-journal" id="cit-100.24.1780.8"
                             data-doi="10.1136/bmj.331.7521.897">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Caldwell</span>  <span class="cit-name-given-names">DM</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Ades</span>  <span class="cit-name-given-names">AE</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Higgins</span>  <span class="cit-name-given-names">JP</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Simultaneous comparison of multiple treatments: combining direct and indirect evidence</span>. <abbr class="cit-jnl-abbrev">BMJ</abbr> <span class="cit-pub-date">2005</span>;<span class="cit-vol">331</span>(<span class="cit-issue">7521</span>):<span class="cit-fpage">897</span>-<span class="cit-lpage">900</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=FULL&amp;journalCode=bmj&amp;resid=331/7521/897"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">9.</span><a class="rev-xref-ref" href="#xref-ref-9-1" title="View reference 9. in text"
                           id="ref-9">↵</a><div class="cit ref-cit ref-journal" id="cit-100.24.1780.9"
                             data-doi="10.1002/sim.1191">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Hopewell</span>  <span class="cit-name-given-names">S</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Clarke</span>  <span class="cit-name-given-names">M</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Lusher</span>  <span class="cit-name-given-names">A</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Lefebvre</span>  <span class="cit-name-given-names">C</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Westby</span>  <span class="cit-name-given-names">M</span></span></li>
                              </ol><cite>. <span class="cit-article-title">A comparison of handsearching versus MEDLINE searching to identify reports of randomized controlled trials</span>. <abbr class="cit-jnl-abbrev">Stat Med</abbr> <span class="cit-pub-date">2002</span>;<span class="cit-vol">21</span>(<span class="cit-issue">11</span>):<span class="cit-fpage">1625</span>-<span class="cit-lpage">1634</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1002/sim.1191&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=12111923&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000176016900009&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=A%20comparison%20of%20handsearching%20versus%20MEDLINE%20searching%20to%20identify%20reports%20of%20randomized%20controlled%20trials&amp;author=S%20Hopewell&amp;author=M%20Clarke&amp;author=A%20Lusher&amp;author=C%20Lefebvre&amp;author=M%20Westby&amp;publication_year=2002&amp;journal=Stat%20Med&amp;volume=21&amp;issue=11&amp;pages=1625-1634">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">10.</span><a class="rev-xref-ref" href="#xref-ref-10-1" title="View reference 10. in text"
                           id="ref-10">↵</a><div class="cit ref-cit ref-journal" id="cit-100.24.1780.10">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Glenny</span>  <span class="cit-name-given-names">AM</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Altman</span>  <span class="cit-name-given-names">DG</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Song</span>  <span class="cit-name-given-names">F</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Indirect comparisons of competing interventions</span>. <abbr class="cit-jnl-abbrev">Health Technol Assess</abbr> <span class="cit-pub-date">2005</span>;<span class="cit-vol">9</span>(<span class="cit-issue">26</span>):<span class="cit-fpage">1</span>-<span class="cit-lpage">134</span>. <span class="cit-comment">iii–iv</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=15985189&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000230929600001&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Indirect%20comparisons%20of%20competing%20interventions&amp;author=AM%20Glenny&amp;author=DG%20Altman&amp;author=F%20Song&amp;publication_year=2005&amp;journal=Health%20Technol%20Assess&amp;volume=9&amp;issue=26&amp;pages=1-134">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">11.</span><a class="rev-xref-ref" href="#xref-ref-11-1" title="View reference 11. in text"
                           id="ref-11">↵</a><div class="cit ref-cit ref-journal" id="cit-100.24.1780.11"
                             data-doi="10.3816/CBC.2006.n.011">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Rivera</span>  <span class="cit-name-given-names">E</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Smith</span>  <span class="cit-name-given-names">RE</span>  <span class="cit-name-suffix">Jr</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Trends in recommendations of myelosuppressive chemotherapy for the treatment of breast cancer: evolution of the national comprehensive
                                    cancer network guidelines and the cooperative group studies</span>. <abbr class="cit-jnl-abbrev">Clin Breast Cancer</abbr> <span class="cit-pub-date">2006</span>;<span class="cit-vol">7</span>(<span class="cit-issue">1</span>):<span class="cit-fpage">33</span>-<span class="cit-lpage">41</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.3816/CBC.2006.n.011&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=16764742&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000242699300003&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Trends%20in%20recommendations%20of%20myelosuppressive%20chemotherapy%20for%20the%20treatment%20of%20breast%20cancer%3A%20evolution%20of%20the%20national%20comprehensive%20cancer%20network%20guidelines%20and%20the%20cooperative%20group%20studies&amp;author=E%20Rivera&amp;author=RE%20Smith&amp;publication_year=2006&amp;journal=Clin%20Breast%20Cancer&amp;volume=7&amp;issue=1&amp;pages=33-41">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">12.</span><a class="rev-xref-ref" href="#xref-ref-12-1" title="View reference 12. in text"
                           id="ref-12">↵</a><div class="cit ref-cit ref-journal" id="cit-100.24.1780.12"
                             data-doi="10.1016/0305-7372(93)90036-Q">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Launchbury</span>  <span class="cit-name-given-names">AP</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Habboubi</span>  <span class="cit-name-given-names">N</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicity</span>. <abbr class="cit-jnl-abbrev">Cancer Treat Rev.</abbr> <span class="cit-pub-date">1993</span>;<span class="cit-vol">19</span>(<span class="cit-issue">3</span>):<span class="cit-fpage">197</span>-<span class="cit-lpage">228</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1016/0305-7372(93)90036-Q&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=8334677&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1993LQ29900001&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Epirubicin%20and%20doxorubicin%3A%20a%20comparison%20of%20their%20characteristics%2C%20therapeutic%20activity%20and%20toxicity&amp;author=AP%20Launchbury&amp;author=N%20Habboubi&amp;publication_year=1993&amp;journal=Cancer%20Treat%20Rev.&amp;volume=19&amp;issue=3&amp;pages=197-228">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">13.</span><a class="rev-xref-ref" href="#xref-ref-13-1" title="View reference 13. in text"
                           id="ref-13">↵</a><div class="cit ref-cit ref-journal" id="cit-100.24.1780.13"
                             data-doi="10.7326/0003-4819-148-7-200804010-00011">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Salanti</span>  <span class="cit-name-given-names">G</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Kavvoura</span>  <span class="cit-name-given-names">FK</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Ioannidis</span>  <span class="cit-name-given-names">JP</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Exploring the geometry of treatment networks</span>. <abbr class="cit-jnl-abbrev">Ann Intern Med</abbr> <span class="cit-pub-date">2008</span>;<span class="cit-vol">148</span>(<span class="cit-issue">7</span>):<span class="cit-fpage">544</span>-<span class="cit-lpage">553</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.7326/0003-4819-148-7-200804010-00011&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=18378949&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000254701000007&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Exploring%20the%20geometry%20of%20treatment%20networks&amp;author=G%20Salanti&amp;author=FK%20Kavvoura&amp;author=JP%20Ioannidis&amp;publication_year=2008&amp;journal=Ann%20Intern%20Med&amp;volume=148&amp;issue=7&amp;pages=544-553">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">14.</span><a class="rev-xref-ref" href="#xref-ref-14-1" title="View reference 14. in text"
                           id="ref-14">↵</a><div class="cit ref-cit ref-journal" id="cit-100.24.1780.14"
                             data-doi="10.1002/sim.1186">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Higgins</span>  <span class="cit-name-given-names">JP</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Thompson</span>  <span class="cit-name-given-names">SG</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Quantifying heterogeneity in a meta-analysis</span>. <abbr class="cit-jnl-abbrev">Stat Med</abbr> <span class="cit-pub-date">2002</span>;<span class="cit-vol">21</span>(<span class="cit-issue">11</span>):<span class="cit-fpage">1539</span>-<span class="cit-lpage">1558</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1002/sim.1186&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=12111919&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000176016900005&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Quantifying%20heterogeneity%20in%20a%20meta-analysis&amp;author=JP%20Higgins&amp;author=SG%20Thompson&amp;publication_year=2002&amp;journal=Stat%20Med&amp;volume=21&amp;issue=11&amp;pages=1539-1558">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">15.</span><a class="rev-xref-ref" href="#xref-ref-15-1" title="View reference 15. in text"
                           id="ref-15">↵</a><div class="cit ref-cit ref-journal" id="cit-100.24.1780.15"
                             data-doi="10.1186/1471-2288-2-13">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Baker</span>  <span class="cit-name-given-names">SG</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Kramer</span>  <span class="cit-name-given-names">BS</span></span></li>
                              </ol><cite>. <span class="cit-article-title">The transitive fallacy for randomised trials: if A bests B and B bests C in separate trials, is A better than C?</span> <abbr class="cit-jnl-abbrev">BMC Med Res Methodol</abbr> <span class="cit-pub-date">2002</span>;<span class="cit-vol">2</span>:<span class="cit-fpage">13</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1186/1471-2288-2-13&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=12429069&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=The%20transitive%20fallacy%20for%20randomised%20trials%3A%20if%20A%20bests%20B%20and%20B%20bests%20C%20in%20separate%20trials%2C%20is%20A%20better%20than%20C%3F&amp;author=SG%20Baker&amp;author=BS%20Kramer&amp;publication_year=2002&amp;journal=BMC%20Med%20Res%20Methodol&amp;volume=2&amp;pages=13">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">16.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.16"
                             data-doi="10.1002/sim.1201">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Lumley</span>  <span class="cit-name-given-names">T</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Network meta-analysis for indirect treatment comparisons</span>. <abbr class="cit-jnl-abbrev">Stat Med</abbr> <span class="cit-pub-date">2002</span>;<span class="cit-vol">21</span>(<span class="cit-issue">16</span>):<span class="cit-fpage">2313</span>-<span class="cit-lpage">2324</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1002/sim.1201&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=12210616&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000177458600002&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Network%20meta-analysis%20for%20indirect%20treatment%20comparisons&amp;author=T%20Lumley&amp;publication_year=2002&amp;journal=Stat%20Med&amp;volume=21&amp;issue=16&amp;pages=2313-2324">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">17.</span><a class="rev-xref-ref" href="#xref-ref-17-1" title="View reference 17. in text"
                           id="ref-17">↵</a><div class="cit ref-cit ref-journal" id="cit-100.24.1780.17"
                             data-doi="10.1016/S0140-6736(06)69615-3">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Ioannidis</span>  <span class="cit-name-given-names">JP</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Indirect comparisons: the mesh and mess of clinical trials</span>. <abbr class="cit-jnl-abbrev">Lancet</abbr> <span class="cit-pub-date">2006</span>;<span class="cit-vol">368</span>(<span class="cit-issue">9546</span>):<span class="cit-fpage">1470</span>-<span class="cit-lpage">1472</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1016/S0140-6736(06)69615-3&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=17071265&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000241582700005&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Indirect%20comparisons%3A%20the%20mesh%20and%20mess%20of%20clinical%20trials&amp;author=JP%20Ioannidis&amp;publication_year=2006&amp;journal=Lancet&amp;volume=368&amp;issue=9546&amp;pages=1470-1472">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">18.</span><a class="rev-xref-ref" href="#xref-ref-18-1" title="View reference 18. in text"
                           id="ref-18">↵</a><div class="cit ref-cit ref-journal" id="cit-100.24.1780.18"
                             data-doi="10.1016/0277-5379(83)90094-9">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Cavalli</span>  <span class="cit-name-given-names">F</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Pedrazzini</span>  <span class="cit-name-given-names">A</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Martz</span>  <span class="cit-name-given-names">G</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Randomized trial of 3 different regimens of combination chemotherapy in patients receiving simultaneously a hormonal treatment
                                    for advanced breast cancer</span>. <abbr class="cit-jnl-abbrev">Eur J Cancer Clin Oncol</abbr> <span class="cit-pub-date">1983</span>;<span class="cit-vol">19</span>(<span class="cit-issue">11</span>):<span class="cit-fpage">1615</span>-<span class="cit-lpage">1624</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1016/0277-5379(83)90094-9&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=6685644&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1983RS63600017&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Randomized%20trial%20of%203%20different%20regimens%20of%20combination%20chemotherapy%20in%20patients%20receiving%20simultaneously%20a%20hormonal%20treatment%20for%20advanced%20breast%20cancer&amp;author=F%20Cavalli&amp;author=A%20Pedrazzini&amp;author=G%20Martz&amp;publication_year=1983&amp;journal=Eur%20J%20Cancer%20Clin%20Oncol&amp;volume=19&amp;issue=11&amp;pages=1615-1624">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">19.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.19">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Lorusso</span>  <span class="cit-name-given-names">V</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Vici</span>  <span class="cit-name-given-names">P</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Bianco</span>  <span class="cit-name-given-names">AR</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Combination chemotherapy with CMF (cyclophosphamide, methotrexate, 5-fluorouracil) versus CNF (mitoxantrone, 5-fluorouracil,
                                    cyclophosphamide) in advanced breast cancer: a multicenter randomized study</span>. <abbr class="cit-jnl-abbrev">Int J Oncol</abbr> <span class="cit-pub-date">1993</span>;<span class="cit-vol">4</span>(<span class="cit-issue">2</span>):<span class="cit-fpage">531</span>-<span class="cit-lpage">535</span>.</cite></div>
                           <div class="cit-extra"><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Combination%20chemotherapy%20with%20CMF%20%28cyclophosphamide%2C%20methotrexate%2C%205-fluorouracil%29%20versus%20CNF%20%28mitoxantrone%2C%205-fluorouracil%2C%20cyclophosphamide%29%20in%20advanced%20breast%20cancer%3A%20a%20multicenter%20randomized%20study&amp;author=V%20Lorusso&amp;author=P%20Vici&amp;author=AR%20Bianco&amp;publication_year=1993&amp;journal=Int%20J%20Oncol&amp;volume=4&amp;issue=2&amp;pages=531-535">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">20.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.20">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Hori</span>  <span class="cit-name-given-names">T</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Kodama</span>  <span class="cit-name-given-names">H</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Nishimura</span>  <span class="cit-name-given-names">S</span></span></li>
                              </ol><cite>. <span class="cit-article-title">A randomized study comparing oral and standard regimens for metastatic breast cancer</span>. <abbr class="cit-jnl-abbrev">Oncol Rep</abbr> <span class="cit-pub-date">2001</span>;<span class="cit-vol">8</span>(<span class="cit-issue">5</span>):<span class="cit-fpage">1067</span>-<span class="cit-lpage">1071</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=11496318&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000170413000020&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=A%20randomized%20study%20comparing%20oral%20and%20standard%20regimens%20for%20metastatic%20breast%20cancer&amp;author=T%20Hori&amp;author=H%20Kodama&amp;author=S%20Nishimura&amp;publication_year=2001&amp;journal=Oncol%20Rep&amp;volume=8&amp;issue=5&amp;pages=1067-1071">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">21.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.21"
                             data-doi="10.1002/1097-0142(197806)41:6&lt;2073::AID-CNCR2820410601&gt;3.0.CO;2-7">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Nemoto</span>  <span class="cit-name-given-names">T</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Rosner</span>  <span class="cit-name-given-names">D</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Diaz</span>  <span class="cit-name-given-names">R</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Combination chemotherapy for metastatic breast cancer: comparison of multiple drug therapy with 5-fluorouracil, cytoxan and
                                    prednisone with adriamycin or adrenalectomy</span>. <abbr class="cit-jnl-abbrev">Cancer</abbr> <span class="cit-pub-date">1978</span>;<span class="cit-vol">41</span>(<span class="cit-issue">6</span>):<span class="cit-fpage">2073</span>-<span class="cit-lpage">2077</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1002/1097-0142(197806)41:6%3C2073::AID-CNCR2820410601%3E3.0.CO;2-7&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=657080&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1978FD13400001&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Combination%20chemotherapy%20for%20metastatic%20breast%20cancer%3A%20comparison%20of%20multiple%20drug%20therapy%20with%205-fluorouracil%2C%20cytoxan%20and%20prednisone%20with%20adriamycin%20or%20adrenalectomy&amp;author=T%20Nemoto&amp;author=D%20Rosner&amp;author=R%20Diaz&amp;publication_year=1978&amp;journal=Cancer&amp;volume=41&amp;issue=6&amp;pages=2073-2077">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">22.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.22">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Dieras</span>  <span class="cit-name-given-names">V</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Marty</span>  <span class="cit-name-given-names">M</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Tubiana</span>  <span class="cit-name-given-names">N</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Phase II randomized study of paclitaxel versus mitomycin in advanced breast cancer</span>. <abbr class="cit-jnl-abbrev">Semin Oncol</abbr> <span class="cit-pub-date">1995</span>;<span class="cit-vol">22</span> <span class="cit-supplement">4 suppl 8</span>:<span class="cit-fpage">33</span>-<span class="cit-lpage">39</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=7638640&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1995RQ17000007&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Phase%20II%20randomized%20study%20of%20paclitaxel%20versus%20mitomycin%20in%20advanced%20breast%20cancer&amp;author=V%20Dieras&amp;author=M%20Marty&amp;author=N%20Tubiana&amp;publication_year=1995&amp;journal=Semin%20Oncol&amp;volume=22&amp;pages=33-39">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">23.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.23">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Rubens</span>  <span class="cit-name-given-names">RD</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Knight</span>  <span class="cit-name-given-names">RK</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Hayward</span>  <span class="cit-name-given-names">JL</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Chemotherapy of advanced breast cancer: a controlled randomized trial of cyclophosphamide versus a four-drug combination</span>. <abbr class="cit-jnl-abbrev">Br J Cancer</abbr> <span class="cit-pub-date">1975</span>;<span class="cit-vol">32</span>(<span class="cit-issue">6</span>):<span class="cit-fpage">730</span>-<span class="cit-lpage">736</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=766800&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1975BC36800010&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Chemotherapy%20of%20advanced%20breast%20cancer%3A%20a%20controlled%20randomized%20trial%20of%20cyclophosphamide%20versus%20a%20four-drug%20combination&amp;author=RD%20Rubens&amp;author=RK%20Knight&amp;author=JL%20Hayward&amp;publication_year=1975&amp;journal=Br%20J%20Cancer&amp;volume=32&amp;issue=6&amp;pages=730-736">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">24.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.24">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Nielsen</span>  <span class="cit-name-given-names">D</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Dombernowsky</span>  <span class="cit-name-given-names">P</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Skovsgaard</span>  <span class="cit-name-given-names">T</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Epirubicin or epirubicin and vindesine in advanced breast cancer. A phase III study</span>. <abbr class="cit-jnl-abbrev">Ann Oncol</abbr> <span class="cit-pub-date">1990</span>;<span class="cit-vol">1</span>(<span class="cit-issue">4</span>):<span class="cit-fpage">275</span>-<span class="cit-lpage">280</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=annonc&amp;resid=1/4/275"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">25.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.25">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Cocconi</span>  <span class="cit-name-given-names">G</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Bisagni</span>  <span class="cit-name-given-names">G</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Bacchi</span>  <span class="cit-name-given-names">M</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">A comparison of continuation versus late intensification followed by discontinuation of chemotherapy in advanced breast cancer.
                                    A prospective randomized trial of the Italian Oncology Group for Clinical Research (G.O.I.R.C.)</span>. <abbr class="cit-jnl-abbrev">Ann Oncol</abbr> <span class="cit-pub-date">1990</span>;<span class="cit-vol">1</span>(<span class="cit-issue">1</span>):<span class="cit-fpage">36</span>-<span class="cit-lpage">44</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=annonc&amp;resid=1/1/36"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">26.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.26"
                             data-doi="10.1007/BF01803563">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Smalley</span>  <span class="cit-name-given-names">RV</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Lefante</span>  <span class="cit-name-given-names">J</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Bartolucci</span>  <span class="cit-name-given-names">A</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">A comparison of cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil,
                                    vincristine, and prednisone (CMFVP) in patients with advanced breast cancer</span>. <abbr class="cit-jnl-abbrev">Breast Cancer Res Treat</abbr> <span class="cit-pub-date">1983</span>;<span class="cit-vol">3</span>(<span class="cit-issue">2</span>):<span class="cit-fpage">209</span>-<span class="cit-lpage">220</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1007/BF01803563&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=6688538&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1983QW74900010&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=A%20comparison%20of%20cyclophosphamide%2C%20adriamycin%2C%20and%205-fluorouracil%20%28CAF%29%20and%20cyclophosphamide%2C%20methotrexate%2C%205-fluorouracil%2C%20vincristine%2C%20and%20prednisone%20%28CMFVP%29%20in%20patients%20with%20advanced%20breast%20cancer&amp;author=RV%20Smalley&amp;author=J%20Lefante&amp;author=A%20Bartolucci&amp;publication_year=1983&amp;journal=Breast%20Cancer%20Res%20Treat&amp;volume=3&amp;issue=2&amp;pages=209-220">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">27.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.27"
                             data-doi="10.1002/1097-0142(19841201)54:11&lt;2338::AID-CNCR2820541105&gt;3.0.CO;2-4">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Zekan</span>  <span class="cit-name-given-names">PJ</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Muss</span>  <span class="cit-name-given-names">HB</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Capizzi</span>  <span class="cit-name-given-names">RL</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">High-dose cyclophosphamide and 5-fluorouracil versus vincristine, doxorubicin, and cyclophosphamide in advanced carcinoma
                                    of the breast. A phase III study of the Piedmont Oncology Association (POA)</span>. <abbr class="cit-jnl-abbrev">Cancer</abbr> <span class="cit-pub-date">1984</span>;<span class="cit-vol">54</span>(<span class="cit-issue">11</span>):<span class="cit-fpage">2338</span>-<span class="cit-lpage">2343</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1002/1097-0142(19841201)54:11%3C2338::AID-CNCR2820541105%3E3.0.CO;2-4&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=6388802&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1984TU45200004&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=High-dose%20cyclophosphamide%20and%205-fluorouracil%20versus%20vincristine%2C%20doxorubicin%2C%20and%20cyclophosphamide%20in%20advanced%20carcinoma%20of%20the%20breast.%20A%20phase%20III%20study%20of%20the%20Piedmont%20Oncology%20Association%20%28POA%29&amp;author=PJ%20Zekan&amp;author=HB%20Muss&amp;author=RL%20Capizzi&amp;publication_year=1984&amp;journal=Cancer&amp;volume=54&amp;issue=11&amp;pages=2338-2343">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">28.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.28">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Pavesi</span>  <span class="cit-name-given-names">L</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Preti</span>  <span class="cit-name-given-names">P</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Da Prada</span>  <span class="cit-name-given-names">G</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Epirubicin versus mitoxantrone in combination chemotherapy for metastatic breast cancer</span>. <abbr class="cit-jnl-abbrev">Anticancer Res.</abbr> <span class="cit-pub-date">1995</span>;<span class="cit-vol">15</span>(<span class="cit-issue">2</span>):<span class="cit-fpage">495</span>-<span class="cit-lpage">501</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=7763029&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1995QZ54300043&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Epirubicin%20versus%20mitoxantrone%20in%20combination%20chemotherapy%20for%20metastatic%20breast%20cancer&amp;author=L%20Pavesi&amp;author=P%20Preti&amp;author=G%20Da%20Prada&amp;publication_year=1995&amp;journal=Anticancer%20Res.&amp;volume=15&amp;issue=2&amp;pages=495-501">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">29.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.29"
                             data-doi="10.1038/sj.bjc.6990694">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Harper-Wynne</span>  <span class="cit-name-given-names">C</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">English</span>  <span class="cit-name-given-names">J</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Meyer</span>  <span class="cit-name-given-names">L</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Randomized trial to compare the efficacy and toxicity of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) with methotrexate
                                    mitoxantrone (MM) in advanced carcinoma of the breast</span>. <abbr class="cit-jnl-abbrev">Br J Cancer</abbr> <span class="cit-pub-date">1999</span>;<span class="cit-vol">81</span>(<span class="cit-issue">2</span>):<span class="cit-fpage">316</span>-<span class="cit-lpage">322</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1038/sj.bjc.6990694&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=10496359&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000082539400020&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Randomized%20trial%20to%20compare%20the%20efficacy%20and%20toxicity%20of%20cyclophosphamide%2C%20methotrexate%20and%205-fluorouracil%20%28CMF%29%20with%20methotrexate%20mitoxantrone%20%28MM%29%20in%20advanced%20carcinoma%20of%20the%20breast&amp;author=C%20Harper-Wynne&amp;author=J%20English&amp;author=L%20Meyer&amp;publication_year=1999&amp;journal=Br%20J%20Cancer&amp;volume=81&amp;issue=2&amp;pages=316-322">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">30.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.30">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Moiseenko</span>  <span class="cit-name-given-names">VM</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">O’Reilly</span>  <span class="cit-name-given-names">SM</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Dalbot</span>  <span class="cit-name-given-names">DC</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">A comparative randomized phase-II study of Xeloda (capecitabine) and paclitaxel in patients with breast cancer progressing
                                    after anthracycline antibiotics</span>. <abbr class="cit-jnl-abbrev">Vopr Onkol</abbr> <span class="cit-pub-date">2000</span>;<span class="cit-vol">46</span>(<span class="cit-issue">3</span>):<span class="cit-fpage">285</span>-<span class="cit-lpage">289</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10976273&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=A%20comparative%20randomized%20phase-II%20study%20of%20Xeloda%20%28capecitabine%29%20and%20paclitaxel%20in%20patients%20with%20breast%20cancer%20progressing%20after%20anthracycline%20antibiotics&amp;author=VM%20Moiseenko&amp;author=SM%20O%E2%80%99Reilly&amp;author=DC%20Dalbot&amp;publication_year=2000&amp;journal=Vopr%20Onkol&amp;volume=46&amp;issue=3&amp;pages=285-289">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">31.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.31"
                             data-doi="10.1016/S0959-8049(99)00122-7">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Sjöström</span>  <span class="cit-name-given-names">J</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Blomqvist</span>  <span class="cit-name-given-names">C</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Mouridsen</span>  <span class="cit-name-given-names">H</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline
                                    failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group</span>. <abbr class="cit-jnl-abbrev">Eur J Cancer</abbr> <span class="cit-pub-date">1999</span>;<span class="cit-vol">35</span>(<span class="cit-issue">8</span>):<span class="cit-fpage">1194</span>-<span class="cit-lpage">1201</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1016/S0959-8049(99)00122-7&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=10615229&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000082153500017&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Docetaxel%20compared%20with%20sequential%20methotrexate%20and%205-fluorouracil%20in%20patients%20with%20advanced%20breast%20cancer%20after%20anthracycline%20failure%3A%20a%20randomised%20phase%20III%20study%20with%20crossover%20on%20progression%20by%20the%20Scandinavian%20Breast%20Group&amp;author=J%20Sj%C3%B6str%C3%B6m&amp;author=C%20Blomqvist&amp;author=H%20Mouridsen&amp;publication_year=1999&amp;journal=Eur%20J%20Cancer&amp;volume=35&amp;issue=8&amp;pages=1194-1201">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">32.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.32">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Bishop</span>  <span class="cit-name-given-names">JF</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Dewar</span>  <span class="cit-name-given-names">J</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Toner</span>  <span class="cit-name-given-names">GC</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic
                                    breast cancer</span>. <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr> <span class="cit-pub-date">1999</span>;<span class="cit-vol">17</span>(<span class="cit-issue">8</span>):<span class="cit-fpage">2355</span>-<span class="cit-lpage">2364</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=17/8/2355"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">33.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.33">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Falkson</span>  <span class="cit-name-given-names">G</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Gelman</span>  <span class="cit-name-given-names">RS</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Tormey</span>  <span class="cit-name-given-names">DC</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Taylor</span>  <span class="cit-name-given-names">SG</span>  <span class="cit-name-suffix">IV</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Falkson</span>  <span class="cit-name-given-names">HC</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Mitomycin and tamoxifen versus mitolactol, doxorubicin, and tamoxifen in patients with previously treated breast cancer</span>. <abbr class="cit-jnl-abbrev">Cancer Treat Rep</abbr> <span class="cit-pub-date">1985</span>;<span class="cit-vol">69</span>(<span class="cit-issue">7–8</span>):<span class="cit-fpage">755</span>-<span class="cit-lpage">760</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=4016786&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1985APC8900004&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Mitomycin%20and%20tamoxifen%20versus%20mitolactol%2C%20doxorubicin%2C%20and%20tamoxifen%20in%20patients%20with%20previously%20treated%20breast%20cancer&amp;author=G%20Falkson&amp;author=RS%20Gelman&amp;author=DC%20Tormey&amp;author=SG%20Taylor&amp;author=HC%20Falkson&amp;publication_year=1985&amp;journal=Cancer%20Treat%20Rep&amp;volume=69&amp;issue=7%E2%80%938&amp;pages=755-760">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">34.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.34"
                             data-doi="10.1023/A:1008295427877">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Brufman</span>  <span class="cit-name-given-names">G</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Colajori</span>  <span class="cit-name-given-names">E</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Ghilezan</span>  <span class="cit-name-given-names">N</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Doubling epirubicin dose intensity (100 mg/m2 versus 50 mg/m2) in the FEC regimen significantly increases response rates.
                                    An international randomised phase III study in metastatic breast cancer. The Epirubicin High Dose (HEPI 010) Study Group</span>. <abbr class="cit-jnl-abbrev">Ann Oncol</abbr> <span class="cit-pub-date">1997</span>;<span class="cit-vol">8</span>(<span class="cit-issue">2</span>):<span class="cit-fpage">155</span>-<span class="cit-lpage">162</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=annonc&amp;resid=8/2/155"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">35.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.35">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Athanassiou</span>  <span class="cit-name-given-names">A</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Dose intensification by using human recombinant granulocyte-macrophage colony stimulating factor in advanced breast cancer
                                    patients</span>. <abbr class="cit-jnl-abbrev">Eur J Gynaecol Oncol</abbr> <span class="cit-pub-date">1996</span>;<span class="cit-vol">17</span>(<span class="cit-issue">5</span>):<span class="cit-fpage">411</span>-<span class="cit-lpage">413</span>.</cite></div>
                           <div class="cit-extra"><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Dose%20intensification%20by%20using%20human%20recombinant%20granulocyte-macrophage%20colony%20stimulating%20factor%20in%20advanced%20breast%20cancer%20patients&amp;author=A%20Athanassiou&amp;publication_year=1996&amp;journal=Eur%20J%20Gynaecol%20Oncol&amp;volume=17&amp;issue=5&amp;pages=411-413">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">36.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.36">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Pouillart</span>  <span class="cit-name-given-names">P</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Follézou</span>  <span class="cit-name-given-names">JY</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Palangie</span>  <span class="cit-name-given-names">T</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Feuilhade</span>  <span class="cit-name-given-names">F</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">George</span>  <span class="cit-name-given-names">C</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Richards</span>  <span class="cit-name-given-names">E</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Long-term results of a randomised trial comparing regimens of cyclophosphamide and fluorouracil with either mitoxantrone or
                                    doxorubicin in patients with advanced breast cancer</span>. <abbr class="cit-jnl-abbrev">Eur J Cancer</abbr> <span class="cit-pub-date">1994</span>;<span class="cit-vol">30A</span>(<span class="cit-issue">5</span>):<span class="cit-fpage">715</span>-<span class="cit-lpage">716</span>.</cite></div>
                           <div class="cit-extra"><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Long-term%20results%20of%20a%20randomised%20trial%20comparing%20regimens%20of%20cyclophosphamide%20and%20fluorouracil%20with%20either%20mitoxantrone%20or%20doxorubicin%20in%20patients%20with%20advanced%20breast%20cancer&amp;author=P%20Pouillart&amp;author=JY%20Foll%C3%A9zou&amp;author=T%20Palangie&amp;author=F%20Feuilhade&amp;author=C%20George&amp;author=E%20Richards&amp;publication_year=1994&amp;journal=Eur%20J%20Cancer&amp;volume=30A&amp;issue=5&amp;pages=715-716">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">37.</span><a class="rev-xref-ref" href="#xref-ref-37-1" title="View reference 37. in text"
                           id="ref-37">↵</a><div class="cit ref-cit ref-journal" id="cit-100.24.1780.37"
                             data-doi="10.1023/A:1012281104865">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Oshaughnessy</span>  <span class="cit-name-given-names">JA</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Blum</span>  <span class="cit-name-given-names">J</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Moiseyenko</span>  <span class="cit-name-given-names">V</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide,
                                    methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer</span>. <abbr class="cit-jnl-abbrev">Ann Oncol</abbr> <span class="cit-pub-date">2001</span>;<span class="cit-vol">12</span>(<span class="cit-issue">9</span>):<span class="cit-fpage">1247</span>-<span class="cit-lpage">1254</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=annonc&amp;resid=12/9/1247"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">38.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.38"
                             data-doi="10.1093/annonc/mdf306">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Heidemann</span>  <span class="cit-name-given-names">E</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Stoeger</span>  <span class="cit-name-given-names">H</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Souchon</span>  <span class="cit-name-given-names">R</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Is first-line single-agent mitoxantrone in the treatment of high-risk metastatic breast cancer patients as effective as combination
                                    chemotherapy? No difference in survival but higher quality of life were found in a multicenter randomized trial</span>. <abbr class="cit-jnl-abbrev">Ann Oncol</abbr> <span class="cit-pub-date">2002</span>;<span class="cit-vol">13</span>(<span class="cit-issue">11</span>):<span class="cit-fpage">1717</span>-<span class="cit-lpage">1729</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=annonc&amp;resid=13/11/1717"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">39.</span><a class="rev-xref-ref" href="#xref-ref-39-1" title="View reference 39. in text"
                           id="ref-39">↵</a><div class="cit ref-cit ref-journal" id="cit-100.24.1780.39"
                             data-doi="10.1200/JCO.2002.09.002">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">O’Shaughnessy</span>  <span class="cit-name-given-names">J</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Miles</span>  <span class="cit-name-given-names">D</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Vukelja</span>  <span class="cit-name-given-names">S</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced
                                    breast cancer: phase III trial results</span>. <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr> <span class="cit-pub-date">2002</span>;<span class="cit-vol">20</span>(<span class="cit-issue">12</span>):<span class="cit-fpage">2812</span>-<span class="cit-lpage">2823</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=20/12/2812"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">40.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.40">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Andersson</span>  <span class="cit-name-given-names">M</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Daugaard</span>  <span class="cit-name-given-names">S</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">von der Maase</span>  <span class="cit-name-given-names">H</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Mouridsen</span>  <span class="cit-name-given-names">HT</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Doxorubicin versus mitomycin versus doxorubicin plus mitomycin in advanced breast cancer: a randomized study</span>. <abbr class="cit-jnl-abbrev">Cancer Treat Rep</abbr> <span class="cit-pub-date">1986</span>;<span class="cit-vol">70</span>(<span class="cit-issue">10</span>):<span class="cit-fpage">1181</span>-<span class="cit-lpage">1186</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=3530444&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1986E599800007&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Doxorubicin%20versus%20mitomycin%20versus%20doxorubicin%20plus%20mitomycin%20in%20advanced%20breast%20cancer%3A%20a%20randomized%20study&amp;author=M%20Andersson&amp;author=S%20Daugaard&amp;author=H%20von%20der%20Maase&amp;author=HT%20Mouridsen&amp;publication_year=1986&amp;journal=Cancer%20Treat%20Rep&amp;volume=70&amp;issue=10&amp;pages=1181-1186">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">41.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.41"
                             data-doi="10.1023/A:1006350602108">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Venturino</span>  <span class="cit-name-given-names">A</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Comandini</span>  <span class="cit-name-given-names">D</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Simoni</span>  <span class="cit-name-given-names">C</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Is salvage chemotherapy for metastatic breast cancer always effective and well tolerated? A phase II randomized trial of vinorelbine
                                    versus 5-fluorouracil plus leucovorin versus combination of mitoxantrone, 5-fluorouracil plus leucovorin</span>. <abbr class="cit-jnl-abbrev">Breast Cancer Res Treat</abbr> <span class="cit-pub-date">2000</span>;<span class="cit-vol">60</span>(<span class="cit-issue">3</span>):<span class="cit-fpage">195</span>-<span class="cit-lpage">200</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1023/A:1006350602108&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=10930106&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000087586200001&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Is%20salvage%20chemotherapy%20for%20metastatic%20breast%20cancer%20always%20effective%20and%20well%20tolerated%3F%20A%20phase%20II%20randomized%20trial%20of%20vinorelbine%20versus%205-fluorouracil%20plus%20leucovorin%20versus%20combination%20of%20mitoxantrone%2C%205-fluorouracil%20plus%20leucovorin&amp;author=A%20Venturino&amp;author=D%20Comandini&amp;author=C%20Simoni&amp;publication_year=2000&amp;journal=Breast%20Cancer%20Res%20Treat&amp;volume=60&amp;issue=3&amp;pages=195-200">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">42.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.42">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Paridaens</span>  <span class="cit-name-given-names">RJ</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Biganzoli</span>  <span class="cit-name-given-names">L</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Bruning</span>  <span class="cit-name-given-names">P</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization
                                    for Research and Treatment of Cancer randomized study with cross-over</span>. <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr> <span class="cit-pub-date">2000</span>;<span class="cit-vol">18</span>(<span class="cit-issue">4</span>):<span class="cit-fpage">724</span>-<span class="cit-lpage">733</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=18/4/724"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">43.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.43"
                             data-doi="10.1136/bmj.1.6013.801">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Brambilla</span>  <span class="cit-name-given-names">C</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">De Lena</span>  <span class="cit-name-given-names">M</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Rossi</span>  <span class="cit-name-given-names">A</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Valagussa</span>  <span class="cit-name-given-names">P</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Bonadonna</span>  <span class="cit-name-given-names">G</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Response and survival in advanced breast cancer after two non-cross-resistant combinations</span>. <abbr class="cit-jnl-abbrev">Br Med J</abbr> <span class="cit-pub-date">1976</span>;<span class="cit-vol">1</span>(<span class="cit-issue">6013</span>):<span class="cit-fpage">801</span>-<span class="cit-lpage">804</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=bmj&amp;resid=1/6013/801"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">44.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.44"
                             data-doi="10.1093/jnci/83.15.1077">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Cowan</span>  <span class="cit-name-given-names">JD</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Neidhart</span>  <span class="cit-name-given-names">J</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">McClure</span>  <span class="cit-name-given-names">S</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Randomized trial of doxorubicin, bisantrene, and mitoxantrone in advanced breast cancer: a Southwest Oncology Group study</span>. <abbr class="cit-jnl-abbrev">J Natl Cancer Inst</abbr> <span class="cit-pub-date">1991</span>;<span class="cit-vol">83</span>(<span class="cit-issue">15</span>):<span class="cit-fpage">1077</span>-<span class="cit-lpage">1084</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jnci&amp;resid=83/15/1077"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">45.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.45">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Henderson</span>  <span class="cit-name-given-names">IC</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Allegra</span>  <span class="cit-name-given-names">JC</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Woodcock</span>  <span class="cit-name-given-names">T</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer</span>. <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr> <span class="cit-pub-date">1989</span>;<span class="cit-vol">7</span>(<span class="cit-issue">5</span>):<span class="cit-fpage">560</span>-<span class="cit-lpage">571</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=7/5/560"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">46.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.46">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Habeshaw</span>  <span class="cit-name-given-names">T</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Paul</span>  <span class="cit-name-given-names">J</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Jones</span>  <span class="cit-name-given-names">R</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Epirubicin at two dose levels with prednisolone as treatment for advanced breast cancer: the results of a randomized trial</span>. <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr> <span class="cit-pub-date">1991</span>;<span class="cit-vol">9</span>(<span class="cit-issue">2</span>):<span class="cit-fpage">295</span>-<span class="cit-lpage">304</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=9/2/295"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">47.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.47"
                             data-doi="10.1002/1097-0142(197402)33:2&lt;519::AID-CNCR2820330229&gt;3.0.CO;2-X">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Gottlieb</span>  <span class="cit-name-given-names">JA</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Rivkin</span>  <span class="cit-name-given-names">SE</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Spigel</span>  <span class="cit-name-given-names">SC</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Proceedings: superiority of adriamycin over oral nitrosoureas in patients with advanced breast carcinoma. A Southwest Cancer
                                    Chemotherapy Group study</span>. <abbr class="cit-jnl-abbrev">Cancer</abbr> <span class="cit-pub-date">1974</span>;<span class="cit-vol">33</span>(<span class="cit-issue">2</span>):<span class="cit-fpage">519</span>-<span class="cit-lpage">526</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1002/1097-0142(197402)33:2%3C519::AID-CNCR2820330229%3E3.0.CO;2-X&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=4812769&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1974S085600029&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Proceedings%3A%20superiority%20of%20adriamycin%20over%20oral%20nitrosoureas%20in%20patients%20with%20advanced%20breast%20carcinoma.%20A%20Southwest%20Cancer%20Chemotherapy%20Group%20study&amp;author=JA%20Gottlieb&amp;author=SE%20Rivkin&amp;author=SC%20Spigel&amp;publication_year=1974&amp;journal=Cancer&amp;volume=33&amp;issue=2&amp;pages=519-526">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">48.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.48"
                             data-doi="10.1200/JCO.2002.11.005">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Biganzoli</span>  <span class="cit-name-given-names">L</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Cufer</span>  <span class="cit-name-given-names">T</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Bruning</span>  <span class="cit-name-given-names">P</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer:
                                    the European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial</span>. <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr> <span class="cit-pub-date">2002</span>;<span class="cit-vol">20</span>(<span class="cit-issue">14</span>):<span class="cit-fpage">3114</span>-<span class="cit-lpage">3121</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=20/14/3114"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">49.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.49"
                             data-doi="10.1002/1097-0142(197611)38:5&lt;1882::AID-CNCR2820380503&gt;3.0.CO;2-H">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Canellos</span>  <span class="cit-name-given-names">GP</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Pocock</span>  <span class="cit-name-given-names">SJ</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Taylor</span>  <span class="cit-name-given-names">SG</span>  <span class="cit-name-suffix">III</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Sears</span>  <span class="cit-name-given-names">ME</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Klaasen</span>  <span class="cit-name-given-names">DJ</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Band</span>  <span class="cit-name-given-names">PR</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Combination chemotherapy for metastatic breast carcinoma. Prospective comparison of multiple drug therapy with L-phenylalanine
                                    mustard</span>. <abbr class="cit-jnl-abbrev">Cancer</abbr> <span class="cit-pub-date">1976</span>;<span class="cit-vol">38</span>(<span class="cit-issue">5</span>):<span class="cit-fpage">1882</span>-<span class="cit-lpage">1886</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1002/1097-0142(197611)38:5%3C1882::AID-CNCR2820380503%3E3.0.CO;2-H&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=991103&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1976CM10700002&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Combination%20chemotherapy%20for%20metastatic%20breast%20carcinoma.%20Prospective%20comparison%20of%20multiple%20drug%20therapy%20with%20L-phenylalanine%20mustard&amp;author=GP%20Canellos&amp;author=SJ%20Pocock&amp;author=SG%20Taylor&amp;author=ME%20Sears&amp;author=DJ%20Klaasen&amp;author=PR%20Band&amp;publication_year=1976&amp;journal=Cancer&amp;volume=38&amp;issue=5&amp;pages=1882-1886">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">50.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.50">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Kolaric</span>  <span class="cit-name-given-names">K</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Vukas</span>  <span class="cit-name-given-names">D</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Potrebica</span>  <span class="cit-name-given-names">V</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Combination of cyclophosphamide, adriamycin and platinum (CAP) versus 5-fluorouracil, adriamycin and cyclophosphamide (FAC)
                                    as primary treatment in metastatic breast cancer: results of a prospective randomized study</span>. <abbr class="cit-jnl-abbrev">Tumori</abbr> <span class="cit-pub-date">1989</span>;<span class="cit-vol">75</span>(<span class="cit-issue">2</span>):<span class="cit-fpage">132</span>-<span class="cit-lpage">136</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=2741218&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1989AB30100010&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Combination%20of%20cyclophosphamide%2C%20adriamycin%20and%20platinum%20%28CAP%29%20versus%205-fluorouracil%2C%20adriamycin%20and%20cyclophosphamide%20%28FAC%29%20as%20primary%20treatment%20in%20metastatic%20breast%20cancer%3A%20results%20of%20a%20prospective%20randomized%20study&amp;author=K%20Kolaric&amp;author=D%20Vukas&amp;author=V%20Potrebica&amp;publication_year=1989&amp;journal=Tumori&amp;volume=75&amp;issue=2&amp;pages=132-136">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">51.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.51">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Ingle</span>  <span class="cit-name-given-names">JN</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Pfeifle</span>  <span class="cit-name-given-names">DM</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Green</span>  <span class="cit-name-given-names">SJ</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Randomized clinical trial of doxorubicin alone or combined with mitolactol in women with advanced breast cancer and prior
                                    chemotherapy exposure</span>. <abbr class="cit-jnl-abbrev">Am J Clin Oncol</abbr> <span class="cit-pub-date">1985</span>;<span class="cit-vol">8</span>(<span class="cit-issue">4</span>):<span class="cit-fpage">275</span>-<span class="cit-lpage">282</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=3909798&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1985ATS2500001&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Randomized%20clinical%20trial%20of%20doxorubicin%20alone%20or%20combined%20with%20mitolactol%20in%20women%20with%20advanced%20breast%20cancer%20and%20prior%20chemotherapy%20exposure&amp;author=JN%20Ingle&amp;author=DM%20Pfeifle&amp;author=SJ%20Green&amp;publication_year=1985&amp;journal=Am%20J%20Clin%20Oncol&amp;volume=8&amp;issue=4&amp;pages=275-282">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">52.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.52">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Tormey</span>  <span class="cit-name-given-names">DC</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Weinberg</span>  <span class="cit-name-given-names">VE</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Leone</span>  <span class="cit-name-given-names">LA</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">A comparison of intermittent vs. continuous and of adriamycin vs. methotrexate 5-drug chemotherapy for advanced breast cancer.
                                    A Cancer and Leukemia Group B study</span>. <abbr class="cit-jnl-abbrev">Am J Clin Oncol</abbr> <span class="cit-pub-date">1984</span>;<span class="cit-vol">7</span>(<span class="cit-issue">3</span>):<span class="cit-fpage">231</span>-<span class="cit-lpage">239</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=6375344&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1984SS81200007&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=A%20comparison%20of%20intermittent%20vs.%20continuous%20and%20of%20adriamycin%20vs.%20methotrexate%205-drug%20chemotherapy%20for%20advanced%20breast%20cancer.%20A%20Cancer%20and%20Leukemia%20Group%20B%20study&amp;author=DC%20Tormey&amp;author=VE%20Weinberg&amp;author=LA%20Leone&amp;publication_year=1984&amp;journal=Am%20J%20Clin%20Oncol&amp;volume=7&amp;issue=3&amp;pages=231-239">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">53.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.53"
                             data-doi="10.1097/00000421-198205050-00010">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Chang</span>  <span class="cit-name-given-names">YC</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Falkson</span>  <span class="cit-name-given-names">G</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Tormey</span>  <span class="cit-name-given-names">DC</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Crowley</span>  <span class="cit-name-given-names">J</span></span></li>
                              </ol><cite>. <span class="cit-article-title">A pilot study of mitomycin-C and tamoxifen (MT) versus dibromodulcitol, adriamycin, and tamoxifen (DAT)</span>. <abbr class="cit-jnl-abbrev">Am J Clin Oncol</abbr> <span class="cit-pub-date">1982</span>;<span class="cit-vol">5</span>(<span class="cit-issue">5</span>):<span class="cit-fpage">521</span>-<span class="cit-lpage">525</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1097/00000421-198205050-00010&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=7180830&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1982PJ05400009&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=A%20pilot%20study%20of%20mitomycin-C%20and%20tamoxifen%20%28MT%29%20versus%20dibromodulcitol%2C%20adriamycin%2C%20and%20tamoxifen%20%28DAT%29&amp;author=YC%20Chang&amp;author=G%20Falkson&amp;author=DC%20Tormey&amp;author=J%20Crowley&amp;publication_year=1982&amp;journal=Am%20J%20Clin%20Oncol&amp;volume=5&amp;issue=5&amp;pages=521-525">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">54.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.54">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Bennett</span>  <span class="cit-name-given-names">JM</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Muss</span>  <span class="cit-name-given-names">HB</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Doroshow</span>  <span class="cit-name-given-names">JH</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide,
                                    and fluorouracil in the therapy of metastatic breast carcinoma</span>. <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr> <span class="cit-pub-date">1988</span>;<span class="cit-vol">6</span>(<span class="cit-issue">10</span>):<span class="cit-fpage">1611</span>-<span class="cit-lpage">1620</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=6/10/1611"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">55.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.55">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Lawton</span>  <span class="cit-name-given-names">PA</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Spittle</span>  <span class="cit-name-given-names">MF</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Ostrowski</span>  <span class="cit-name-given-names">MJ</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">A comparison of doxorubicin, epirubicin and mitozantrone as single agents in advanced breast carcinoma</span>. <abbr class="cit-jnl-abbrev">Clin Oncol (R Coll Radiol)</abbr> <span class="cit-pub-date">1993</span>;<span class="cit-vol">5</span>(<span class="cit-issue">2</span>):<span class="cit-fpage">80</span>-<span class="cit-lpage">84</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=8481365&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=A%20comparison%20of%20doxorubicin%2C%20epirubicin%20and%20mitozantrone%20as%20single%20agents%20in%20advanced%20breast%20carcinoma&amp;author=PA%20Lawton&amp;author=MF%20Spittle&amp;author=MJ%20Ostrowski&amp;publication_year=1993&amp;journal=Clin%20Oncol%20%28R%20Coll%20Radiol%29&amp;volume=5&amp;issue=2&amp;pages=80-84">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">56.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.56">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Creagan</span>  <span class="cit-name-given-names">ET</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Green</span>  <span class="cit-name-given-names">SJ</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Ahmann</span>  <span class="cit-name-given-names">DL</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Ingle</span>  <span class="cit-name-given-names">JN</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Edmonson</span>  <span class="cit-name-given-names">JH</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Marschke</span>  <span class="cit-name-given-names">RF</span>  <span class="cit-name-suffix">Jr</span></span></li>
                              </ol><cite>. <span class="cit-article-title">A phase III clinical trial comparing the combination cyclophosphamide, adriamycin, cisplatin with cyclophosphamide, 5-fluorouracil,
                                    prednisone in patients with advanced breast cancer</span>. <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr> <span class="cit-pub-date">1984</span>;<span class="cit-vol">2</span>(<span class="cit-issue">11</span>):<span class="cit-fpage">1260</span>-<span class="cit-lpage">1265</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=2/11/1260"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">57.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.57">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Cummings</span>  <span class="cit-name-given-names">FJ</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Gelman</span>  <span class="cit-name-given-names">R</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Tormey</span>  <span class="cit-name-given-names">DC</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">DeWys</span>  <span class="cit-name-given-names">W</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Glick</span>  <span class="cit-name-given-names">J</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Adriamycin plus vincristine alone or with dibromodulcitol or ICRF-159 in metastatic breast cancer</span>. <abbr class="cit-jnl-abbrev">Cancer Clin Trials</abbr> <span class="cit-pub-date">1981</span>;<span class="cit-vol">4</span>(<span class="cit-issue">3</span>):<span class="cit-fpage">253</span>-<span class="cit-lpage">260</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=7026074&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1981MC59000004&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Adriamycin%20plus%20vincristine%20alone%20or%20with%20dibromodulcitol%20or%20ICRF-159%20in%20metastatic%20breast%20cancer&amp;author=FJ%20Cummings&amp;author=R%20Gelman&amp;author=DC%20Tormey&amp;author=W%20DeWys&amp;author=J%20Glick&amp;publication_year=1981&amp;journal=Cancer%20Clin%20Trials&amp;volume=4&amp;issue=3&amp;pages=253-260">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">58.</span><a class="rev-xref-ref" href="#xref-ref-58-1" title="View reference 58. in text"
                           id="ref-58">↵</a><div class="cit ref-cit ref-journal" id="cit-100.24.1780.58">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Vogel</span>  <span class="cit-name-given-names">CL</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Smalley</span>  <span class="cit-name-given-names">RV</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Raney</span>  <span class="cit-name-given-names">M</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Randomized trial of cyclophosphamide, doxorubicin, and 5-fluorouracil alone or alternating with a “cycle active” non-cross-resistant
                                    combination in women with visceral metastatic breast cancer: a Southeastern Cancer Study Group project</span>. <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr> <span class="cit-pub-date">1984</span>;<span class="cit-vol">2</span>(<span class="cit-issue">6</span>):<span class="cit-fpage">643</span>-<span class="cit-lpage">651</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=2/6/643"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">59.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.59">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Jones</span>  <span class="cit-name-given-names">S</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Winer</span>  <span class="cit-name-given-names">E</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Vogel</span>  <span class="cit-name-given-names">C</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer</span>. <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr> <span class="cit-pub-date">1995</span>;<span class="cit-vol">13</span>(<span class="cit-issue">10</span>):<span class="cit-fpage">2567</span>-<span class="cit-lpage">2574</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=13/10/2567"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">60.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.60">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Leonard</span>  <span class="cit-name-given-names">RC</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Cornbleet</span>  <span class="cit-name-given-names">MA</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Kaye</span>  <span class="cit-name-given-names">SB</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Mitoxantrone versus doxorubicin in combination chemotherapy for advanced carcinoma of the breast</span>. <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr> <span class="cit-pub-date">1987</span>;<span class="cit-vol">5</span>(<span class="cit-issue">7</span>):<span class="cit-fpage">1056</span>-<span class="cit-lpage">1063</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=5/7/1056"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">61.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.61">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Dogliotti</span>  <span class="cit-name-given-names">L</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Berruti</span>  <span class="cit-name-given-names">A</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Buniva</span>  <span class="cit-name-given-names">T</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Lonidamine significantly increases the activity of epirubicin in patients with advanced breast cancer: results from a multicenter
                                    prospective randomized trial</span>. <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr> <span class="cit-pub-date">1996</span>;<span class="cit-vol">14</span>(<span class="cit-issue">4</span>):<span class="cit-fpage">1165</span>-<span class="cit-lpage">1172</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=14/4/1165"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">62.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.62">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Kolarić</span>  <span class="cit-name-given-names">K</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Vukas</span>  <span class="cit-name-given-names">D</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Roth</span>  <span class="cit-name-given-names">A</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Potrebica</span>  <span class="cit-name-given-names">V</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Cervek</span>  <span class="cit-name-given-names">J</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Cerar</span>  <span class="cit-name-given-names">O</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Cyclophosphamide, adriamycin and platinum (CAP) combination chemotherapy, a new effective approach in the treatment of disseminated
                                    breast cancer. Preliminary report</span>. <abbr class="cit-jnl-abbrev">Tumori</abbr> <span class="cit-pub-date">1985</span>;<span class="cit-vol">71</span>(<span class="cit-issue">2</span>):<span class="cit-fpage">159</span>-<span class="cit-lpage">165</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=3890307&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1985AJK8400012&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Cyclophosphamide%2C%20adriamycin%20and%20platinum%20%28CAP%29%20combination%20chemotherapy%2C%20a%20new%20effective%20approach%20in%20the%20treatment%20of%20disseminated%20breast%20cancer.%20Preliminary%20report&amp;author=K%20Kolari%C4%87&amp;author=D%20Vukas&amp;author=A%20Roth&amp;author=V%20Potrebica&amp;author=J%20Cervek&amp;author=O%20Cerar&amp;publication_year=1985&amp;journal=Tumori&amp;volume=71&amp;issue=2&amp;pages=159-165">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">63.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.63"
                             data-doi="10.1002/(SICI)1097-0142(19970215)79:4&lt;740::AID-CNCR11&gt;3.0.CO;2-#">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Hainsworth</span>  <span class="cit-name-given-names">JD</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Jolivet</span>  <span class="cit-name-given-names">J</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Birch</span>  <span class="cit-name-given-names">R</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Hopkins</span>  <span class="cit-name-given-names">LG</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Greco</span>  <span class="cit-name-given-names">FA</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Mitoxantrone, 5-fluorouracil, and high dose leucovorin (NFL) versus intravenous cyclophosphamide, methotrexate, and 5-fluorouracil
                                    (CMF) in first-line chemotherapy for patients with metastatic breast carcinoma: a randomized phase II trial</span>. <abbr class="cit-jnl-abbrev">Cancer</abbr> <span class="cit-pub-date">1997</span>;<span class="cit-vol">79</span>(<span class="cit-issue">4</span>):<span class="cit-fpage">740</span>-<span class="cit-lpage">748</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1002/(SICI)1097-0142(19970215)79:4%3C740::AID-CNCR11%3E3.0.CO;2-%23&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=9024712&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1997WG45100011&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Mitoxantrone%2C%205-fluorouracil%2C%20and%20high%20dose%20leucovorin%20%28NFL%29%20versus%20intravenous%20cyclophosphamide%2C%20methotrexate%2C%20and%205-fluorouracil%20%28CMF%29%20in%20first-line%20chemotherapy%20for%20patients%20with%20metastatic%20breast%20carcinoma%3A%20a%20randomized%20phase%20II%20trial&amp;author=JD%20Hainsworth&amp;author=J%20Jolivet&amp;author=R%20Birch&amp;author=LG%20Hopkins&amp;author=FA%20Greco&amp;publication_year=1997&amp;journal=Cancer&amp;volume=79&amp;issue=4&amp;pages=740-748">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">64.</span><a class="rev-xref-ref" href="#xref-ref-64-1" title="View reference 64. in text"
                           id="ref-64">↵</a><div class="cit ref-cit ref-journal" id="cit-100.24.1780.64">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Bastholt</span>  <span class="cit-name-given-names">L</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Dalmark</span>  <span class="cit-name-given-names">M</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Gjedde</span>  <span class="cit-name-given-names">SB</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: a randomized
                                    study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group</span>. <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr> <span class="cit-pub-date">1996</span>;<span class="cit-vol">14</span>(<span class="cit-issue">4</span>):<span class="cit-fpage">1146</span>-<span class="cit-lpage">1155</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=14/4/1146"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">65.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.65"
                             data-doi="10.1002/1097-0142(19821201)50:11&lt;2269::AID-CNCR2820501107&gt;3.0.CO;2-L">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Muss</span>  <span class="cit-name-given-names">HB</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Richards</span>  <span class="cit-name-given-names">F</span>  <span class="cit-name-suffix">II</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Jackson</span>  <span class="cit-name-given-names">DV</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Vincristine, doxorubicin, and cyclophosphamide versus low-dose intravenous cyclophosphamide, methotrexate, and 5-fluorouracil
                                    in advanced breast cancer: a randomized trial of the Piedmont Oncology Association</span>. <abbr class="cit-jnl-abbrev">Cancer</abbr> <span class="cit-pub-date">1982</span>;<span class="cit-vol">50</span>(<span class="cit-issue">11</span>):<span class="cit-fpage">2269</span>-<span class="cit-lpage">2274</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1002/1097-0142(19821201)50:11%3C2269::AID-CNCR2820501107%3E3.0.CO;2-L&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=6754062&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1982PQ88600006&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Vincristine%2C%20doxorubicin%2C%20and%20cyclophosphamide%20versus%20low-dose%20intravenous%20cyclophosphamide%2C%20methotrexate%2C%20and%205-fluorouracil%20in%20advanced%20breast%20cancer%3A%20a%20randomized%20trial%20of%20the%20Piedmont%20Oncology%20Association&amp;author=HB%20Muss&amp;author=F%20Richards&amp;author=DV%20Jackson&amp;publication_year=1982&amp;journal=Cancer&amp;volume=50&amp;issue=11&amp;pages=2269-2274">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">66.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.66"
                             data-doi="10.1002/1097-0142(19821001)50:7&lt;1235::AID-CNCR2820500703&gt;3.0.CO;2-L">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Tormey</span>  <span class="cit-name-given-names">DC</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Gelman</span>  <span class="cit-name-given-names">R</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Band</span>  <span class="cit-name-given-names">PR</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Comparison of induction chemotherapies for metastatic breast cancer. An Eastern Cooperative Oncology Group trial</span>. <abbr class="cit-jnl-abbrev">Cancer</abbr> <span class="cit-pub-date">1982</span>;<span class="cit-vol">50</span>(<span class="cit-issue">7</span>):<span class="cit-fpage">1235</span>-<span class="cit-lpage">1244</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1002/1097-0142(19821001)50:7%3C1235::AID-CNCR2820500703%3E3.0.CO;2-L&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=7049347&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1982PH63000002&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Comparison%20of%20induction%20chemotherapies%20for%20metastatic%20breast%20cancer.%20An%20Eastern%20Cooperative%20Oncology%20Group%20trial&amp;author=DC%20Tormey&amp;author=R%20Gelman&amp;author=PR%20Band&amp;publication_year=1982&amp;journal=Cancer&amp;volume=50&amp;issue=7&amp;pages=1235-1244">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">67.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.67"
                             data-doi="10.1002/1097-0142(19890701)64:1&lt;6::AID-CNCR2820640103&gt;3.0.CO;2-L">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Rosner</span>  <span class="cit-name-given-names">D</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Lane</span>  <span class="cit-name-given-names">WW</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Nemoto</span>  <span class="cit-name-given-names">T</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Differential response to chemotherapy in metastatic breast cancer in relation to estrogen receptor level. Results of a prospective
                                    randomized study</span>. <abbr class="cit-jnl-abbrev">Cancer</abbr> <span class="cit-pub-date">1989</span>;<span class="cit-vol">64</span>(<span class="cit-issue">1</span>):<span class="cit-fpage">6</span>-<span class="cit-lpage">15</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1002/1097-0142(19890701)64:1%3C6::AID-CNCR2820640103%3E3.0.CO;2-L&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=2731120&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1989AB56100002&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Differential%20response%20to%20chemotherapy%20in%20metastatic%20breast%20cancer%20in%20relation%20to%20estrogen%20receptor%20level.%20Results%20of%20a%20prospective%20randomized%20study&amp;author=D%20Rosner&amp;author=WW%20Lane&amp;author=T%20Nemoto&amp;publication_year=1989&amp;journal=Cancer&amp;volume=64&amp;issue=1&amp;pages=6-15">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">68.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.68"
                             data-doi="10.1002/1097-0142(19870301)59:5&lt;874::AID-CNCR2820590503&gt;3.0.CO;2-O">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Rosner</span>  <span class="cit-name-given-names">D</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Nemoto</span>  <span class="cit-name-given-names">T</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Lane</span>  <span class="cit-name-given-names">WW</span></span></li>
                              </ol><cite>. <span class="cit-article-title">A randomized study of intensive versus moderate chemotherapy programs in metastatic breast cancer</span>. <abbr class="cit-jnl-abbrev">Cancer</abbr> <span class="cit-pub-date">1987</span>;<span class="cit-vol">59</span>(<span class="cit-issue">5</span>):<span class="cit-fpage">874</span>-<span class="cit-lpage">883</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1002/1097-0142(19870301)59:5%3C874::AID-CNCR2820590503%3E3.0.CO;2-O&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=3815266&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1987G215000002&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=A%20randomized%20study%20of%20intensive%20versus%20moderate%20chemotherapy%20programs%20in%20metastatic%20breast%20cancer&amp;author=D%20Rosner&amp;author=T%20Nemoto&amp;author=WW%20Lane&amp;publication_year=1987&amp;journal=Cancer&amp;volume=59&amp;issue=5&amp;pages=874-883">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">69.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.69">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Costanza</span>  <span class="cit-name-given-names">ME</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Weiss</span>  <span class="cit-name-given-names">RB</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Henderson</span>  <span class="cit-name-given-names">IC</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Safety and efficacy of using a single agent or a phase II agent before instituting standard combination chemotherapy in previously
                                    untreated metastatic breast cancer patients: report of a randomized study—Cancer and Leukemia Group B 8642</span>. <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr> <span class="cit-pub-date">1999</span>;<span class="cit-vol">17</span>(<span class="cit-issue">5</span>):<span class="cit-fpage">1397</span>-<span class="cit-lpage">1406</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=17/5/1397"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">70.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.70">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Nabholtz</span>  <span class="cit-name-given-names">JM</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Senn</span>  <span class="cit-name-given-names">HJ</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Bezwoda</span>  <span class="cit-name-given-names">WR</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing
                                    despite previous anthracycline-containing chemotherapy. 304 Study Group</span>. <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr> <span class="cit-pub-date">1999</span>;<span class="cit-vol">17</span>(<span class="cit-issue">5</span>):<span class="cit-fpage">1413</span>-<span class="cit-lpage">1424</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=17/5/1413"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">71.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.71">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Stewart</span>  <span class="cit-name-given-names">DJ</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Evans</span>  <span class="cit-name-given-names">WK</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Shepherd</span>  <span class="cit-name-given-names">FA</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Cyclophosphamide and fluorouracil combined with mitoxantrone versus doxorubicin for breast cancer: superiority of doxorubicin</span>. <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr> <span class="cit-pub-date">1997</span>;<span class="cit-vol">15</span>(<span class="cit-issue">5</span>):<span class="cit-fpage">1897</span>-<span class="cit-lpage">1905</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=15/5/1897"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">72.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.72">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Chan</span>  <span class="cit-name-given-names">S</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Friedrichs</span>  <span class="cit-name-given-names">K</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Noel</span>  <span class="cit-name-given-names">D</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer</span>. <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr> <span class="cit-pub-date">1999</span>;<span class="cit-vol">17</span>(<span class="cit-issue">8</span>):<span class="cit-fpage">2341</span>-<span class="cit-lpage">2354</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=17/8/2341"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">73.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.73"
                             data-doi="10.1038/sj.bjc.6600645">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Bonneterre</span>  <span class="cit-name-given-names">J</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Roché</span>  <span class="cit-name-given-names">H</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Monnier</span>  <span class="cit-name-given-names">A</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure</span>. <abbr class="cit-jnl-abbrev">Br J Cancer</abbr> <span class="cit-pub-date">2002</span>;<span class="cit-vol">87</span>(<span class="cit-issue">11</span>):<span class="cit-fpage">1210</span>-<span class="cit-lpage">1215</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1038/sj.bjc.6600645&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=12439707&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000179819900004&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Docetaxel%20vs%205-fluorouracil%20plus%20vinorelbine%20in%20metastatic%20breast%20cancer%20after%20anthracycline%20therapy%20failure&amp;author=J%20Bonneterre&amp;author=H%20Roch%C3%A9&amp;author=A%20Monnier&amp;publication_year=2002&amp;journal=Br%20J%20Cancer&amp;volume=87&amp;issue=11&amp;pages=1210-1215">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">74.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.74">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Romero</span>  <span class="cit-name-given-names">A</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Rabinovich</span>  <span class="cit-name-given-names">MG</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Pérez</span>  <span class="cit-name-given-names">JE</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Alternating versus sequential therapy in advanced breast cancer</span>. <abbr class="cit-jnl-abbrev">Medicina (B Aires)</abbr> <span class="cit-pub-date">1987</span>;<span class="cit-vol">47</span>(<span class="cit-issue">3</span>):<span class="cit-fpage">243</span>-<span class="cit-lpage">248</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=3326994&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Alternating%20versus%20sequential%20therapy%20in%20advanced%20breast%20cancer&amp;author=A%20Romero&amp;author=MG%20Rabinovich&amp;author=JE%20P%C3%A9rez&amp;publication_year=1987&amp;journal=Medicina%20%28B%20Aires%29&amp;volume=47&amp;issue=3&amp;pages=243-248">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">75.</span><a class="rev-xref-ref" href="#xref-ref-75-1" title="View reference 75. in text"
                           id="ref-75">↵</a><div class="cit ref-cit ref-journal" id="cit-100.24.1780.75">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Joensuu</span>  <span class="cit-name-given-names">H</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Holli</span>  <span class="cit-name-given-names">K</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Heikkinen</span>  <span class="cit-name-given-names">M</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Combination chemotherapy versus single-agent therapy as first- and second-line treatment in metastatic breast cancer: a prospective
                                    randomized trial</span>. <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr> <span class="cit-pub-date">1998</span>;<span class="cit-vol">16</span>(<span class="cit-issue">12</span>):<span class="cit-fpage">3720</span>-<span class="cit-lpage">3730</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=16/12/3720"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">76.</span><a class="rev-xref-ref" href="#xref-ref-76-1" title="View reference 76. in text"
                           id="ref-76">↵</a><div class="cit ref-cit ref-journal" id="cit-100.24.1780.76">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Gebbia</span>  <span class="cit-name-given-names">V</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Testa</span>  <span class="cit-name-given-names">A</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Valenza</span>  <span class="cit-name-given-names">R</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Levo folinic acid and 5-fluorouracil plus high dose epidoxorubicin as first line treatment for metastatic breast carcinoma</span>. <abbr class="cit-jnl-abbrev">Anticancer Res.</abbr> <span class="cit-pub-date">1993</span>;<span class="cit-vol">13</span>(<span class="cit-issue">1</span>):<span class="cit-fpage">141</span>-<span class="cit-lpage">144</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=8386492&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1993KX84300026&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Levo%20folinic%20acid%20and%205-fluorouracil%20plus%20high%20dose%20epidoxorubicin%20as%20first%20line%20treatment%20for%20metastatic%20breast%20carcinoma&amp;author=V%20Gebbia&amp;author=A%20Testa&amp;author=R%20Valenza&amp;publication_year=1993&amp;journal=Anticancer%20Res.&amp;volume=13&amp;issue=1&amp;pages=141-144">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">77.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.77">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Carmo-Pereira</span>  <span class="cit-name-given-names">J</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Costa</span>  <span class="cit-name-given-names">FO</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Henriques</span>  <span class="cit-name-given-names">E</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Single-drug vs combination cytotoxic chemotherapy in advanced breast cancer: a randomized study</span>. <abbr class="cit-jnl-abbrev">Eur J Cancer</abbr> <span class="cit-pub-date">1980</span>;<span class="cit-vol">16</span>(<span class="cit-issue">12</span>):<span class="cit-fpage">1621</span>-<span class="cit-lpage">1625</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=7014228&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1980KS20900014&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Single-drug%20vs%20combination%20cytotoxic%20chemotherapy%20in%20advanced%20breast%20cancer%3A%20a%20randomized%20study&amp;author=J%20Carmo-Pereira&amp;author=FO%20Costa&amp;author=E%20Henriques&amp;publication_year=1980&amp;journal=Eur%20J%20Cancer&amp;volume=16&amp;issue=12&amp;pages=1621-1625">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">78.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.78">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Ebbs</span>  <span class="cit-name-given-names">SR</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Saunders</span>  <span class="cit-name-given-names">JA</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Graham</span>  <span class="cit-name-given-names">H</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">A’Hern</span>  <span class="cit-name-given-names">RP</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Bates</span>  <span class="cit-name-given-names">T</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Baum</span>  <span class="cit-name-given-names">M</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Advanced breast cancer. A randomised trial of epidoxorubicin at two different dosages and two administration systems</span>. <abbr class="cit-jnl-abbrev">Acta Oncol</abbr> <span class="cit-pub-date">1989</span>;<span class="cit-vol">28</span>(<span class="cit-issue">6</span>):<span class="cit-fpage">887</span>-<span class="cit-lpage">892</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=2692652&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1989CL21600020&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Advanced%20breast%20cancer.%20A%20randomised%20trial%20of%20epidoxorubicin%20at%20two%20different%20dosages%20and%20two%20administration%20systems&amp;author=SR%20Ebbs&amp;author=JA%20Saunders&amp;author=H%20Graham&amp;author=RP%20A%E2%80%99Hern&amp;author=T%20Bates&amp;author=M%20Baum&amp;publication_year=1989&amp;journal=Acta%20Oncol&amp;volume=28&amp;issue=6&amp;pages=887-892">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">79.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.79"
                             data-doi="10.1016/0277-5379(86)90075-1">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Gundersen</span>  <span class="cit-name-given-names">S</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Kvinnsland</span>  <span class="cit-name-given-names">S</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Klepp</span>  <span class="cit-name-given-names">O</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Kvaløy</span>  <span class="cit-name-given-names">S</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Lund</span>  <span class="cit-name-given-names">E</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Høst</span>  <span class="cit-name-given-names">H</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Weekly adriamycin versus VAC in advanced breast cancer. A randomized trial</span>. <abbr class="cit-jnl-abbrev">Eur J Cancer Clin Oncol</abbr> <span class="cit-pub-date">1986</span>;<span class="cit-vol">22</span>(<span class="cit-issue">12</span>):<span class="cit-fpage">1431</span>-<span class="cit-lpage">1434</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1016/0277-5379(86)90075-1&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=3595668&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1986F714100004&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Weekly%20adriamycin%20versus%20VAC%20in%20advanced%20breast%20cancer.%20A%20randomized%20trial&amp;author=S%20Gundersen&amp;author=S%20Kvinnsland&amp;author=O%20Klepp&amp;author=S%20Kval%C3%B8y&amp;author=E%20Lund&amp;author=H%20H%C3%B8st&amp;publication_year=1986&amp;journal=Eur%20J%20Cancer%20Clin%20Oncol&amp;volume=22&amp;issue=12&amp;pages=1431-1434">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">80.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.80"
                             data-doi="10.1056/NEJM198712103172402">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Coates</span>  <span class="cit-name-given-names">A</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Gebski</span>  <span class="cit-name-given-names">V</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Bishop</span>  <span class="cit-name-given-names">JF</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous
                                    treatment strategies</span>. <abbr class="cit-jnl-abbrev">N Engl J Med</abbr> <span class="cit-pub-date">1987</span>;<span class="cit-vol">317</span>(<span class="cit-issue">24</span>):<span class="cit-fpage">1490</span>-<span class="cit-lpage">1495</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1056/NEJM198712103172402&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=3683485&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1987L179000002&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Improving%20the%20quality%20of%20life%20during%20chemotherapy%20for%20advanced%20breast%20cancer.%20A%20comparison%20of%20intermittent%20and%20continuous%20treatment%20strategies&amp;author=A%20Coates&amp;author=V%20Gebski&amp;author=JF%20Bishop&amp;publication_year=1987&amp;journal=N%20Engl%20J%20Med&amp;volume=317&amp;issue=24&amp;pages=1490-1495">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">81.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.81">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Focan</span>  <span class="cit-name-given-names">C</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Andrien</span>  <span class="cit-name-given-names">JM</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Closon</span>  <span class="cit-name-given-names">MT</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Dose-response relationship of epirubicin-based first-line chemotherapy for advanced breast cancer: a prospective randomized
                                    trial</span>. <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr> <span class="cit-pub-date">1993</span>;<span class="cit-vol">11</span>(<span class="cit-issue">7</span>):<span class="cit-fpage">1253</span>-<span class="cit-lpage">1263</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=11/7/1253"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">82.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.82">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Andersson</span>  <span class="cit-name-given-names">M</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Madsen</span>  <span class="cit-name-given-names">EL</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Overgaard</span>  <span class="cit-name-given-names">M</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Rose</span>  <span class="cit-name-given-names">C</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Dombernowsky</span>  <span class="cit-name-given-names">P</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Mouridsen</span>  <span class="cit-name-given-names">HT</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Doxorubicin versus methotrexate both combined with cyclophosphamide, 5-fluorouracil and tamoxifen in postmenopausal patients
                                    with advanced breast cancer—a randomised study with more than 10 years follow-up from the Danish Breast Cancer Cooperative
                                    Group. Danish Breast Cancer Cooperative Group (DBCG)</span>. <abbr class="cit-jnl-abbrev">Eur J Cancer</abbr> <span class="cit-pub-date">1999</span>;<span class="cit-vol">35</span>(<span class="cit-issue">1</span>):<span class="cit-fpage">39</span>-<span class="cit-lpage">46</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10211086&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000078642500011&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Doxorubicin%20versus%20methotrexate%20both%20combined%20with%20cyclophosphamide%2C%205-fluorouracil%20and%20tamoxifen%20in%20postmenopausal%20patients%20with%20advanced%20breast%20cancer%E2%80%94a%20randomised%20study%20with%20more%20than%2010%20years%20follow-up%20from%20the%20Danish%20Breast%20Cancer%20Cooperative%20Group.%20Danish%20Breast%20Cancer%20Cooperative%20Group%20%28DBCG%29&amp;author=M%20Andersson&amp;author=EL%20Madsen&amp;author=M%20Overgaard&amp;author=C%20Rose&amp;author=P%20Dombernowsky&amp;author=HT%20Mouridsen&amp;publication_year=1999&amp;journal=Eur%20J%20Cancer&amp;volume=35&amp;issue=1&amp;pages=39-46">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">83.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.83"
                             data-doi="10.1016/0959-8049(95)00489-0">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Hausmaninger</span>  <span class="cit-name-given-names">H</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Lehnert</span>  <span class="cit-name-given-names">M</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Steger</span>  <span class="cit-name-given-names">G</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Randomised phase II study of epirubicin-vindesine versus mitoxantrone-vindesine in metastatic breast cancer</span>. <abbr class="cit-jnl-abbrev">Eur J Cancer</abbr> <span class="cit-pub-date">1995</span>;<span class="cit-vol">31A</span>(<span class="cit-issue">13–14</span>):<span class="cit-fpage">2169</span>-<span class="cit-lpage">2173</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1016/0959-8049(95)00489-0&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Randomised%20phase%20II%20study%20of%20epirubicin-vindesine%20versus%20mitoxantrone-vindesine%20in%20metastatic%20breast%20cancer&amp;author=H%20Hausmaninger&amp;author=M%20Lehnert&amp;author=G%20Steger&amp;publication_year=1995&amp;journal=Eur%20J%20Cancer&amp;volume=31A&amp;issue=13%E2%80%9314&amp;pages=2169-2173">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">84.</span><a class="rev-xref-ref" href="#xref-ref-84-1" title="View reference 84. in text"
                           id="ref-84">↵</a><div class="cit ref-cit ref-journal" id="cit-100.24.1780.84">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Jassem</span>  <span class="cit-name-given-names">J</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Pieńkowski</span>  <span class="cit-name-given-names">T</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Płuzańska</span>  <span class="cit-name-given-names">A</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic
                                    breast cancer: final results of a randomized phase III multicenter trial</span>. <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr> <span class="cit-pub-date">2001</span>;<span class="cit-vol">19</span>(<span class="cit-issue">6</span>):<span class="cit-fpage">1707</span>-<span class="cit-lpage">1715</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=19/6/1707"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">85.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.85"
                             data-doi="10.1056/NEJM200103153441101">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Slamon</span>  <span class="cit-name-given-names">DJ</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Leyland-Jones</span>  <span class="cit-name-given-names">B</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Shak</span>  <span class="cit-name-given-names">S</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2</span>. <abbr class="cit-jnl-abbrev">N Engl J Med</abbr> <span class="cit-pub-date">2001</span>;<span class="cit-vol">344</span>(<span class="cit-issue">11</span>):<span class="cit-fpage">783</span>-<span class="cit-lpage">792</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1056/NEJM200103153441101&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=11248153&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000167440400001&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Use%20of%20chemotherapy%20plus%20a%20monoclonal%20antibody%20against%20HER2%20for%20metastatic%20breast%20cancer%20that%20overexpresses%20HER2&amp;author=DJ%20Slamon&amp;author=B%20Leyland-Jones&amp;author=S%20Shak&amp;publication_year=2001&amp;journal=N%20Engl%20J%20Med&amp;volume=344&amp;issue=11&amp;pages=783-792">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">86.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.86">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Norris</span>  <span class="cit-name-given-names">B</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Pritchard</span>  <span class="cit-name-given-names">KI</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">James</span>  <span class="cit-name-given-names">K</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent
                                    breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8</span>. <abbr class="cit-jnl-abbrev">Clin Oncol</abbr> <span class="cit-pub-date">2000</span>;<span class="cit-vol">18</span>(<span class="cit-issue">12</span>):<span class="cit-fpage">2385</span>-<span class="cit-lpage">2394</span>.</cite></div>
                           <div class="cit-extra"><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Phase%20III%20comparative%20study%20of%20vinorelbine%20combined%20with%20doxorubicin%20versus%20doxorubicin%20alone%20in%20disseminated%20metastatic%2Frecurrent%20breast%20cancer%3A%20National%20Cancer%20Institute%20of%20Canada%20Clinical%20Trials%20Group%20Study%20MA8&amp;author=B%20Norris&amp;author=KI%20Pritchard&amp;author=K%20James&amp;publication_year=2000&amp;journal=Clin%20Oncol&amp;volume=18&amp;issue=12&amp;pages=2385-2394">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">87.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.87">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Ackland</span>  <span class="cit-name-given-names">SP</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Anton</span>  <span class="cit-name-given-names">A</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Breitbach</span>  <span class="cit-name-given-names">GP</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Dose-intensive epirubicin-based chemotherapy is superior to an intensive intravenous cyclophosphamide, methotrexate, and fluorouracil
                                    regimen in metastatic breast cancer: a randomized multinational study</span>. <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr> <span class="cit-pub-date">2001</span>;<span class="cit-vol">19</span>(<span class="cit-issue">4</span>):<span class="cit-fpage">943</span>-<span class="cit-lpage">953</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=19/4/943"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">88.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.88">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Cook</span>  <span class="cit-name-given-names">AM</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Chambers</span>  <span class="cit-name-given-names">EJ</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Rees</span>  <span class="cit-name-given-names">GJ</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Comparison of mitozantrone and epirubicin in advanced breast cancer</span>. <abbr class="cit-jnl-abbrev">Clin Oncol (R Coll Radiol)</abbr> <span class="cit-pub-date">1996</span>;<span class="cit-vol">8</span>(<span class="cit-issue">6</span>):<span class="cit-fpage">363</span>-<span class="cit-lpage">366</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=8973851&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Comparison%20of%20mitozantrone%20and%20epirubicin%20in%20advanced%20breast%20cancer&amp;author=AM%20Cook&amp;author=EJ%20Chambers&amp;author=GJ%20Rees&amp;publication_year=1996&amp;journal=Clin%20Oncol%20%28R%20Coll%20Radiol%29&amp;volume=8&amp;issue=6&amp;pages=363-366">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">89.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.89">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Ingle</span>  <span class="cit-name-given-names">JN</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Mailliard</span>  <span class="cit-name-given-names">JA</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Schaid</span>  <span class="cit-name-given-names">DJ</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Randomized trial of doxorubicin alone or combined with vincristine and mitomycin C in women with metastatic breast cancer</span>. <abbr class="cit-jnl-abbrev">Am J Clin Oncol</abbr> <span class="cit-pub-date">1989</span>;<span class="cit-vol">12</span>(<span class="cit-issue">6</span>):<span class="cit-fpage">474</span>-<span class="cit-lpage">480</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=2686393&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1989CB34700003&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Randomized%20trial%20of%20doxorubicin%20alone%20or%20combined%20with%20vincristine%20and%20mitomycin%20C%20in%20women%20with%20metastatic%20breast%20cancer&amp;author=JN%20Ingle&amp;author=JA%20Mailliard&amp;author=DJ%20Schaid&amp;publication_year=1989&amp;journal=Am%20J%20Clin%20Oncol&amp;volume=12&amp;issue=6&amp;pages=474-480">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">90.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.90"
                             data-doi="10.1007/BF01806182">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Green</span>  <span class="cit-name-given-names">JA</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Slater</span>  <span class="cit-name-given-names">AJ</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Campbell</span>  <span class="cit-name-given-names">IR</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Kelly</span>  <span class="cit-name-given-names">V</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Advanced breast cancer: a randomized study of doxorubicin or mitoxantrone in combination with cyclophosphamide and vincristine</span>. <abbr class="cit-jnl-abbrev">Breast Cancer Res Treat</abbr> <span class="cit-pub-date">1996</span>;<span class="cit-vol">39</span>(<span class="cit-issue">2</span>):<span class="cit-fpage">155</span>-<span class="cit-lpage">163</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1007/BF01806182&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=8872324&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1996VE91200003&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Advanced%20breast%20cancer%3A%20a%20randomized%20study%20of%20doxorubicin%20or%20mitoxantrone%20in%20combination%20with%20cyclophosphamide%20and%20vincristine&amp;author=JA%20Green&amp;author=AJ%20Slater&amp;author=IR%20Campbell&amp;author=V%20Kelly&amp;publication_year=1996&amp;journal=Breast%20Cancer%20Res%20Treat&amp;volume=39&amp;issue=2&amp;pages=155-163">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">91.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.91"
                             data-doi="10.1016/0277-5379(83)90085-8">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Steiner</span>  <span class="cit-name-given-names">R</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Stewart</span>  <span class="cit-name-given-names">JF</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Cantwell</span>  <span class="cit-name-given-names">BM</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Minton</span>  <span class="cit-name-given-names">MJ</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Knight</span>  <span class="cit-name-given-names">RK</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Rubens</span>  <span class="cit-name-given-names">RD</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Adriamycin alone or combined with vincristine in the treatment of advanced breast cancer</span>. <abbr class="cit-jnl-abbrev">Eur J Cancer Clin Oncol</abbr> <span class="cit-pub-date">1983</span>;<span class="cit-vol">19</span>(<span class="cit-issue">11</span>):<span class="cit-fpage">1553</span>-<span class="cit-lpage">1557</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1016/0277-5379(83)90085-8&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=6357805&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1983RS63600008&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Adriamycin%20alone%20or%20combined%20with%20vincristine%20in%20the%20treatment%20of%20advanced%20breast%20cancer&amp;author=R%20Steiner&amp;author=JF%20Stewart&amp;author=BM%20Cantwell&amp;author=MJ%20Minton&amp;author=RK%20Knight&amp;author=RD%20Rubens&amp;publication_year=1983&amp;journal=Eur%20J%20Cancer%20Clin%20Oncol&amp;volume=19&amp;issue=11&amp;pages=1553-1557">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">92.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.92">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Erkisi</span>  <span class="cit-name-given-names">M</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Bilkay</span>  <span class="cit-name-given-names">BC</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Seyrek</span>  <span class="cit-name-given-names">E</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Hazar</span>  <span class="cit-name-given-names">B</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Burgut</span>  <span class="cit-name-given-names">R</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Refractory breast cancer: a comparison of two different chemotherapy regimens</span>. <abbr class="cit-jnl-abbrev">J Chemother</abbr> <span class="cit-pub-date">1997</span>;<span class="cit-vol">9</span>(<span class="cit-issue">6</span>):<span class="cit-fpage">442</span>-<span class="cit-lpage">445</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=9491846&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000071256500010&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Refractory%20breast%20cancer%3A%20a%20comparison%20of%20two%20different%20chemotherapy%20regimens&amp;author=M%20Erkisi&amp;author=BC%20Bilkay&amp;author=E%20Seyrek&amp;author=B%20Hazar&amp;author=R%20Burgut&amp;publication_year=1997&amp;journal=J%20Chemother&amp;volume=9&amp;issue=6&amp;pages=442-445">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">93.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.93">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Capotorto</span>  <span class="cit-name-given-names">AM</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Pavesi</span>  <span class="cit-name-given-names">L</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Pedrazzoli</span>  <span class="cit-name-given-names">P</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Randomized, controlled, multicenter phase III trial of standard-dose fluorouracil-epirubicin-cyclophosphamide (FEC), compared
                                    with time-intensive FEC (FEC-G) and mitoxantrone-methotrexate mitomycin C (MMM-G) in metastatic breast carcinoma</span>. <abbr class="cit-jnl-abbrev">J Chemother</abbr> <span class="cit-pub-date">2003</span>;<span class="cit-vol">15</span>(<span class="cit-issue">2</span>):<span class="cit-fpage">184</span>-<span class="cit-lpage">191</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=12797397&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000183065400014&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Randomized%2C%20controlled%2C%20multicenter%20phase%20III%20trial%20of%20standard-dose%20fluorouracil-epirubicin-cyclophosphamide%20%28FEC%29%2C%20compared%20with%20time-intensive%20FEC%20%28FEC-G%29%20and%20mitoxantrone-methotrexate%20mitomycin%20C%20%28MMM-G%29%20in%20metastatic%20breast%20carcinoma&amp;author=AM%20Capotorto&amp;author=L%20Pavesi&amp;author=P%20Pedrazzoli&amp;publication_year=2003&amp;journal=J%20Chemother&amp;volume=15&amp;issue=2&amp;pages=184-191">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">94.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.94">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Gasparini</span>  <span class="cit-name-given-names">G</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Dal Fior</span>  <span class="cit-name-given-names">S</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Panizzoni</span>  <span class="cit-name-given-names">GA</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Favretto</span>  <span class="cit-name-given-names">S</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Pozza</span>  <span class="cit-name-given-names">F</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Weekly epirubicin versus doxorubicin as second line therapy in advanced breast cancer. A randomized clinical trial</span>. <abbr class="cit-jnl-abbrev">Am J Clin Oncol</abbr> <span class="cit-pub-date">1991</span>;<span class="cit-vol">14</span>(<span class="cit-issue">1</span>):<span class="cit-fpage">38</span>-<span class="cit-lpage">44</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=1987737&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1991EV47900009&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Weekly%20epirubicin%20versus%20doxorubicin%20as%20second%20line%20therapy%20in%20advanced%20breast%20cancer.%20A%20randomized%20clinical%20trial&amp;author=G%20Gasparini&amp;author=S%20Dal%20Fior&amp;author=GA%20Panizzoni&amp;author=S%20Favretto&amp;author=F%20Pozza&amp;publication_year=1991&amp;journal=Am%20J%20Clin%20Oncol&amp;volume=14&amp;issue=1&amp;pages=38-44">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">95.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.95">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Ahmann</span>  <span class="cit-name-given-names">DL</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Schaid</span>  <span class="cit-name-given-names">DJ</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Ingle</span>  <span class="cit-name-given-names">JN</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">A randomized trial of cyclophosphamide, doxorubicin, and prednisone versus cyclophosphamide, 5-fluorouracil, and prednisone
                                    in patients with metastatic breast cancer</span>. <abbr class="cit-jnl-abbrev">Am J Clin Oncol</abbr> <span class="cit-pub-date">1991</span>;<span class="cit-vol">14</span>(<span class="cit-issue">3</span>):<span class="cit-fpage">179</span>-<span class="cit-lpage">183</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=2031502&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1991FN07000001&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=A%20randomized%20trial%20of%20cyclophosphamide%2C%20doxorubicin%2C%20and%20prednisone%20versus%20cyclophosphamide%2C%205-fluorouracil%2C%20and%20prednisone%20in%20patients%20with%20metastatic%20breast%20cancer&amp;author=DL%20Ahmann&amp;author=DJ%20Schaid&amp;author=JN%20Ingle&amp;publication_year=1991&amp;journal=Am%20J%20Clin%20Oncol&amp;volume=14&amp;issue=3&amp;pages=179-183">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">96.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.96"
                             data-doi="10.1097/00000421-199912000-00010">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Cocconi</span>  <span class="cit-name-given-names">G</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Bisagni</span>  <span class="cit-name-given-names">G</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Bella</span>  <span class="cit-name-given-names">M</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Comparison of CMF (cyclophosphamide, methotrexate, and 5-fluorouracil) with a rotational crossing and a sequential intensification
                                    regimen in advanced breast cancer: a prospective randomized study</span>. <abbr class="cit-jnl-abbrev">Am J Clin Oncol</abbr> <span class="cit-pub-date">1999</span>;<span class="cit-vol">22</span>(<span class="cit-issue">6</span>):<span class="cit-fpage">593</span>-<span class="cit-lpage">600</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1097/00000421-199912000-00010&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=10597744&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000084120700010&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Comparison%20of%20CMF%20%28cyclophosphamide%2C%20methotrexate%2C%20and%205-fluorouracil%29%20with%20a%20rotational%20crossing%20and%20a%20sequential%20intensification%20regimen%20in%20advanced%20breast%20cancer%3A%20a%20prospective%20randomized%20study&amp;author=G%20Cocconi&amp;author=G%20Bisagni&amp;author=M%20Bella&amp;publication_year=1999&amp;journal=Am%20J%20Clin%20Oncol&amp;volume=22&amp;issue=6&amp;pages=593-600">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">97.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.97"
                             data-doi="10.1016/0277-5379(87)90149-0">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Spittle</span>  <span class="cit-name-given-names">MF</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Hill</span>  <span class="cit-name-given-names">BT</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Ostrowski</span>  <span class="cit-name-given-names">MJ</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">A randomized, prospective, comparative, multicentre trial of a single combination versus alternating combinations of antitumour
                                    drugs in advanced breast cancer</span>. <abbr class="cit-jnl-abbrev">Eur J Cancer Clin Oncol</abbr> <span class="cit-pub-date">1987</span>;<span class="cit-vol">23</span>(<span class="cit-issue">8</span>):<span class="cit-fpage">1155</span>-<span class="cit-lpage">1162</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1016/0277-5379(87)90149-0&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=3308483&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1987J591400013&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=A%20randomized%2C%20prospective%2C%20comparative%2C%20multicentre%20trial%20of%20a%20single%20combination%20versus%20alternating%20combinations%20of%20antitumour%20drugs%20in%20advanced%20breast%20cancer&amp;author=MF%20Spittle&amp;author=BT%20Hill&amp;author=MJ%20Ostrowski&amp;publication_year=1987&amp;journal=Eur%20J%20Cancer%20Clin%20Oncol&amp;volume=23&amp;issue=8&amp;pages=1155-1162">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">98.</span><a class="rev-xref-ref" href="#xref-ref-98-1" title="View reference 98. in text"
                           id="ref-98">↵</a><div class="cit ref-cit ref-journal" id="cit-100.24.1780.98"
                             data-doi="10.1200/JCO.2002.08.012">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Berruti</span>  <span class="cit-name-given-names">A</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Bitossi</span>  <span class="cit-name-given-names">R</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Gorzegno</span>  <span class="cit-name-given-names">G</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addition of either
                                    cisplatin or lonidamine: final results of a phase III study with a factorial design</span>. <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr> <span class="cit-pub-date">2002</span>;<span class="cit-vol">20</span>(<span class="cit-issue">20</span>):<span class="cit-fpage">4150</span>-<span class="cit-lpage">4159</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=20/20/4150"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">99.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.99"
                             data-doi="10.1200/JCO.2003.08.013">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Sledge</span>  <span class="cit-name-given-names">GW</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Neuberg</span>  <span class="cit-name-given-names">D</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Bernardo</span>  <span class="cit-name-given-names">P</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for
                                    metastatic breast cancer: an intergroup trial (E1193)</span>. <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr> <span class="cit-pub-date">2003</span>;<span class="cit-vol">21</span>(<span class="cit-issue">4</span>):<span class="cit-fpage">588</span>-<span class="cit-lpage">592</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=21/4/588"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">100.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.100"
                             data-doi="10.1200/JCO.2003.04.040">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Nabholtz</span>  <span class="cit-name-given-names">JM</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Falkson</span>  <span class="cit-name-given-names">C</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Campos</span>  <span class="cit-name-given-names">D</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast
                                    cancer: results of a randomized, multicenter, phase III trial</span>. <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr> <span class="cit-pub-date">2003</span>;<span class="cit-vol">21</span>(<span class="cit-issue">6</span>):<span class="cit-fpage">968</span>-<span class="cit-lpage">975</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=21/6/968"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">101.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.101"
                             data-doi="10.1002/(SICI)1097-0142(19990301)85:5&lt;1091::AID-CNCR12&gt;3.0.CO;2-A">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Blajman</span>  <span class="cit-name-given-names">C</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Balbiani</span>  <span class="cit-name-given-names">L</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Block</span>  <span class="cit-name-given-names">J</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">A prospective, randomized phase III trial comparing combination chemotherapy with cyclophosphamide, doxorubicin, and 5-fluorouracil
                                    with vinorelbine plus doxorubicin in the treatment of advanced breast carcinoma</span>. <abbr class="cit-jnl-abbrev">Cancer</abbr> <span class="cit-pub-date">1999</span>;<span class="cit-vol">85</span>(<span class="cit-issue">5</span>):<span class="cit-fpage">1091</span>-<span class="cit-lpage">1097</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1002/(SICI)1097-0142(19990301)85:5%3C1091::AID-CNCR12%3E3.0.CO;2-A&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=10091793&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000078926800012&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=A%20prospective%2C%20randomized%20phase%20III%20trial%20comparing%20combination%20chemotherapy%20with%20cyclophosphamide%2C%20doxorubicin%2C%20and%205-fluorouracil%20with%20vinorelbine%20plus%20doxorubicin%20in%20the%20treatment%20of%20advanced%20breast%20carcinoma&amp;author=C%20Blajman&amp;author=L%20Balbiani&amp;author=J%20Block&amp;publication_year=1999&amp;journal=Cancer&amp;volume=85&amp;issue=5&amp;pages=1091-1097">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">102.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.102"
                             data-doi="10.1002/1097-0142(19891001)64:7&lt;1393::AID-CNCR2820640704&gt;3.0.CO;2-B">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Skeel</span>  <span class="cit-name-given-names">RT</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Andersen</span>  <span class="cit-name-given-names">JW</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Tormey</span>  <span class="cit-name-given-names">DC</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Combination chemotherapy of advanced breast cancer. Comparison of dibromodulcitol, doxorubicin, vincristine, and fluoxymesterone
                                    to thiotepa, doxorubicin, vinblastine, and fluoxymesterone: an Eastern Cooperative Oncology Group study</span>. <abbr class="cit-jnl-abbrev">Cancer</abbr> <span class="cit-pub-date">1989</span>;<span class="cit-vol">64</span>(<span class="cit-issue">7</span>):<span class="cit-fpage">1393</span>-<span class="cit-lpage">1399</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1002/1097-0142(19891001)64:7%3C1393::AID-CNCR2820640704%3E3.0.CO;2-B&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=2505919&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1989AQ66400003&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Combination%20chemotherapy%20of%20advanced%20breast%20cancer.%20Comparison%20of%20dibromodulcitol%2C%20doxorubicin%2C%20vincristine%2C%20and%20fluoxymesterone%20to%20thiotepa%2C%20doxorubicin%2C%20vinblastine%2C%20and%20fluoxymesterone%3A%20an%20Eastern%20Cooperative%20Oncology%20Group%20study&amp;author=RT%20Skeel&amp;author=JW%20Andersen&amp;author=DC%20Tormey&amp;publication_year=1989&amp;journal=Cancer&amp;volume=64&amp;issue=7&amp;pages=1393-1399">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">103.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.103">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Fraser</span>  <span class="cit-name-given-names">SC</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Dobbs</span>  <span class="cit-name-given-names">HJ</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Ebbs</span>  <span class="cit-name-given-names">SR</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Fallowfield</span>  <span class="cit-name-given-names">LJ</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Bates</span>  <span class="cit-name-given-names">T</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Baum</span>  <span class="cit-name-given-names">M</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Combination or mild single agent chemotherapy for advanced breast cancer? CMF vs epirubicin measuring quality of life</span>. <abbr class="cit-jnl-abbrev">Br J Cancer</abbr> <span class="cit-pub-date">1993</span>;<span class="cit-vol">67</span>(<span class="cit-issue">2</span>):<span class="cit-fpage">402</span>-<span class="cit-lpage">406</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=8431375&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1993KK59600035&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Combination%20or%20mild%20single%20agent%20chemotherapy%20for%20advanced%20breast%20cancer%3F%20CMF%20vs%20epirubicin%20measuring%20quality%20of%20life&amp;author=SC%20Fraser&amp;author=HJ%20Dobbs&amp;author=SR%20Ebbs&amp;author=LJ%20Fallowfield&amp;author=T%20Bates&amp;author=M%20Baum&amp;publication_year=1993&amp;journal=Br%20J%20Cancer&amp;volume=67&amp;issue=2&amp;pages=402-406">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">104.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.104">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Carmo-Pereira</span>  <span class="cit-name-given-names">J</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Costa</span>  <span class="cit-name-given-names">FO</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Henriques</span>  <span class="cit-name-given-names">E</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">A comparison of two doses of adriamycin in the primary chemotherapy of disseminated breast carcinoma</span>. <abbr class="cit-jnl-abbrev">Br J Cancer</abbr> <span class="cit-pub-date">1987</span>;<span class="cit-vol">56</span>(<span class="cit-issue">4</span>):<span class="cit-fpage">471</span>-<span class="cit-lpage">473</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=3318902&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1987K709000016&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=A%20comparison%20of%20two%20doses%20of%20adriamycin%20in%20the%20primary%20chemotherapy%20of%20disseminated%20breast%20carcinoma&amp;author=J%20Carmo-Pereira&amp;author=FO%20Costa&amp;author=E%20Henriques&amp;publication_year=1987&amp;journal=Br%20J%20Cancer&amp;volume=56&amp;issue=4&amp;pages=471-473">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">105.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.105"
                             data-doi="10.1023/A:1006387801960">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Estaban</span>  <span class="cit-name-given-names">E</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Lacave</span>  <span class="cit-name-given-names">AJ</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Fernández</span>  <span class="cit-name-given-names">JL</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Phase III trial of cyclophosphamide, epirubicin, fluorouracil (CEF) versus cyclophosphamide, mitoxantrone, fluorouracil (CNF)
                                    in women with metastatic breast cancer</span>. <abbr class="cit-jnl-abbrev">Breast Cancer Res Treat</abbr> <span class="cit-pub-date">1999</span>;<span class="cit-vol">58</span>(<span class="cit-issue">2</span>):<span class="cit-fpage">141</span>-<span class="cit-lpage">150</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1023/A:1006387801960&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=10674879&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000084980000008&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Phase%20III%20trial%20of%20cyclophosphamide%2C%20epirubicin%2C%20fluorouracil%20%28CEF%29%20versus%20cyclophosphamide%2C%20mitoxantrone%2C%20fluorouracil%20%28CNF%29%20in%20women%20with%20metastatic%20breast%20cancer&amp;author=E%20Estaban&amp;author=AJ%20Lacave&amp;author=JL%20Fern%C3%A1ndez&amp;publication_year=1999&amp;journal=Breast%20Cancer%20Res%20Treat&amp;volume=58&amp;issue=2&amp;pages=141-150">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">106.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.106"
                             data-doi="10.1007/s002800000178">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Nielsen</span>  <span class="cit-name-given-names">D</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Dombernowsky</span>  <span class="cit-name-given-names">P</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Larsen</span>  <span class="cit-name-given-names">SK</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Hansen</span>  <span class="cit-name-given-names">OP</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Skovsgaard</span>  <span class="cit-name-given-names">T</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Epirubicin or epirubicin and cisplatin as first-line therapy in advanced breast cancer. A phase III study</span>. <abbr class="cit-jnl-abbrev">Cancer Chemother Pharmacol</abbr> <span class="cit-pub-date">2000</span>;<span class="cit-vol">46</span>(<span class="cit-issue">6</span>):<span class="cit-fpage">459</span>-<span class="cit-lpage">466</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1007/s002800000178&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=11138459&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000165740300004&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Epirubicin%20or%20epirubicin%20and%20cisplatin%20as%20first-line%20therapy%20in%20advanced%20breast%20cancer.%20A%20phase%20III%20study&amp;author=D%20Nielsen&amp;author=P%20Dombernowsky&amp;author=SK%20Larsen&amp;author=OP%20Hansen&amp;author=T%20Skovsgaard&amp;publication_year=2000&amp;journal=Cancer%20Chemother%20Pharmacol&amp;volume=46&amp;issue=6&amp;pages=459-466">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">107.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.107">
                           <div class="cit-metadata"><cite><span class="cit-auth cit-collab">French Epirubicin Study Group</span>. <span class="cit-article-title">A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either
                                    doxorubicin or epirubicin</span>. <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr> <span class="cit-pub-date">1988</span>;<span class="cit-vol">6</span>(<span class="cit-issue">4</span>):<span class="cit-fpage">679</span>-<span class="cit-lpage">688</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=6/4/679"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">108.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.108">
                           <div class="cit-metadata"><cite><span class="cit-auth cit-collab">French Epirubicin Study Group</span>. <span class="cit-article-title">A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide, and epirubicin
                                    regimens differing in epirubicin dose in advanced breast cancer patients</span>. <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr> <span class="cit-pub-date">1991</span>;<span class="cit-vol">9</span>(<span class="cit-issue">2</span>):<span class="cit-fpage">305</span>-<span class="cit-lpage">312</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=9/2/305"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">109.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.109">
                           <div class="cit-metadata"><cite><span class="cit-auth cit-collab">Italian Multicentre Breast Study</span>. <span class="cit-article-title">Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide vs fluorouracil, doxorubicin, and cyclophosphamide
                                    in advanced breast cancer: an Italian multicentre trial</span>. <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr> <span class="cit-pub-date">1988</span>;<span class="cit-vol">6</span>(<span class="cit-issue">6</span>):<span class="cit-fpage">976</span>-<span class="cit-lpage">982</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=6/6/976"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">110.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.110"
                             data-doi="10.1200/JCO.2004.11.503">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Ejlertsen</span>  <span class="cit-name-given-names">B</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Mouridsen</span>  <span class="cit-name-given-names">HT</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Langkjer</span>  <span class="cit-name-given-names">ST</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Phase III study of intravenous vinorelbine in combination with epirubicin versus epirubicin alone in patients with advanced
                                    breast cancer: a Scandinavian Breast Group trial (SBG9403)</span>. <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr> <span class="cit-pub-date">2004</span>;<span class="cit-vol">22</span>(<span class="cit-issue">12</span>):<span class="cit-fpage">2313</span>-<span class="cit-lpage">2320</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=22/12/2313"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">111.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.111"
                             data-doi="10.1038/sj.bjc.6602388">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Icli</span>  <span class="cit-name-given-names">F</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Akbulut</span>  <span class="cit-name-given-names">H</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Uner</span>  <span class="cit-name-given-names">A</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Cisplatin plus oral etoposide (EoP) combination is more effective than paclitaxel in patients with advanced breast cancer
                                    pretreated with anthracyclines: a randomised phase III trial of Turkish Oncology Group</span>. <abbr class="cit-jnl-abbrev">Br J Cancer</abbr> <span class="cit-pub-date">2005</span>;<span class="cit-vol">92</span>(<span class="cit-issue">4</span>):<span class="cit-fpage">639</span>-<span class="cit-lpage">644</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1038/sj.bjc.6602388&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=15726120&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000227167500007&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Cisplatin%20plus%20oral%20etoposide%20%28EoP%29%20combination%20is%20more%20effective%20than%20paclitaxel%20in%20patients%20with%20advanced%20breast%20cancer%20pretreated%20with%20anthracyclines%3A%20a%20randomised%20phase%20III%20trial%20of%20Turkish%20Oncology%20Group&amp;author=F%20Icli&amp;author=H%20Akbulut&amp;author=A%20Uner&amp;publication_year=2005&amp;journal=Br%20J%20Cancer&amp;volume=92&amp;issue=4&amp;pages=639-644">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">112.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.112">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Bonneterre</span>  <span class="cit-name-given-names">J</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Dieras</span>  <span class="cit-name-given-names">V</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Tubiana-Hulin</span>  <span class="cit-name-given-names">M</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Phase II multicentre randomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide
                                    in metastatic breast cancer</span>. <abbr class="cit-jnl-abbrev">Br J Cancer</abbr> <span class="cit-pub-date">2004</span>;<span class="cit-vol">91</span>(<span class="cit-issue">8</span>):<span class="cit-fpage">1466</span>-<span class="cit-lpage">1471</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=15381937&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000224412500010&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Phase%20II%20multicentre%20randomised%20study%20of%20docetaxel%20plus%20epirubicin%20vs%205-fluorouracil%20plus%20epirubicin%20and%20cyclophosphamide%20in%20metastatic%20breast%20cancer&amp;author=J%20Bonneterre&amp;author=V%20Dieras&amp;author=M%20Tubiana-Hulin&amp;publication_year=2004&amp;journal=Br%20J%20Cancer&amp;volume=91&amp;issue=8&amp;pages=1466-1471">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">113.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.113"
                             data-doi="10.1200/JCO.2004.08.157">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Keller</span>  <span class="cit-name-given-names">AM</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Mennel</span>  <span class="cit-name-given-names">RG</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Georgoulias</span>  <span class="cit-name-given-names">VA</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women
                                    with taxane-refractory advanced breast cancer</span>. <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr> <span class="cit-pub-date">2004</span>;<span class="cit-vol">22</span>(<span class="cit-issue">19</span>):<span class="cit-fpage">3893</span>-<span class="cit-lpage">3901</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=22/19/3893"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">114.</span><a class="rev-xref-ref" href="#xref-ref-114-1" title="View reference 114. in text"
                           id="ref-114">↵</a><div class="cit ref-cit ref-journal" id="cit-100.24.1780.114"
                             data-doi="10.1200/JCO.2005.12.106">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Zielinski</span>  <span class="cit-name-given-names">C</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Beslija</span>  <span class="cit-name-given-names">S</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Mrsic-Krmpotic</span>  <span class="cit-name-given-names">Z</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Gemcitabine, epirubicin, and paclitaxel versus fluorouracil, epirubicin, and cyclophosphamide as first-line chemotherapy in
                                    metastatic breast cancer: a Central European Cooperative Oncology Group International, multicenter, prospective, randomized
                                    phase III trial</span>. <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr> <span class="cit-pub-date">2005</span>;<span class="cit-vol">23</span>(<span class="cit-issue">7</span>):<span class="cit-fpage">1401</span>-<span class="cit-lpage">1408</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=23/7/1401"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">115.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.115"
                             data-doi="10.1200/JCO.2005.05.098">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Miller</span>  <span class="cit-name-given-names">KD</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Chap</span>  <span class="cit-name-given-names">LI</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Holmes</span>  <span class="cit-name-given-names">FA</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated
                                    metastatic breast cancer</span>. <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr> <span class="cit-pub-date">2005</span>;<span class="cit-vol">23</span>(<span class="cit-issue">4</span>):<span class="cit-fpage">792</span>-<span class="cit-lpage">799</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=23/4/792"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">116.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.116"
                             data-doi="10.1093/annonc/mdh395">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Fountzilas</span>  <span class="cit-name-given-names">G</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Kalofonos</span>  <span class="cit-name-given-names">HP</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Dafni</span>  <span class="cit-name-given-names">U</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer:
                                    a phase III study conducted by the Hellenic Cooperative Oncology Group</span>. <abbr class="cit-jnl-abbrev">Ann Oncol</abbr> <span class="cit-pub-date">2004</span>;<span class="cit-vol">15</span>(<span class="cit-issue">10</span>):<span class="cit-fpage">1517</span>-<span class="cit-lpage">1526</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=annonc&amp;resid=15/10/1517"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">117.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.117"
                             data-doi="10.1023/B:BREA.0000025405.63953.f9">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Lyman</span>  <span class="cit-name-given-names">GH</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Green</span>  <span class="cit-name-given-names">SJ</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Ravdin</span>  <span class="cit-name-given-names">PM</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">A Southwest Oncology Group Randomized Phase II Study of doxorubicin and paclitaxel as frontline chemotherapy for women with
                                    metastatic breast cancer</span>. <abbr class="cit-jnl-abbrev">Breast Cancer Res Treat</abbr> <span class="cit-pub-date">2004</span>;<span class="cit-vol">85</span>(<span class="cit-issue">2</span>):<span class="cit-fpage">143</span>-<span class="cit-lpage">150</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1023/B:BREA.0000025405.63953.f9&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=15111772&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000221057400005&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=A%20Southwest%20Oncology%20Group%20Randomized%20Phase%20II%20Study%20of%20doxorubicin%20and%20paclitaxel%20as%20frontline%20chemotherapy%20for%20women%20with%20metastatic%20breast%20cancer&amp;author=GH%20Lyman&amp;author=SJ%20Green&amp;author=PM%20Ravdin&amp;publication_year=2004&amp;journal=Breast%20Cancer%20Res%20Treat&amp;volume=85&amp;issue=2&amp;pages=143-150">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">118.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.118">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Buyukunal</span>  <span class="cit-name-given-names">E</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Derman</span>  <span class="cit-name-given-names">U</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Serdengecti</span>  <span class="cit-name-given-names">S</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Berkarda</span>  <span class="cit-name-given-names">B</span></span></li>
                              </ol><cite>. <span class="cit-article-title">A clinical trial of mitoxantrone (novantrone) versus doxorubicin (adriamycin) in combination chemotherapy for metastatic breast
                                    cancer</span>. <abbr class="cit-jnl-abbrev">Chemioterapia</abbr> <span class="cit-pub-date">1987</span>;<span class="cit-vol">6</span>(<span class="cit-issue">5</span>):<span class="cit-fpage">377</span>-<span class="cit-lpage">379</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=3334580&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1987K705900013&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=A%20clinical%20trial%20of%20mitoxantrone%20%28novantrone%29%20versus%20doxorubicin%20%28adriamycin%29%20in%20combination%20chemotherapy%20for%20metastatic%20breast%20cancer&amp;author=E%20Buyukunal&amp;author=U%20Derman&amp;author=S%20Serdengecti&amp;author=B%20Berkarda&amp;publication_year=1987&amp;journal=Chemioterapia&amp;volume=6&amp;issue=5&amp;pages=377-379">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">119.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.119"
                             data-doi="10.1093/annonc/mdi181">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Feher</span>  <span class="cit-name-given-names">O</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Vodvarka</span>  <span class="cit-name-given-names">P</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Jassem</span>  <span class="cit-name-given-names">J</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">First-line gemcitabine versus epirubicin in postmenopausal women aged 60 or older with metastatic breast cancer: a multicenter,
                                    randomized, phase III study</span>. <abbr class="cit-jnl-abbrev">Ann Oncol</abbr> <span class="cit-pub-date">2005</span>;<span class="cit-vol">16</span>(<span class="cit-issue">6</span>):<span class="cit-fpage">899</span>-<span class="cit-lpage">908</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=annonc&amp;resid=16/6/899"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">120.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.120"
                             data-doi="10.1200/JCO.2005.04.173">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Marty</span>  <span class="cit-name-given-names">M</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Cognetti</span>  <span class="cit-name-given-names">F</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Maraninchi</span>  <span class="cit-name-given-names">D</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal
                                    growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group</span>. <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr> <span class="cit-pub-date">2005</span>;<span class="cit-vol">23</span>(<span class="cit-issue">19</span>):<span class="cit-fpage">4265</span>-<span class="cit-lpage">4274</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=23/19/4265"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">121.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.121"
                             data-doi="10.1200/JCO.2005.01.1817">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Langley</span>  <span class="cit-name-given-names">RE</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Carmichael</span>  <span class="cit-name-given-names">J</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Jones</span>  <span class="cit-name-given-names">AL</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Phase III trial of epirubicin plus paclitaxel compared with epirubicin plus cyclophosphamide as first-line chemotherapy for
                                    metastatic breast cancer: United Kingdom National Cancer Research Institute trial AB01</span>. <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr> <span class="cit-pub-date">2005</span>;<span class="cit-vol">23</span>(<span class="cit-issue">33</span>):<span class="cit-fpage">8322</span>-<span class="cit-lpage">8330</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=23/33/8322"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">122.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.122"
                             data-doi="10.1200/JCO.2005.06.236">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Bontenbal</span>  <span class="cit-name-given-names">M</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Creemers</span>  <span class="cit-name-given-names">GJ</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Braun</span>  <span class="cit-name-given-names">HJ</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line
                                    chemotherapy in patients with metastatic breast cancer: results of a Dutch Community Setting Trial for the Clinical Trial
                                    Group of the Comprehensive Cancer Centre</span>. <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr> <span class="cit-pub-date">2005</span>;<span class="cit-vol">23</span>(<span class="cit-issue">28</span>):<span class="cit-fpage">7081</span>-<span class="cit-lpage">7088</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=23/28/7081"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">123.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.123"
                             data-doi="10.1016/S1470-2045(07)70041-4">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Martín</span>  <span class="cit-name-given-names">M</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Ruiz</span>  <span class="cit-name-given-names">A</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Muñoz</span>  <span class="cit-name-given-names">M</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with
                                    anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial</span>. <abbr class="cit-jnl-abbrev">Lancet Oncol</abbr> <span class="cit-pub-date">2007</span>;<span class="cit-vol">8</span>(<span class="cit-issue">3</span>):<span class="cit-fpage">219</span>-<span class="cit-lpage">225</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1016/S1470-2045(07)70041-4&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=17329192&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000244929300025&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Gemcitabine%20plus%20vinorelbine%20versus%20vinorelbine%20monotherapy%20in%20patients%20with%20metastatic%20breast%20cancer%20previously%20treated%20with%20anthracyclines%20and%20taxanes%3A%20final%20results%20of%20the%20phase%20III%20Spanish%20Breast%20Cancer%20Research%20Group%20%28GEICAM%29%20trial&amp;author=M%20Mart%C3%ADn&amp;author=A%20Ruiz&amp;author=M%20Mu%C3%B1oz&amp;publication_year=2007&amp;journal=Lancet%20Oncol&amp;volume=8&amp;issue=3&amp;pages=219-225">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">124.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.124"
                             data-doi="10.1056/NEJMoa064320">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Geyer</span>  <span class="cit-name-given-names">CE</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Forster</span>  <span class="cit-name-given-names">J</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Lindquist</span>  <span class="cit-name-given-names">D</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Lapatinib plus capecitabine for HER2-positive advanced breast cancer</span>. <abbr class="cit-jnl-abbrev">N Engl J Med</abbr> <span class="cit-pub-date">2006</span>;<span class="cit-vol">355</span>(<span class="cit-issue">26</span>):<span class="cit-fpage">2733</span>-<span class="cit-lpage">2743</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1056/NEJMoa064320&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=17192538&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000243110500005&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Lapatinib%20plus%20capecitabine%20for%20HER2-positive%20advanced%20breast%20cancer&amp;author=CE%20Geyer&amp;author=J%20Forster&amp;author=D%20Lindquist&amp;publication_year=2006&amp;journal=N%20Engl%20J%20Med&amp;volume=355&amp;issue=26&amp;pages=2733-2743">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">125.</span><a class="rev-xref-ref" href="#xref-ref-125-1" title="View reference 125. in text"
                           id="ref-125">↵</a><div class="cit ref-cit ref-journal" id="cit-100.24.1780.125"
                             data-doi="10.2165/00024669-200504050-00007">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Moen</span>  <span class="cit-name-given-names">MD</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Wellington</span>  <span class="cit-name-given-names">K</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Gemcitabine: in combination with paclitaxel in the first-line treatment of metastatic breast cancer</span>. <abbr class="cit-jnl-abbrev">Am J Cancer</abbr> <span class="cit-pub-date">2005</span>;<span class="cit-vol">4</span>(<span class="cit-issue">5</span>):<span class="cit-fpage">327</span>-<span class="cit-lpage">323</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.2165/00024669-200504050-00007&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Gemcitabine%3A%20in%20combination%20with%20paclitaxel%20in%20the%20first-line%20treatment%20of%20metastatic%20breast%20cancer&amp;author=MD%20Moen&amp;author=K%20Wellington&amp;publication_year=2005&amp;journal=Am%20J%20Cancer&amp;volume=4&amp;issue=5&amp;pages=327-323">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">126.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.126"
                             data-doi="10.1097/01.coc.0000251244.60473.c5">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Pandya</span>  <span class="cit-name-given-names">KJ</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Phase III study of standard combination versus rotating regimen of induction chemotherapy in patients with hormone insensitive
                                    metastatic breast cancer: an Eastern Cooperative Oncology Group intergroup study (E3185)</span>. <abbr class="cit-jnl-abbrev">Am J Clin Oncol</abbr> <span class="cit-pub-date">2007</span>;<span class="cit-vol">30</span>(<span class="cit-issue">2</span>):<span class="cit-fpage">113</span>-<span class="cit-lpage">125</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1097/01.coc.0000251244.60473.c5&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=17414459&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000245637100003&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Phase%20III%20study%20of%20standard%20combination%20versus%20rotating%20regimen%20of%20induction%20chemotherapy%20in%20patients%20with%20hormone%20insensitive%20metastatic%20breast%20cancer%3A%20an%20Eastern%20Cooperative%20Oncology%20Group%20intergroup%20study%20%28E3185%29&amp;author=KJ%20Pandya&amp;publication_year=2007&amp;journal=Am%20J%20Clin%20Oncol&amp;volume=30&amp;issue=2&amp;pages=113-125">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">127.</span><a class="rev-xref-ref" href="#xref-ref-127-1" title="View reference 127. in text"
                           id="ref-127">↵</a><div class="cit ref-cit ref-journal" id="cit-100.24.1780.127">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Stockler</span>  <span class="cit-name-given-names">M</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Sourjina</span>  <span class="cit-name-given-names">T</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Grimison</span>  <span class="cit-name-given-names">P</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">A randomized trial of capecitabine (C) given intermittently (IC) rather than continuously (CC) compared to classical CMF as
                                    first-line chemotherapy for advanced breast cancer (ABC)</span>. <abbr class="cit-jnl-abbrev">J Clin Oncol. (2007 ASCO Annual Meeting Proceedings Part I)</abbr> <span class="cit-pub-date">2007</span>;<span class="cit-vol">25</span>(<span class="cit-issue">18S</span>):<span class="cit-fpage">1031</span>.</cite></div>
                           <div class="cit-extra"><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=A%20randomized%20trial%20of%20capecitabine%20%28C%29%20given%20intermittently%20%28IC%29%20rather%20than%20continuously%20%28CC%29%20compared%20to%20classical%20CMF%20as%20first-line%20chemotherapy%20for%20advanced%20breast%20cancer%20%28ABC%29&amp;author=M%20Stockler&amp;author=T%20Sourjina&amp;author=P%20Grimison&amp;publication_year=2007&amp;journal=J%20Clin%20Oncol.%20%282007%20ASCO%20Annual%20Meeting%20Proceedings%20Part%20I%29&amp;volume=25&amp;issue=18S&amp;pages=1031">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">128.</span><a class="rev-xref-ref" href="#xref-ref-128-1" title="View reference 128. in text"
                           id="ref-128">↵</a><div class="cit ref-cit ref-journal" id="cit-100.24.1780.128">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Beslija</span>  <span class="cit-name-given-names">S</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Obralic</span>  <span class="cit-name-given-names">N</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Basic</span>  <span class="cit-name-given-names">H</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Randomized trial of sequence vs. combination of capecitabine (X) and docetaxel (T): XT vs. T followed by X after progression
                                    as first-line therapy for patients (pts) with metastatic breast cancer (MBC)</span>. <abbr class="cit-jnl-abbrev">J Clin Oncol. (2006 ASCO Annual Meeting Proceedings Part I)</abbr> <span class="cit-pub-date">2006</span>;<span class="cit-vol">24</span>(<span class="cit-issue">18S</span>):<span class="cit-fpage">571</span>.</cite></div>
                           <div class="cit-extra"><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Randomized%20trial%20of%20sequence%20vs.%20combination%20of%20capecitabine%20%28X%29%20and%20docetaxel%20%28T%29%3A%20XT%20vs.%20T%20followed%20by%20X%20after%20progression%20as%20first-line%20therapy%20for%20patients%20%28pts%29%20with%20metastatic%20breast%20cancer%20%28MBC%29&amp;author=S%20Beslija&amp;author=N%20Obralic&amp;author=H%20Basic&amp;publication_year=2006&amp;journal=J%20Clin%20Oncol.%20%282006%20ASCO%20Annual%20Meeting%20Proceedings%20Part%20I%29&amp;volume=24&amp;issue=18S&amp;pages=571">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">129.</span><a class="rev-xref-ref" href="#xref-ref-129-1" title="View reference 129. in text"
                           id="ref-129">↵</a><div class="cit ref-cit ref-journal" id="cit-100.24.1780.129">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Di Leo</span>  <span class="cit-name-given-names">A</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Gomez</span>  <span class="cit-name-given-names">H</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Aziz</span>  <span class="cit-name-given-names">Z</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Lapatinib (L) with paclitaxel compared to paclitaxel as first-line treatment for patients with metastatic breast cancer: a
                                    phase III randomized, double-blind study of 580 patients</span>. <abbr class="cit-jnl-abbrev">J Clin Oncol. (2007 ASCO Annual Meeting Proceedings Part I)</abbr> <span class="cit-pub-date">2007</span>;<span class="cit-vol">25</span>(<span class="cit-issue">18S</span>):<span class="cit-fpage">1011</span>.</cite></div>
                           <div class="cit-extra"><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Lapatinib%20%28L%29%20with%20paclitaxel%20compared%20to%20paclitaxel%20as%20first-line%20treatment%20for%20patients%20with%20metastatic%20breast%20cancer%3A%20a%20phase%20III%20randomized%2C%20double-blind%20study%20of%20580%20patients&amp;author=A%20Di%20Leo&amp;author=H%20Gomez&amp;author=Z%20Aziz&amp;publication_year=2007&amp;journal=J%20Clin%20Oncol.%20%282007%20ASCO%20Annual%20Meeting%20Proceedings%20Part%20I%29&amp;volume=25&amp;issue=18S&amp;pages=1011">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">130.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.130">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Falkson</span>  <span class="cit-name-given-names">G</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Tormey</span>  <span class="cit-name-given-names">DC</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Carey</span>  <span class="cit-name-given-names">P</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Witte</span>  <span class="cit-name-given-names">R</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Falkson</span>  <span class="cit-name-given-names">HC</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Long-term survival of patients treated with combination chemotherapy for metastatic breast cancer</span>. <abbr class="cit-jnl-abbrev">Eur J Cancer</abbr> <span class="cit-pub-date">1991</span>;<span class="cit-vol">27</span>(<span class="cit-issue">8</span>):<span class="cit-fpage">973</span>-<span class="cit-lpage">977</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=1832906&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1991GC83300010&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Long-term%20survival%20of%20patients%20treated%20with%20combination%20chemotherapy%20for%20metastatic%20breast%20cancer&amp;author=G%20Falkson&amp;author=DC%20Tormey&amp;author=P%20Carey&amp;author=R%20Witte&amp;author=HC%20Falkson&amp;publication_year=1991&amp;journal=Eur%20J%20Cancer&amp;volume=27&amp;issue=8&amp;pages=973-977">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">131.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.131">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Chlebowski</span>  <span class="cit-name-given-names">RT</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Smalley</span>  <span class="cit-name-given-names">RV</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Weiner</span>  <span class="cit-name-given-names">JM</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Irwin</span>  <span class="cit-name-given-names">LE</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Bartolucci</span>  <span class="cit-name-given-names">AA</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Bateman</span>  <span class="cit-name-given-names">JR</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Combination versus sequential single agent chemotherapy in advanced breast cancer: associations with metastatic sites and
                                    long-term survival. The Western Cancer Study Group and the Southeastern Cancer Study Group</span>. <abbr class="cit-jnl-abbrev">Br J Cancer</abbr> <span class="cit-pub-date">1989</span>;<span class="cit-vol">59</span>(<span class="cit-issue">2</span>):<span class="cit-fpage">227</span>-<span class="cit-lpage">230</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=2649130&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1989T680900017&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Combination%20versus%20sequential%20single%20agent%20chemotherapy%20in%20advanced%20breast%20cancer%3A%20associations%20with%20metastatic%20sites%20and%20long-term%20survival.%20The%20Western%20Cancer%20Study%20Group%20and%20the%20Southeastern%20Cancer%20Study%20Group&amp;author=RT%20Chlebowski&amp;author=RV%20Smalley&amp;author=JM%20Weiner&amp;author=LE%20Irwin&amp;author=AA%20Bartolucci&amp;author=JR%20Bateman&amp;publication_year=1989&amp;journal=Br%20J%20Cancer&amp;volume=59&amp;issue=2&amp;pages=227-230">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">132.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.132"
                             data-doi="10.1002/1097-0142(197708)40:2&lt;625::AID-CNCR2820400206&gt;3.0.CO;2-M">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Smalley</span>  <span class="cit-name-given-names">RV</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Carpenter</span>  <span class="cit-name-given-names">J</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Bartolucci</span>  <span class="cit-name-given-names">A</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Vogel</span>  <span class="cit-name-given-names">C</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Krauss</span>  <span class="cit-name-given-names">S</span></span></li>
                              </ol><cite>. <span class="cit-article-title">A comparison of cyclophosphamide, adriamycin, 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine,
                                    prednisone (CMFVP) in patients with metastatic breast cancer: a Southeastern Cancer Study Group project</span>. <abbr class="cit-jnl-abbrev">Cancer</abbr> <span class="cit-pub-date">1977</span>;<span class="cit-vol">40</span>(<span class="cit-issue">2</span>):<span class="cit-fpage">625</span>-<span class="cit-lpage">632</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1002/1097-0142(197708)40:2%3C625::AID-CNCR2820400206%3E3.0.CO;2-M&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=329975&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1977DU12000005&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=A%20comparison%20of%20cyclophosphamide%2C%20adriamycin%2C%205-fluorouracil%20%28CAF%29%20and%20cyclophosphamide%2C%20methotrexate%2C%205-fluorouracil%2C%20vincristine%2C%20prednisone%20%28CMFVP%29%20in%20patients%20with%20metastatic%20breast%20cancer%3A%20a%20Southeastern%20Cancer%20Study%20Group%20project&amp;author=RV%20Smalley&amp;author=J%20Carpenter&amp;author=A%20Bartolucci&amp;author=C%20Vogel&amp;author=S%20Krauss&amp;publication_year=1977&amp;journal=Cancer&amp;volume=40&amp;issue=2&amp;pages=625-632">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">133.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.133">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Smalley</span>  <span class="cit-name-given-names">RV</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Bartolucci</span>  <span class="cit-name-given-names">AA</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Variations in responsiveness and survival of clinical subsets of patients with metastatic breast cancer to two chemotherapy
                                    combinations</span>. <abbr class="cit-jnl-abbrev">Eur J Cancer</abbr> <span class="cit-pub-date">1980</span>;<span class="cit-vol">16</span> <span class="cit-supplement">suppl 1</span>:<span class="cit-fpage">141</span>-<span class="cit-lpage">146</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=7053202&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1980JB86300029&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Variations%20in%20responsiveness%20and%20survival%20of%20clinical%20subsets%20of%20patients%20with%20metastatic%20breast%20cancer%20to%20two%20chemotherapy%20combinations&amp;author=RV%20Smalley&amp;author=AA%20Bartolucci&amp;publication_year=1980&amp;journal=Eur%20J%20Cancer&amp;volume=16&amp;pages=141-146">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">134.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.134">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Vaughn</span>  <span class="cit-name-given-names">CB</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Green</span>  <span class="cit-name-given-names">SJ</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">O’Bryan</span>  <span class="cit-name-given-names">R</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">VP-16 + adriamycin vs. adriamycin alone in advanced adenocarcinoma of the breast, phase II, a randomized trial: a Southwest
                                    Oncology Group study</span>. <abbr class="cit-jnl-abbrev">Med Pediatr Oncol</abbr> <span class="cit-pub-date">1988</span>;<span class="cit-vol">16</span>(<span class="cit-issue">5</span>):<span class="cit-fpage">312</span>-<span class="cit-lpage">319</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=3054453&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1988Q620100004&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=VP-16%20%2B%20adriamycin%20vs.%20adriamycin%20alone%20in%20advanced%20adenocarcinoma%20of%20the%20breast%2C%20phase%20II%2C%20a%20randomized%20trial%3A%20a%20Southwest%20Oncology%20Group%20study&amp;author=CB%20Vaughn&amp;author=SJ%20Green&amp;author=R%20O%E2%80%99Bryan&amp;publication_year=1988&amp;journal=Med%20Pediatr%20Oncol&amp;volume=16&amp;issue=5&amp;pages=312-319">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">135.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.135">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Aisner</span>  <span class="cit-name-given-names">J</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Weinberg</span>  <span class="cit-name-given-names">V</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Perloff</span>  <span class="cit-name-given-names">M</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Chemotherapy versus chemoimmunotherapy (CAF v CAFVP v CMF each +/− MER) for metastatic carcinoma of the breast: a CALGB study.
                                    Cancer and Leukemia Group B</span>. <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr> <span class="cit-pub-date">1987</span>;<span class="cit-vol">5</span>(<span class="cit-issue">10</span>):<span class="cit-fpage">1523</span>-<span class="cit-lpage">1533</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=5/10/1523"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">136.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.136"
                             data-doi="10.1002/1097-0142(19901001)66:7&lt;1621::AID-CNCR2820660729&gt;3.0.CO;2-G">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Falkson</span>  <span class="cit-name-given-names">G</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Gelman</span>  <span class="cit-name-given-names">RS</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Leone</span>  <span class="cit-name-given-names">L</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Falkson</span>  <span class="cit-name-given-names">CI</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Survival of premenopausal women with metastatic breast cancer. Long-term follow-up of Eastern Cooperative Group and Cancer
                                    and Leukemia Group B studies</span>. <abbr class="cit-jnl-abbrev">Cancer</abbr> <span class="cit-pub-date">1990</span>;<span class="cit-vol">66</span>(<span class="cit-issue">7</span>):<span class="cit-fpage">1621</span>-<span class="cit-lpage">1629</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1002/1097-0142(19901001)66:7%3C1621::AID-CNCR2820660729%3E3.0.CO;2-G&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=2208013&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1990ED41300028&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Survival%20of%20premenopausal%20women%20with%20metastatic%20breast%20cancer.%20Long-term%20follow-up%20of%20Eastern%20Cooperative%20Group%20and%20Cancer%20and%20Leukemia%20Group%20B%20studies&amp;author=G%20Falkson&amp;author=RS%20Gelman&amp;author=L%20Leone&amp;author=CI%20Falkson&amp;publication_year=1990&amp;journal=Cancer&amp;volume=66&amp;issue=7&amp;pages=1621-1629">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">137.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.137"
                             data-doi="10.1002/1097-0142(19820515)49:10&lt;1988::AID-CNCR2820491007&gt;3.0.CO;2-L">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Nemoto</span>  <span class="cit-name-given-names">T</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Horton</span>  <span class="cit-name-given-names">J</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Simon</span>  <span class="cit-name-given-names">R</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Comparison of four-combination chemotherapy programs in metastatic breast cancer: comparison of multiple drug therapy with
                                    cytoxan, 5-FU and prednisone versus cytoxan and adriamycin, versus cytoxan, 5-FU and adriamycin, versus cytoxan, 5-FU and
                                    prednisone alternating with cytoxan and adriamycin</span>. <abbr class="cit-jnl-abbrev">Cancer</abbr> <span class="cit-pub-date">1982</span>;<span class="cit-vol">49</span>(<span class="cit-issue">10</span>):<span class="cit-fpage">1988</span>-<span class="cit-lpage">1993</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1002/1097-0142(19820515)49:10%3C1988::AID-CNCR2820491007%3E3.0.CO;2-L&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=7074523&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1982NN04400006&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Comparison%20of%20four-combination%20chemotherapy%20programs%20in%20metastatic%20breast%20cancer%3A%20comparison%20of%20multiple%20drug%20therapy%20with%20cytoxan%2C%205-FU%20and%20prednisone%20versus%20cytoxan%20and%20adriamycin%2C%20versus%20cytoxan%2C%205-FU%20and%20adriamycin%2C%20versus%20cytoxan%2C%205-FU%20and%20prednisone%20alternating%20with%20cytoxan%20and%20adriamycin&amp;author=T%20Nemoto&amp;author=J%20Horton&amp;author=R%20Simon&amp;publication_year=1982&amp;journal=Cancer&amp;volume=49&amp;issue=10&amp;pages=1988-1993">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">138.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.138"
                             data-doi="10.1002/1097-0142(19810801)48:3&lt;681::AID-CNCR2820480304&gt;3.0.CO;2-J">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Cummings</span>  <span class="cit-name-given-names">FJ</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Gelman</span>  <span class="cit-name-given-names">R</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Skeel</span>  <span class="cit-name-given-names">RT</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Phase II trials of Baker's antifol, bleomycin, CCNU, streptozotocin, tilorone, and 5-fluorodeoxyuridine plus arabinosyl cytosine
                                    in metastatic breast cancer</span>. <abbr class="cit-jnl-abbrev">Cancer</abbr> <span class="cit-pub-date">1981</span>;<span class="cit-vol">48</span>(<span class="cit-issue">3</span>):<span class="cit-fpage">681</span>-<span class="cit-lpage">685</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1002/1097-0142(19810801)48:3%3C681::AID-CNCR2820480304%3E3.0.CO;2-J&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=6166363&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1981LY87400003&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Phase%20II%20trials%20of%20Baker%27s%20antifol%2C%20bleomycin%2C%20CCNU%2C%20streptozotocin%2C%20tilorone%2C%20and%205-fluorodeoxyuridine%20plus%20arabinosyl%20cytosine%20in%20metastatic%20breast%20cancer&amp;author=FJ%20Cummings&amp;author=R%20Gelman&amp;author=RT%20Skeel&amp;publication_year=1981&amp;journal=Cancer&amp;volume=48&amp;issue=3&amp;pages=681-685">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">139.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.139">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Thormey</span>  <span class="cit-name-given-names">DC</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Falkson</span>  <span class="cit-name-given-names">G</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Simon</span>  <span class="cit-name-given-names">RM</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">A randomized comparison of two sequentially administered combinations to a single regimen in metastatic breast cancer</span>. <abbr class="cit-jnl-abbrev">Cancer Clin Cancer Clin Trials</abbr> <span class="cit-pub-date">1979</span>;<span class="cit-vol">2</span>(<span class="cit-issue">2</span>):<span class="cit-fpage">247</span>-<span class="cit-lpage">256</span>.</cite></div>
                           <div class="cit-extra"><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=A%20randomized%20comparison%20of%20two%20sequentially%20administered%20combinations%20to%20a%20single%20regimen%20in%20metastatic%20breast%20cancer&amp;author=DC%20Thormey&amp;author=G%20Falkson&amp;author=RM%20Simon&amp;publication_year=1979&amp;journal=Cancer%20Clin%20Cancer%20Clin%20Trials&amp;volume=2&amp;issue=2&amp;pages=247-256">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">140.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.140">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Pannuti</span>  <span class="cit-name-given-names">F</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Iafelice</span>  <span class="cit-name-given-names">G</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Martoni</span>  <span class="cit-name-given-names">A</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Fruet</span>  <span class="cit-name-given-names">F</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Angelelli</span>  <span class="cit-name-given-names">B</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Casadei</span>  <span class="cit-name-given-names">M</span></span></li>
                              </ol><cite>. <span class="cit-article-title">A new six-drug antiblastic regimen (R 14) at low doses (micropolychemotherapy) compared to CMF in the treatment of metastatic
                                    breast cancer: phase III study</span>. <abbr class="cit-jnl-abbrev">Chemioterapia</abbr> <span class="cit-pub-date">1984</span>;<span class="cit-vol">3</span>(<span class="cit-issue">4</span>):<span class="cit-fpage">216</span>-<span class="cit-lpage">219</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=6398121&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1984TJ41600003&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=A%20new%20six-drug%20antiblastic%20regimen%20%28R%2014%29%20at%20low%20doses%20%28micropolychemotherapy%29%20compared%20to%20CMF%20in%20the%20treatment%20of%20metastatic%20breast%20cancer%3A%20phase%20III%20study&amp;author=F%20Pannuti&amp;author=G%20Iafelice&amp;author=A%20Martoni&amp;author=F%20Fruet&amp;author=B%20Angelelli&amp;author=M%20Casadei&amp;publication_year=1984&amp;journal=Chemioterapia&amp;volume=3&amp;issue=4&amp;pages=216-219">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">141.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.141">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Cummings</span>  <span class="cit-name-given-names">FJ</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Gelman</span>  <span class="cit-name-given-names">R</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Horton</span>  <span class="cit-name-given-names">J</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Comparison of CAF versus CMFP in metastatic breast cancer: analysis of prognostic factors</span>. <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr> <span class="cit-pub-date">1985</span>;<span class="cit-vol">3</span>(<span class="cit-issue">7</span>):<span class="cit-fpage">932</span>-<span class="cit-lpage">940</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=3/7/932"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">142.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.142">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Ahmann</span>  <span class="cit-name-given-names">DL</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Bisel</span>  <span class="cit-name-given-names">HF</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Hahn</span>  <span class="cit-name-given-names">RG</span></span></li>
                              </ol><cite>. <span class="cit-article-title">A phase 2 evaluation of 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea (NSC 95441) in patients with advanced breast
                                    cancer</span>. <abbr class="cit-jnl-abbrev">Cancer Res.</abbr> <span class="cit-pub-date">1974</span>;<span class="cit-vol">34</span>(<span class="cit-issue">1</span>):<span class="cit-fpage">27</span>-<span class="cit-lpage">30</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=canres&amp;resid=34/1/27"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">143.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.143">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Ahmann</span>  <span class="cit-name-given-names">DL</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Bisel</span>  <span class="cit-name-given-names">HF</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Hahn</span>  <span class="cit-name-given-names">RG</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Phase II clinical trial of isophosphamide (NSC-109724) in patients with advanced breast cancer</span>. <abbr class="cit-jnl-abbrev">Cancer Chemother Rep</abbr> <span class="cit-pub-date">1974</span>;<span class="cit-vol">58</span>(<span class="cit-issue">6</span>):<span class="cit-fpage">861</span>-<span class="cit-lpage">865</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=4615785&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1974V090000013&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Phase%20II%20clinical%20trial%20of%20isophosphamide%20%28NSC-109724%29%20in%20patients%20with%20advanced%20breast%20cancer&amp;author=DL%20Ahmann&amp;author=HF%20Bisel&amp;author=RG%20Hahn&amp;publication_year=1974&amp;journal=Cancer%20Chemother%20Rep&amp;volume=58&amp;issue=6&amp;pages=861-865">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">144.</span><a class="rev-xref-ref" href="#xref-ref-144-1" title="View reference 144. in text"
                           id="ref-144">↵</a><div class="cit ref-cit ref-journal" id="cit-100.24.1780.144">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Ahmann</span>  <span class="cit-name-given-names">DL</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Schaid</span>  <span class="cit-name-given-names">DJ</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Bisel</span>  <span class="cit-name-given-names">HF</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Hahn</span>  <span class="cit-name-given-names">RG</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Edmonson</span>  <span class="cit-name-given-names">JH</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Ingle</span>  <span class="cit-name-given-names">JN</span></span></li>
                              </ol><cite>. <span class="cit-article-title">The effect on survival of initial chemotherapy in advanced breast cancer: polychemotherapy versus single drug</span>. <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr> <span class="cit-pub-date">1987</span>;<span class="cit-vol">5</span>(<span class="cit-issue">12</span>):<span class="cit-fpage">1928</span>-<span class="cit-lpage">1932</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=5/12/1928"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">145.</span><a class="rev-xref-ref" href="#xref-ref-145-1" title="View reference 145. in text"
                           id="ref-145">↵</a><div class="cit ref-cit ref-journal" id="cit-100.24.1780.145"
                             data-doi="10.1002/1097-0142(197504)35:4&lt;1108::AID-CNCR2820350414&gt;3.0.CO;2-Z">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">De Lena</span>  <span class="cit-name-given-names">M</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Brambilla</span>  <span class="cit-name-given-names">C</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Morabito</span>  <span class="cit-name-given-names">A</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Bonadonna</span>  <span class="cit-name-given-names">G</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Adriamycin plus vincristine compared to and combined with cyclophosphamide, methotrexate, and 5-fluorouracil for advanced
                                    breast cancer</span>. <abbr class="cit-jnl-abbrev">Cancer</abbr> <span class="cit-pub-date">1975</span>;<span class="cit-vol">35</span>(<span class="cit-issue">4</span>):<span class="cit-fpage">1108</span>-<span class="cit-lpage">1115</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1002/1097-0142(197504)35:4%3C1108::AID-CNCR2820350414%3E3.0.CO;2-Z&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=1116104&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=A1975W165600012&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Adriamycin%20plus%20vincristine%20compared%20to%20and%20combined%20with%20cyclophosphamide%2C%20methotrexate%2C%20and%205-fluorouracil%20for%20advanced%20breast%20cancer&amp;author=M%20De%20Lena&amp;author=C%20Brambilla&amp;author=A%20Morabito&amp;author=G%20Bonadonna&amp;publication_year=1975&amp;journal=Cancer&amp;volume=35&amp;issue=4&amp;pages=1108-1115">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">146.</span><a class="rev-xref-ref" href="#xref-ref-146-1" title="View reference 146. in text"
                           id="ref-146">↵</a><div class="cit ref-cit ref-journal" id="cit-100.24.1780.146">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Carmichael</span>  <span class="cit-name-given-names">J</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Possinger</span>  <span class="cit-name-given-names">K</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Phillip</span>  <span class="cit-name-given-names">P</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Advanced breast cancer: a phase II trial with gemcitabine</span>. <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr> <span class="cit-pub-date">1995</span>;<span class="cit-vol">13</span>(<span class="cit-issue">11</span>):<span class="cit-fpage">2731</span>-<span class="cit-lpage">2736</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=13/11/2731"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">147.</span><div class="cit ref-cit ref-journal no-rev-xref" id="cit-100.24.1780.147">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Blum</span>  <span class="cit-name-given-names">JL</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Jones</span>  <span class="cit-name-given-names">SE</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Buzdar</span>  <span class="cit-name-given-names">AU</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer</span>. <abbr class="cit-jnl-abbrev">J Clin Oncol</abbr> <span class="cit-pub-date">1999</span>;<span class="cit-vol">17</span>(<span class="cit-issue">2</span>):<span class="cit-fpage">485</span>-<span class="cit-lpage">493</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jco&amp;resid=17/2/485"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">148.</span><a class="rev-xref-ref" href="#xref-ref-148-1" title="View reference 148. in text"
                           id="ref-148">↵</a><div class="cit ref-cit ref-journal" id="cit-100.24.1780.148"
                             data-doi="10.1093/jnci/83.24.1797-a">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Holmes</span>  <span class="cit-name-given-names">FA</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Walters</span>  <span class="cit-name-given-names">RS</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Theriault</span>  <span class="cit-name-given-names">RL</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer</span>. <abbr class="cit-jnl-abbrev">J Natl Cancer Inst</abbr> <span class="cit-pub-date">1991</span>;<span class="cit-vol">83</span>(<span class="cit-issue">24</span>):<span class="cit-fpage">1797</span>-<span class="cit-lpage">1805</span>.</cite></div>
                           <div class="cit-extra"><a href="/cgi/ijlink?linkType=ABST&amp;journalCode=jnci&amp;resid=83/24/1797-a"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-ijlinks"><span class="cit-reflinks-abstract">Abstract</span><span class="cit-sep cit-reflinks-variant-name-sep">/</span><span class="cit-reflinks-full-text"><span class="free-full-text">FREE </span>Full Text</span></a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">149.</span><a class="rev-xref-ref" href="#xref-ref-149-1" title="View reference 149. in text"
                           id="ref-149">↵</a><div class="cit ref-cit ref-book" id="cit-100.24.1780.149">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Engebraaten</span>  <span class="cit-name-given-names">O</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Natarajan</span>  <span class="cit-name-given-names">V</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Lokkevik</span>  <span class="cit-name-given-names">E</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-comment">A randomized phase II trial with gefitinib and docetaxel in metastatic breast cancer: an evaluation of the treatment regimen
                                    and the factors associated with toxicity. San Antonio Breast Cancer Symposium 2006. Available at: <a href="http://www.sabcs.org">http://www.sabcs.org</a>. Accessed January 13, 2008. Abstract 1093</span>.</cite></div>
                           <div class="cit-extra"></div>
                        </div>
                     </li>
                     <li><span class="ref-label">150.</span><a class="rev-xref-ref" href="#xref-ref-150-1" title="View reference 150. in text"
                           id="ref-150">↵</a><div class="cit ref-cit ref-journal" id="cit-100.24.1780.150"
                             data-doi="10.1056/NEJMoa072113">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Miller</span>  <span class="cit-name-given-names">K</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Wang</span>  <span class="cit-name-given-names">M</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Gralow</span>  <span class="cit-name-given-names">J</span></span>, 
                                 </li>
                                 <li><span class="cit-etal">et al</span></li>
                              </ol><cite>. <span class="cit-article-title">Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer</span>. <abbr class="cit-jnl-abbrev">N Engl J Med</abbr> <span class="cit-pub-date">2007</span>;<span class="cit-vol">357</span>(<span class="cit-issue">26</span>):<span class="cit-fpage">2666</span>-<span class="cit-lpage">2676</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1056/NEJMoa072113&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=18160686&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000251964500005&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Paclitaxel%20plus%20bevacizumab%20versus%20paclitaxel%20alone%20for%20metastatic%20breast%20cancer&amp;author=K%20Miller&amp;author=M%20Wang&amp;author=J%20Gralow&amp;publication_year=2007&amp;journal=N%20Engl%20J%20Med&amp;volume=357&amp;issue=26&amp;pages=2666-2676">Google Scholar</a></div>
                        </div>
                     </li>
                     <li><span class="ref-label">151.</span><a class="rev-xref-ref" href="#xref-ref-151-1" title="View reference 151. in text"
                           id="ref-151">↵</a><div class="cit ref-cit ref-journal" id="cit-100.24.1780.151"
                             data-doi="10.1016/S0895-4356(00)00311-5">
                           <div class="cit-metadata">
                              <ol class="cit-auth-list">
                                 <li><span class="cit-auth"><span class="cit-name-surname">Trikalinos</span>  <span class="cit-name-given-names">TA</span></span>, 
                                 </li>
                                 <li><span class="cit-auth"><span class="cit-name-surname">Ioannidis</span>  <span class="cit-name-given-names">JP</span></span></li>
                              </ol><cite>. <span class="cit-article-title">Predictive modeling and heterogeneity of baseline risk in meta-analysis of individual patient data</span>. <abbr class="cit-jnl-abbrev">J Clin Epidemiol</abbr> <span class="cit-pub-date">2001</span>;<span class="cit-vol">54</span>(<span class="cit-issue">3</span>):<span class="cit-fpage">245</span>-<span class="cit-lpage">252</span>.</cite></div>
                           <div class="cit-extra"><a href="/external-ref?access_num=10.1016/S0895-4356(00)00311-5&amp;link_type=DOI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">CrossRef</a><a href="/external-ref?access_num=11223322&amp;link_type=MED"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-medline">Medline</a><a href="/external-ref?access_num=000167162300005&amp;link_type=ISI"
                                 class="cit-ref-sprinkles cit-ref-sprinkles-webofscience">Web of Science</a><a target="_blank"
                                 href="http://scholar.google.com/scholar_lookup?title=Predictive%20modeling%20and%20heterogeneity%20of%20baseline%20risk%20in%20meta-analysis%20of%20individual%20patient%20data&amp;author=TA%20Trikalinos&amp;author=JP%20Ioannidis&amp;publication_year=2001&amp;journal=J%20Clin%20Epidemiol&amp;volume=54&amp;issue=3&amp;pages=245-252">Google Scholar</a></div>
                        </div>
                     </li>
                  </ol>
               </div><span class="highwire-journal-article-marker-end"></span></div>
            <div id="related">
               <h2>Related articles</h2>
               <ul class="related-list">
                  <div class="cit">
                     <div class="cit-metadata"><span class="cit-first-element cit-section">IN THIS ISSUE<span class="cit-sep cit-sep-after-article-section">:</span> </span><span class="cit-title">IN THIS ISSUE </span> <cite><abbr title="Journal of the National Cancer Institute" class="site-title">JNCI J Natl Cancer Inst</abbr> <span class="cit-print-date"><span class="cit-sep cit-sep-before-article-print-date">(</span>2008<span class="cit-sep cit-sep-after-article-print-date">)</span> </span><span class="cit-vol">100 </span><span class="cit-issue"><span class="cit-sep cit-sep-before-article-issue">(</span>24<span class="cit-sep cit-sep-after-article-issue">):</span> </span><span class="cit-pages"><span class="cit-first-page">1741</span> </span><span class="cit-doi"><span class="cit-sep cit-sep-before-article-doi"> doi:</span>10.1093/jnci/djn459 </span><span class="cit-online-date"><span class="cit-sep cit-sep-before-article-online-date">First published online </span>December 16, 2008 </span></cite>  
                     </div>
                     <div class="cit-extra"><span class="accesscheck jnci;100/24/1741 pdf_extract,full,reprint"></span> 
                        <ul class="cit-views">
                           <li class="first-item"><a href="/content/100/24/1741.1.extract" rel="extract">Extract</a></li>
                           <li><a href="/content/100/24/1741.1.full" rel="full-text">Full Text (HTML)</a></li>
                           <li class="last-item"><a href="/content/100/24/1741.1.full.pdf+html" rel="full-text.pdf">Full Text (PDF)</a></li>
                        </ul>  
                     </div> 
                  </div>
               </ul>
            </div><span id="related-urls"></span></div>
         <div id="col-2">
            
            <div class="article-nav sidebar-nav">
               <a href="/content/100/24/1771.short" title="Previous article" class="previous">« Previous</a><span class="article-nav-sep"> | </span><a href="/content/100/24/1792.short" title="Next article" class="next">Next Article »</a>
               
               <span class="toc-link">
                  				<a href="/content/100/24.toc" title="Table of Contents">Table of Contents</a>
                  			</span>
               
               
            </div>
            <div class="content-box" id="article-cb-main">
               <div class="cb-contents">
                  <h3 class="cb-contents-header"><span>This Article</span></h3>
                  <div class="cb-section cb-slug">
                     <ol>
                        <li>
                           <div id="slugline">
                              
                              <cite>
                                 <abbr title="JNCI Journal of the National Cancer Institute" class="slug-jnl-abbrev">
                                    <nlm:abbrev-journal-title xmlns:nlm="http://schema.highwire.org/NLM/Journal" abbrev-type="publisher">JNCI J Natl Cancer Inst</nlm:abbrev-journal-title></abbr><span class="slug-pub-date" itemprop="datePublished">
                                    (2008) 
                                    </span>
                                 
                                 <span class="slug-vol">
                                    100
                                    </span><span class="slug-issue">
                                    (24):
                                    </span><span class="slug-pages">
                                    1780-1791.
                                    </span>
                                 <span class="slug-doi-wrapper">
                                    
                                    doi:
                                    
                                    <span title="10.1093/jnci/djn414" class="slug-doi">10.1093/jnci/djn414</span>
                                    </span>
                                 </cite>
                              
                              
                              <span class="slug-metadata-note ahead-of-print">
                                 
                                 First published online
                                 
                                 <span class="slug-ahead-of-print-date">December 9, 2008</span>
                                 </span>
                              
                              
                              
                              
                              
                              
                              
                              
                              
                           </div>
                        </li>
                     </ol>
                  </div>
                  <div class="cb-section cb-views">
                     <ol>
                        <li class="abstract-view-link primary"><a href="/content/100/24/1780.abstract" rel="view-abstract">Abstract</a><span class="free">Free</span></li>
                        <li class="notice full-text-view-link"><span class="variant-indicator">» <span>Full Text (HTML)</span></span><span class="free">Free</span></li>
                        <li class="notice full-text-pdf-view-link"><a href="/content/100/24/1780.full.pdf+html" rel="view-full-text.pdf">Full Text (PDF)</a><span class="free">Free</span></li>
                        <li><a href="/content/100/24/1780/suppl/DC1" rel="supplemental-data"
                              class="dslink-supplementary-material">Supplementary Material</a></li>
                        <li class="cb-versions">
                           <div><span id="pap-all-versions-label">All Versions of this Article:</span><ol class="version-list">
                                 <li><a href="/content/early/2008/12/09/jnci.djn414">djn414v1</a></li>
                                 <li class="current-li"><span>100/24/1780</span> <span class="current-version">most recent</span></li>
                              </ol>
                           </div>
                        </li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible" id="cb-art-cat">
                     <h4 class="cb-section-header"><span>Classifications</span></h4>
                     <ol>
                        <li>
                           <ul class="subject-headings last-child">
                              <li><a class="tocsection-search"
                                    href="/search?tocsectionid=ARTICLES&amp;sortspec=date&amp;submit=Submit">Article</a></li>
                           </ul>
                        </li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible" id="cb-art-svcs">
                     <h4 class="cb-section-header"><span>Services</span></h4>
                     <ol>
                        <li class="usage-stats-link icon-link"><a href="/articleusage?gca=jnci;100/24/1780" rel="nofollow">Article metrics</a></li>
                        <li class="alert-link icon-link"><a href="/cgi/alerts/ctalert?alertType=citedby&amp;addAlert=cited_by&amp;cited_by_criteria_resid=jnci%3B100%2F24%2F1780&amp;saveAlert=no&amp;return-type=article&amp;return_url=http://jnci.oxfordjournals.org/content/100/24/1780.full">Alert me when cited</a></li>
                        <li class="alert-link icon-link"><a href="/cgi/alerts/ctalert?alertType=correction&amp;addAlert=correction&amp;correction_criteria_value=100/24/1780&amp;saveAlert=no&amp;return-type=article&amp;return_url=http://jnci.oxfordjournals.org/content/100/24/1780.full">Alert me if corrected</a></li>
                        <li class="similar-link"><a href="/search?qbe=jnci%3Bdjn414&amp;citation=Mauri%20et%20al.%20100%20%2824%29:%201780&amp;submit=yes">Find similar articles</a></li>
                        <li class="similar-link"><a href="/external-ref?access_num=jnci%3B100%2F24%2F1780&amp;link_type=ISI_RELATEDRECORDS"
                              id="cb-isi-similar-articles"
                              class="similar-link">Similar articles in Web of Science</a></li>
                        <li class="similar-link"><a href="/external-ref?access_num=19066278&amp;link_type=MED_NBRS"
                              class="similar-link">Similar articles in PubMed</a></li>
                        <li class="folder-link icon-link"><a href="/cgi/folders?action=addtofolder&amp;wherefrom=JOURNALS&amp;wrapped_id=jnci%3B100%2F24%2F1780">Add to my archive</a></li>
                        <li class="cit-man-link icon-link cite-link"><a href="/citmgr?gca=jnci%3B100%2F24%2F1780">Download citation</a></li>
                        <li><a class="request-permissions"
                              href="https://s100.copyright.com/AppDispatchServlet?publisherName=oup&amp;publication=jnci&amp;title=Multiple-Treatments%20Meta-analysis%20of%20Chemotherapy%20and%20Targeted%20Therapies%20in%20Advanced%20Breast%20Cancer%3A%20&amp;publicationDate=12%2F17%2F2008&amp;author=Davide%20Mauri%2C%20Nikolaos%20P.%20Polyzos%2C%20Georgia%20Salanti%2C%20Nicholas%20Pavlidis%2C%20John%20P.%20A.%20Ioannidis&amp;copyright=Oxford%20University%20Press&amp;contentID=10.1093%2Fjnci%2Fdjn414&amp;volumeNum=100&amp;issueNum=24&amp;startPage=1780&amp;endPage=1791&amp;orderBeanReset=true"
                              target="_blank">Request Permissions</a></li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible default-closed" id="cb-art-cit">
                     <h4 class="cb-section-header"><span>Citing Articles</span></h4>
                     <ol>
                        <li class="hw-citing-link"><a href="/content/100/24/1780.full?cited-by=yes&amp;legid=jnci;100/24/1780#cited-by"
                              id="cb-hw-citing-articles">Load citing article information</a></li>
                        <li><a href="/cgi/crossref-forward-links/100/24/1780" rel="external-nw"
                              id="cb-crossref-citing-articles">Citing articles via CrossRef</a></li>
                        <li><a href="/scopus-links/jnci/100/24/1780?access_num=/jnci/100/24/1780"
                              rel="external-nw"
                              id="cb-scopus-citing-articles">Citing articles via Scopus</a></li>
                        <li><a href="/external-ref?access_num=%2Fjnci%2F100%2F24%2F1780&amp;link_type=ISI_CITING&amp;accnum_type=native"
                              rel="external-nw"
                              id="cb-isi-citing-articles">Citing articles via Web of Science</a></li>
                        <li><a href="/external-ref?access_num=http://jnci.oxfordjournals.org/content/100/24/1780.abstract&amp;link_type=GOOGLESCHOLAR">Citing articles via Google Scholar</a></li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible default-closed" id="cb-art-gs">
                     <h4 class="cb-section-header"><span>Google Scholar</span></h4>
                     <ol>
                        <li class="cb-art-gs-auth author-link"><a href="http://scholar.google.com/scholar?q=%22author%3AMauri%20author%3AD.%22"
                              class="cb-art-gs-auth author-link">Articles by  Mauri, D.</a></li>
                        <li class="cb-art-gs-auth author-link"><a href="http://scholar.google.com/scholar?q=%22author%3AIoannidis%20author%3AJ.P.A.%22"
                              class="cb-art-gs-auth author-link">Articles by  Ioannidis, J. P. A.</a></li>
                        <li class="cb-art-gs-rel similar-link"><a href="/external-ref?access_num=http://jnci.oxfordjournals.org/content/100/24/1780.abstract&amp;link_type=GOOGLESCHOLARRELATED">Search for related content</a></li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible default-closed" id="cb-art-pm">
                     <h4 class="cb-section-header"><span>PubMed</span></h4>
                     <ol>
                        <li class="cb-art-pm-cite cite-link icon-link"><a href="/external-ref?access_num=19066278&amp;link_type=PUBMED"
                              class="cb-art-pm-cite cite-link icon-link">PubMed citation</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Mauri%20D&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Mauri, D.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Polyzos%20NP&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Polyzos, N. P.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Salanti%20G&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Salanti, G.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Pavlidis%20N&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Pavlidis, N.</a></li>
                        <li class="cb-art-pm-auth author-link"><a href="/external-ref?access_num=Ioannidis%20JP&amp;link_type=AUTHORSEARCH"
                              class="cb-art-pm-auth author-link">Articles by  Ioannidis, J. P. A.</a></li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible default-closed" id="cb-art-rel">
                     <h4 class="cb-section-header"><span>Related Content</span></h4>
                     <ol>
                        <li><a href="#related">Related articles in this journal</a></li>
                        <li><a href="/content/100/24/1780.full?related-urls=yes&amp;legid=jnci;100/24/1780#related-urls"
                              id="cb-related-urls">Load related web page information</a></li>
                     </ol>
                  </div>
                  <div class="cb-section collapsible" id="cb-art-soc">
                     <h4 class="cb-section-header"><span>Share</span></h4>
                     <ol>
                        <li><a href="/email?gca=jnci%3B100%2F24%2F1780&amp;current-view-path=/content/100/24/1780.full">
                              Email this article</a></li>
                        <li>
                           <div class="social-bookmarking">
                              
                              <ul class="social-bookmark-links">
                                 <li class="social-bookmarking-item social-bookmarking-item-citeulike"><a href="/external-ref?tag_url=http://jnci.oxfordjournals.org/cgi/content/long/100/24/1780&amp;title=Multiple-Treatments%20Meta-analysis%20of%20Chemotherapy%20and%20Targeted%20Therapies%20in%20Advanced%20Breast%20Cancer+--+Mauri%20et%20al.%20100%20%2824%29%3A%201780+--+jnci&amp;doi=10.1093/jnci/djn414&amp;link_type=CITEULIKE"><img src="/shared/img/common/social-bookmarking/citeulike.gif"
                                            alt="Add to CiteULike"
                                            title="CiteULike" /></a><span class="soc-bm-link-text">CiteULike</span></li>
                                 <li class="social-bookmarking-item social-bookmarking-item-delicious"><a href="/external-ref?tag_url=http://jnci.oxfordjournals.org/cgi/content/long/100/24/1780&amp;title=Multiple-Treatments%20Meta-analysis%20of%20Chemotherapy%20and%20Targeted%20Therapies%20in%20Advanced%20Breast%20Cancer+--+Mauri%20et%20al.%20100%20%2824%29%3A%201780+--+jnci&amp;doi=10.1093/jnci/djn414&amp;link_type=DEL_ICIO_US"><img src="/shared/img/common/social-bookmarking/delicious.gif"
                                            alt="Add to Delicious"
                                            title="Delicious" /></a><span class="soc-bm-link-text">Delicious</span></li>
                                 <li class="social-bookmarking-item social-bookmarking-item-facebook"><a href="/external-ref?tag_url=http://jnci.oxfordjournals.org/cgi/content/short/100/24/1780&amp;title=Multiple-Treatments%20Meta-analysis%20of%20Chemotherapy%20and%20Targeted%20Therapies%20in%20Advanced%20Breast%20Cancer+--+Mauri%20et%20al.%20100%20%2824%29%3A%201780+--+jnci&amp;doi=10.1093/jnci/djn414&amp;link_type=FACEBOOK"
                                       class="sb-facebook"
                                       rel="external-nw"><img src="/shared/img/common/social-bookmarking/facebook.gif" alt="Add to Facebook"
                                            title="Facebook" /></a><span class="soc-bm-link-text">Facebook</span></li>
                                 <li class="social-bookmarking-item social-bookmarking-item-googleplus"><a href="/external-ref?tag_url=http://jnci.oxfordjournals.org/cgi/content/long/100/24/1780&amp;title=Multiple-Treatments%20Meta-analysis%20of%20Chemotherapy%20and%20Targeted%20Therapies%20in%20Advanced%20Breast%20Cancer+--+Mauri%20et%20al.%20100%20%2824%29%3A%201780+--+jnci&amp;doi=10.1093/jnci/djn414&amp;link_type=GOOGLEPLUS&amp;log_only=yes"><img src="/shared/img/common/social-bookmarking/googleplus.jpg" alt="Add to Google+"
                                            title="Google+" /></a><span class="soc-bm-link-text">Google+</span></li>
                                 <li class="social-bookmarking-item social-bookmarking-item-mendeley"><a href="/external-ref?tag_url=http://jnci.oxfordjournals.org/cgi/content/long/100/24/1780&amp;title=Multiple-Treatments%20Meta-analysis%20of%20Chemotherapy%20and%20Targeted%20Therapies%20in%20Advanced%20Breast%20Cancer+--+Mauri%20et%20al.%20100%20%2824%29%3A%201780+--+jnci&amp;doi=10.1093/jnci/djn414&amp;link_type=MENDELEY"><img src="/shared/img/common/social-bookmarking/mendeley.gif" alt="Add to Mendeley"
                                            title="Mendeley" /></a><span class="soc-bm-link-text">Mendeley</span></li>
                                 <li class="social-bookmarking-item social-bookmarking-item-twitter"><a href="/external-ref?tag_url=http://jnci.oxfordjournals.org/cgi/content/long/100/24/1780&amp;title=Multiple-Treatments%20Meta-analysis%20of%20Chemotherapy%20and%20Targeted%20Therapies%20in%20Advanced%20Breast%20Cancer+--+Mauri%20et%20al.%20100%20%2824%29%3A%201780+--+jnci&amp;doi=10.1093/jnci/djn414&amp;link_type=TWITTER"><img src="/shared/img/common/social-bookmarking/twitter.gif" alt="Add to Twitter"
                                            title="Twitter" /></a><span class="soc-bm-link-text">Twitter</span></li>
                              </ul>
                              
                              <p class="social-bookmarking-help"><a href="/help/social_bookmarks.dtl">What's this?</a></p>
                              
                           </div>
                        </li>
                     </ol>
                  </div>
               </div>
            </div>
            
            
            <div class="content-box" id="article-dyn-nav">
               <div class="cb-contents">
                  <h3 class="cb-contents-header"><span>Navigate This Article</span></h3>
                  <div class="cb-section" id="cb-art-nav">
                     <ol>
                        <li><a href="#content-block">Top</a></li>
                        <li><a href="#abstract-1">Abstract</a></li>
                        <li><a href="#sec-11">Methods</a></li>
                        <li><a href="#sec-17">Results</a></li>
                        <li><a href="#sec-22">Discussion</a></li>
                        <li><a href="#sec-23">Funding</a></li>
                        <li><a href="#fn-group-1">Footnotes</a></li>
                        <li><a href="#ref-list-1">References</a></li>
                     </ol>
                  </div>
               </div>
            </div>
            
         </div>
         <div id="col-3">
            
            <div id="col-3-qs" class="sidebar-qs">
               
               
               <form class="searchbox" action="/search" method="get">
                  <p>Search this journal:</p>
                  <div>
                     	
                     	
                     	<input value="" type="text" name="fulltext" id="header-qs-input" />
                     <input type="hidden" name="submit" value="yes" />
                     
                     <input class="inline_button" type="image" alt="Go" src="/publisher/img/buttons/go.gif" />
                     
                     <div class="adv-search-link"><a href="/search">Advanced »</a></div>
                     
                     
                  </div>
               </form>
               
            </div>
            <div class="cb-contents">
               
               <div id="sidebar-current-issue" class="content-box">
                  	
                  <h3 class="cb-contents-header">Current Issue</h3>
                  	
                  <div class="cb-section">
                     	  
                     <ol>
                        <li>
                           	      <a href="/content/current"><span>
                                 		  <span class="current-issue-date">
                                    October 2015
                                    </span><span class="toc-citation-volume">
                                    
                                    107
                                    </span><span class="toc-citation-issue">(10)</span>
                                 		  
                                 		</span></a>
                           	    
                        </li>
                     </ol>
                     	
                  </div>
                  	
                  <div class="cb-section">
                     	  
                     <ol>
                        <li>
                           <a href="/content/current"><img src="/content/107/10.cover.gif" alt="JNCI J Natl Cancer Inst" id="cover" /></a>
                           
                        </li>
                     </ol>
                     	
                  </div>
                  	
                  <div class="cb-section sidebar-etoc-link">
                     	  
                     <ol>
                        <li><a href="/cgi/alerts/etoc">Alert me to new issues</a></li>
                     </ol>
                     	
                  </div>
                  
               </div>
               
            </div>
            
            <div id="second">
               
               <div class="ad_hidden" id="oas_right1">
                  <iframe id="id_advertframe_right1"
                          src="/resource/htmlfiles/advert.html?p=Right1&amp;u=jnci.oxfordjournals.org/content/100/24/1780.full"
                          width="0"
                          height="0"
                          frameborder="0"
                          scrolling="no"
                          class="resize_ad"></iframe>
                  
               </div>
               
               <div class="features">
                  
                  <div class="feature separator_after first">
                     
                     <h2 id="the_journal" title="The Journal"><span>The Journal</span></h2>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="http://www.oxfordjournals.org/our_journals/jnci/about.html" rel=""
                              title="About this journal">About this journal</a>
                           
                        </li>
                        <li>
                           <a href="http://www.oxfordjournals.org/our_journals/jnci/contact_us.html" rel=""
                              title="Contact Us">Contact Us</a>
                           
                        </li>
                        <li>
                           <a href="http://www.oxfordjournals.org/access_purchase/rights_permissions.html"
                              rel=""
                              title="Rights &amp; Permissions">Rights &amp; Permissions</a>
                           
                        </li>
                        <li>
                           <a href="HTTP://www.oxfordjournals.org/access_purchase/dispatch_dates.html#JNCI.JP"
                              rel=""
                              title="Dispatch date of next issue">Dispatch date of next issue</a>
                           
                        </li>
                        <li>
                           <a href="http://publicationethics.org/" rel=""
                              title="This journal is a member of the Committee on Publication Ethics (COPE)">This journal is a member of the Committee on Publication Ethics (COPE)</a>
                           
                        </li>
                        <li>
                           <a href="http://www.oxfordjournals.org/mobile_faqs.html" rel=""
                              title="We are mobile – find out more">We are mobile – find out more</a>
                           
                        </li>
                        <li>
                           <a href="http://medicine-and-health-careernetwork.oxfordjournals.org/jobseeker/search/results/?t730=&amp;t732=469986&amp;t731=&amp;t733=&amp;t735=&amp;t737=&amp;max=25&amp;site_id=20102"
                              rel=""
                              title="Journals Career Network">Journals Career Network</a>
                           
                        </li>
                     </ul>
                     
                     <p>
                        <a href="http://www.oxfordjournals.org/our_journals/jnci/episodes_2012.html">
                           <img alt="Podcast Logo" style="float:left"
                                src="http://www.oxfordjournals.org/podcasts/podcast_icon_35x35.gif" />JNCI Podcast</a>
                        <br />
                        <br />
                        
                     </p>
                     
                  </div>
                  
                  <div class="feature separator_after">
                     
                     <h3>Connect with us!</h3>
                     <a href="https://twitter.com/JNCI_Now">
                        <img class="small_margin" alt="Connect with us on Twitter!"
                             src="http://www.oxfordjournals.org/our_journals/phisci/connect_twitter.png"
                             style="vertical-align: top; float: left; " />
                        </a>
                     <a href="https://www.facebook.com/thejnci">
                        <img class="small_margin" alt="Connect with us on Facebook!"
                             src="http://www.oxfordjournals.org/our_journals/phisci/facebook.png"
                             style="vertical-align: top; float: left; " />
                        </a>
                     
                     <p>
                        <br />
                        <br />
                        
                     </p>
                     
                  </div>
                  
                  <div class="feature separator_after">
                     
                     <h3>Editor-in-Chief</h3>
                     
                     <p>Carmen J. Allegra</p>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="http://www.oxfordjournals.org/our_journals/jnci/editorial_board.html"
                              rel=""
                              title="View full editorial board">View full editorial board</a>
                           
                        </li>
                     </ul>
                     
                  </div>
                  
                  <div class="feature separator_after">
                     
                     <h3>Impact factor: 12.583</h3>
                     
                     <h3 class="five_year">5-Yr impact factor: 13.584</h3>
                     
                  </div>
                  
                  <div class="feature">
                     
                     <h3>For the Media</h3>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="http://www.oxfordjournals.org/our_journals/jnci/press_room.html" rel=""
                              title="JNCI PRESS ROOM">JNCI PRESS ROOM</a>
                           
                        </li>
                     </ul>
                     
                  </div>
                  
                  <div class="feature">
                     
                     <h2 id="for_authors" title="For Authors"><span>For Authors</span></h2>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="http://www.oxfordjournals.org/our_journals/jnci/for_authors/index.html"
                              rel=""
                              title="Instructions to authors">Instructions to authors</a>
                           
                        </li>
                        <li>
                           <a href="http://www.oxfordjournals.org/access_purchase/self-archiving_policyb.html"
                              rel=""
                              title="Self Archiving/Public Access Policy">Self Archiving/Public Access Policy</a>
                           
                        </li>
                     </ul>
                     <a href="http://www.oxfordjournals.org/oxfordopen/ ">
                        <img alt="Open access options for authors - visit Oxford Open"
                             src="http://www.oxfordjournals.org/resource/image/promos/oxford_open_small.gif" />
                        </a>
                     <a href="http://www.oxfordjournals.org/oxfordopen/funder_policies/">
                        <img alt="RCUK Wellcome Trust Open Access"
                             src="http://www.oxfordjournals.org/resource/image/wellcome-trust-180x100.jpg" />
                        </a>
                     
                     <p>Open access options for authors - visit <a href="http://www.oxfordjournals.org/oxfordopen/">Oxford Open</a>
                        
                     </p>
                     <a href="http://publicaccess.nih.gov/submit_process_journals.htm">
                        <img alt="PMC Logo" src="http://www.oxfordjournals.org/resource/image/pmc-logo.gif" />
                        </a>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="http://publicaccess.nih.gov/submit_process_journals.htm" rel=""
                              title="This journal enables compliance with the NIH Public Access Policy">This journal enables compliance with the NIH Public Access Policy</a>
                           
                        </li>
                     </ul>
                     
                  </div>
                  
                  <div class="feature">
                     
                     <h2 id="alerting_services" title="Alerting Services"><span>Alerting Services</span></h2>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="/cgi/alerts/etoc" rel="" title="Email table of contents">Email table of contents</a>
                           
                        </li>
                        <li>
                           <a href="/cgi/alerts/etoc" rel="" title="Email Advance Access">Email Advance Access</a>
                           
                        </li>
                        <li>
                           <a href="http://jnci.oxfordjournals.org/help/citetrack/index.dtl" rel=""
                              title="CiteTrack">CiteTrack</a>
                           
                        </li>
                        <li>
                           <a href="/rss" rel="" title="XML RSS feed">XML RSS feed</a>
                           
                        </li>
                     </ul>
                     
                  </div>
                  
                  <div class="feature">
                     
                     <h2 id="corporate_services" title="Corporate Services"><span>Corporate Services</span></h2>
                     
                     <ul class="emphasised">
                        <li>
                           <a href="http://www.oxfordjournals.org/corporate_services/advertising.html" rel=""
                              title="Advertising sales">Advertising sales</a>
                           
                        </li>
                        <li>
                           <a href="http://www.oxfordjournals.org/corporate_services/reprints.html" rel=""
                              title="Reprints">Reprints</a>
                           
                        </li>
                        <li>
                           <a href="http://www.oxfordjournals.org/corporate_services/classifiedadinprint.html"
                              rel=""
                              title="Classified Advertising">Classified Advertising</a>
                           
                        </li>
                     </ul>
                     
                  </div>
                  
               </div>
               <script type="text/javascript">var taxonomies = ["MED00300"];</script>
               </div>
            
            <div class="most-links-box js-marker">
               
               <div class="most-header">
                  
                  <h3>Most</h3>
                  
               </div>
               
               <ul>
                  <li class="most-cur-sel">
                     <h4>Most Read</h4>
                     	  
                     <div class="most-list">
                        	    
                        <ol>
                           <li class="first-item"><a href="http://jnci.oxfordjournals.org/cgi/content/short/92/6/443?rss=1&amp;ssource=mfr">Breast Density and Cancer Risk: What Is the Relationship?</a></li>
                           <li><a href="http://jnci.oxfordjournals.org/cgi/content/short/90/9/713?rss=1&amp;ssource=mfr">The Female Prostate</a></li>
                           <li><a href="http://jnci.oxfordjournals.org/cgi/content/short/91/14/1194?rss=1&amp;ssource=mfr">Tobacco Smoke Carcinogens and Lung Cancer</a></li>
                           <li><a href="http://jnci.oxfordjournals.org/cgi/content/short/107/6/djv048?rss=1&amp;ssource=mfr">Annual Report to the Nation on the Status of Cancer, 1975-2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity,
                                 Poverty, and State</a></li>
                           <li class="last-item"><a href="http://jnci.oxfordjournals.org/cgi/content/short/105/23/1799?rss=1&amp;ssource=mfr">Elevated Plasma Vitamin B12 Levels as a Marker for Cancer: A Population-Based Cohort Study</a></li>
                        </ol>
                        	    <a href="http://jnci.oxfordjournals.org/reports/mfr1.dtl" class="view-all">» View all Most Read articles</a>
                        	  
                     </div>
                     	
                  </li>
                  <li>
                     <h4>Most Cited</h4>
                     	
                     <div class="most-list">
                        	  
                        <ol>
                           <li class="first-item"><a href="http://jnci.oxfordjournals.org/cgi/content/short/92/3/205?rss=1&amp;ssource=mfc">New Guidelines to Evaluate the Response to Treatment in Solid Tumors</a></li>
                           <li><a href="http://jnci.oxfordjournals.org/cgi/content/short/90/18/1371?rss=1&amp;ssource=mfc">Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study</a></li>
                           <li><a href="http://jnci.oxfordjournals.org/cgi/content/short/85/5/365?rss=1&amp;ssource=mfc">The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International
                                 Clinical Trials in Oncology</a></li>
                           <li><a href="http://jnci.oxfordjournals.org/cgi/content/short/82/13/1107?rss=1&amp;ssource=mfc">New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening</a></li>
                           <li class="last-item"><a href="http://jnci.oxfordjournals.org/cgi/content/short/82/1/4?rss=1&amp;ssource=mfc">What Is the Evidence That Tumors Are Angiogenesis Dependent?</a></li>
                        </ol>
                        	  <a href="http://jnci.oxfordjournals.org/reports/mfc1.dtl" class="view-all">» View all Most Cited articles</a>
                        	
                     </div>
                     
                  </li>
               </ul>
               
            </div>
            
            
            
         </div>
         
         
         
         <div id="oas_bottom" class="ad_hidden">
            <iframe id="id_advertframe_bottom"
                    src="/resource/htmlfiles/advert.html?p=Bottom&amp;u=jnci.oxfordjournals.org/content/100/24/1780.full"
                    width="0"
                    height="0"
                    frameborder="0"
                    scrolling="no"
                    class="resize_ad"></iframe>
            
         </div>
         
         
         
         
         
         
         <div id="secondary_footer">
            
            <div id="issn">Online ISSN 1460-2105 - Print ISSN 0027-8874</div>
            
            
            <div id="copyright"><a href="http://www.oxfordjournals.org/our_journals/terms.html">Copyright ©</a> 
               <span>2015</span> Oxford University Press
               
            </div>
            
         </div>
         
         <div id="primary_footer">
            
            <div id="site_logo">
               <strong><span>Oxford Journals</span></strong>
               <em><span>Oxford University Press</span></em>
               
            </div>
            
            
            <div id="third_nav">
               
               <ul>
                  <li><a href="http://www.oxfordjournals.org/site_map.html">Site Map</a></li>
                  <li><a href="http://www.oxfordjournals.org/legal/privacy_policy.html">Privacy Policy</a></li>
                  <li><a href="http://global.oup.com/cookiepolicy/?siteid=journals">Cookie Policy</a></li>
                  <li><a href="http://www.oxfordjournals.org/legal/legal_notices.html">Legal Notices</a></li>
                  <li><a href="http://www.oxfordjournals.org/faq/">Frequently Asked Questions</a></li>
               </ul>
               
            </div>
            
            
            <div id="other_oup_sites">
               
               <form action="http://www.oxfordjournals.org/service/redirect">
                  <div>
                     <label for="site_list">Other Oxford University Press sites:</label>
                     <select name="url" id="site_list">
                        <option value="http://www.oup.com">Oxford University Press</option>
                        <option value="http://www.oxfordjournals.org/china/">Oxford Journals China</option>
                        <option value="http://www.oxfordjournals.org/japan/">Oxford Journals Japan</option>
                        <option value="http://www.oup.com/uk/academic">Academic &amp; Professional books</option>
                        <option value="http://www.oup.com/oxed">Children's &amp; Schools Books</option>
                        <option value="http://www.oup.com/uk/dictionaries">Dictionaries &amp; Reference</option>
                        <option value="http://www.oup.co.uk/newdnb/">Dictionary of National Biography</option>
                        <option value="http://www.oup.com/uk/digital_reference">Digital Reference</option>
                        <option value="http://www.oup.com/elt/">English Language Teaching</option>
                        <option value="http://www.oup.com/uk/textbooks">Higher Education Textbooks</option>
                        <option value="http://www.oup.co.uk/ieu/">International Education Unit</option>
                        <option value="http://www.oup.com/uk/law">Law</option>
                        <option value="http://www.oup.com/uk/medicine">Medicine</option>
                        <option value="http://www.oup.com/uk/music">Music</option>
                        <option value="http://www.oup.com/online">Online Products &amp; Publishing</option>
                        <option value="http://oxfordbibliographiesonline.com">Oxford Bibliographies Online</option>
                        <option value="http://oxforddictionaries.com">Oxford Dictionaries Online</option>
                        <option value="http://www.oed.com">Oxford English Dictionary</option>
                        <option value="http://www.oxfordlanguagedictionaries.com">Oxford Language Dictionaries Online</option>
                        <option value="http://www.oxfordscholarship.com">Oxford Scholarship Online</option>
                        <option value="http://www.oup.com/uk/reference">Reference</option>
                        <option value="http://www.oup.com/uk/rights">Rights and Permissions</option>
                        <option value="http://www.oup.com/uk/booksellers">Resources for Retailers &amp; Wholesalers</option>
                        <option value="http://www.oup.com/uk/corporate">Resources for the Healthcare Industry</option>
                        <option value="http://www.oup.com/vsi">Very Short Introductions</option>
                        <option value="http://www.oup.com/worldsclassics">World's Classics</option></select>
                     
                     <input type="image" src="/resource/image/buttons/go.gif" alt="Go"
                            class="inline_button" />
                     
                  </div>
               </form>
               
            </div>
            
         </div>
         <script type="text/javascript"
                 src="http://gab.cookie.oup.com/aws-cookie/oup.cookiepolicy.pack.js"
                 defer="defer"></script>
         
         <script defer="defer"
                 src="http://oi-underbar.ifactory.com/underbar/js/jquery-ui.min.js"
                 type="text/javascript"></script>
         <script defer="defer"
                 src="http://oi-underbar.ifactory.com/underbar/js/jcarousellite.js"
                 type="text/javascript"></script>
         <script defer="defer"
                 src="http://oi-underbar.ifactory.com/underbar/js/pf_oiunderbarinit.js"
                 type="text/javascript"></script>
         <script defer="defer" src="/resource/js/underbar_local.js" type="text/javascript"></script>
         <script defer="defer" type="text/javascript">
    function fnc_onDomLoaded() {
        var query_context = getQueryContext();
        PF_initOIUnderbar(query_context,":QS:default","","JRN"); 
        PF_insertOIUnderbar(0);
    };
    if (window.addEventListener) { 
        window.addEventListener('load', fnc_onDomLoaded, false); 
    } else if (window.attachEvent) { 
        window.attachEvent('onload', fnc_onDomLoaded); 
    } 
</script>
         <noscript><img src="//ouptag.scholarlyiq.com/ntpagetag.gif?js=0" height="1" width="1"
                 border="0"
                 hspace="0"
                 vspace="0"
                 alt="" /></noscript><script type="text/javascript" src="//ouptag.scholarlyiq.com/ntpagetag.js"></script><script type="text/javascript">
        var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");
        document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));
        </script><script type="text/javascript">
        try {
        var pageTracker = _gat._getTracker("UA-189672-16");
        pageTracker._setDomainName(".oxfordjournals.org");
        pageTracker._trackPageview();
        } catch(err) {}
        </script></div>
   </body>
</html>